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ABSTRACT
Traumatic brain injury (TBI) remains a major public health problem globally. In the United States
the incidence of closed head injuries admitted to hospitals is conservatively estimated to be 200 per
100,000 population, and the incidence of penetrating head injury is estimated to be 12 per 100,000,
the highest of any developed country in the world. This yields an approximate number of 500,000
new cases each year, a sizeable proportion of which demonstrate signficant long-term disabilities. Unfor-
tunately, there is a paucity of proven therapies for this disease. For a variety of reasons, clinical trials for
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TRAUMATIC BRAIN INJURY (TBI) remains a major pub-lic health problem. The incidence of all closed head
injuries admitted to hospitals is conservatively estimated
to be 200 per 100,000 population in the United States.
This yields an approximate number of 500,000 cases in
the United States alone. Of these, 10% are generally clas-
sified at admission as severe (Glasgow Coma Scale
[GCS] # 8), another 10% as moderate (GCS 9–12), and
the rest as mild (GCS 13–15). Of the 50,000 patients who
suffer a severe TBI, approximately one-third die even in
the best of centers. Thus, in the United States, it is esti-
mated that at least 17,500 patients die annually as a re-
sult of TBI, even without accounting for the fewer deaths
among the moderate and the mild TBI groups. Of the sur-
vivors, a sizeable fraction demonstrates significant long-
term disability.
The incidence of penetrating head injury in the United
States is estimated to be 12 per 100,000, the highest of
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this condition have been difficult to design and perform. Despite promising pre-clinical data, most of the
trials that have been performed in recent years have failed to demonstrate any significant improvement
in outcomes. The reasons for these failures have not always been apparent and any insights gained were
not always shared. It was therefore feared that we were running the risk of repeating our mistakes. Rec-
ognizing the importance of TBI, the National Institute of Neurological Disorders and Stroke (NINDS)
sponsored a workshop that brought together experts from clinical, research, and pharmaceutical back-
grounds. This workshop proved to be very informative and yielded many insights into previous and fu-
ture TBI trials. This paper is an attempt to summarize the key points made at the workshop. It is hoped
that these lessons will enhance the planning and design of future efforts in this important field of research.
Key words: clinical trials; head injury; intracranial pressure; outcome measures; traumatic brain injury;
trial design; uniformed consent
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any developed country in the world. Approximately 40%
of battlefield fatalities in the Vietnam War were due to
head and neck wounds. While only 3% of the casualties
admitted to hospitals during this conflict did not survive,
40% of these deaths were due to head injuries.
Despite the obvious public health implications of these
numbers, there is a paucity of proven therapies for this
disease. Furthermore, due to the complexity of the fac-
tors that impact upon the outcome from TBI, clinical tri-
als for this condition have been difficult to design and
conduct. Several trials that have been performed in re-
cent years have failed to demonstrate significant im-
provement in outcomes, despite promising preclinical
data. The reasons for failure were not always apparent
and any insights gained were not always shared. It was
feared that we in the head injury field were running the
risk of repeating our mistakes.
Recognizing the importance of TBI, the National In-
stitute of Neurological Disorders and Stroke (NINDS)
sponsored a workshop in May 2000 that brought together
experts from clinical, research, and pharmaceutical back-
grounds. The goals of the workshop were to review pre-
vious clinical trials and to glean lessons that could be ap-
plied to future studies. The workshop was very successful
in facilitating a free and lively exchange of ideas across
disciplines and across commercial boundaries. This pa-
per is broadly based on the proceedings of that meeting.
However, the material has been edited and reorganized
to make it more cohesive and to eliminate redundancies
and ambiguities. Although not all participants presented
papers, each one was actively involved in the discussions.
All participants have recently reviewed the manuscript,
added key references, and included any recent develop-
ments in the field, in order to make the information cur-
rent and valuable. Any errors or omissions represent the
failings of the authors who have attempted to faithfully
yet concisely summarize a large volume of information
and opinions. While the reader will obviously make the
final judgment, we believe that the manuscript contains
very valuable insights that are lucidly presented. It is
hoped that this exercise has allowed us to learn from past
experiences so that we may design the best possible stud-
ies in the future. We owe this to our patients, our field,
and ourselves.
EXECUTIVE SUMMARY
Several issues related to the design and conduct of clin-
ical trials in TBI were discussed in the workshop. While
it is impractical to recapitulate all of the issues or all of
the lessons learned, some of the key recommendations
are summarized below. We must realize that the failure
of TBI trials to date may not be due to poor trial design
alone, but perhaps due to ineffective therapies or the se-
lection of inappropriate target mechanisms. We must dis-
tinguish between these possibilities.
Identify and target specific mechanisms of cellular injury
 Obtain better understanding of the pathophysiology
of TBI through continued research
 Target study drug or therapy to a mechanism that is
known to occur in TBI
 Establish that a drug/therapy has the desired effect
on the mechanism of injury in vivo
Obtain adequate preclinical data
 Model in the lab the severity of injury to be tested
clinically
 Establish animal intensive care units (ICUs) to study
severe TBI
 Study pharmacokinetics in multiple animal models to
establish the dose, how soon, how frequently, and for
how long to give drug or initiate and continue therapy
 Test the intervention in at least two rodent models
(maybe two models of TBI such as weight drop or
fluid percussion, or similar models in two rodent
species) and in a larger animal if possible
 Test the intervention in more than one lab
 Try to model for both diffuse and focal injury, sub-
arachnoid hemorrhage and ischemia
 Ensure adequate transport of a pharmaceutical agent
into the cerebrospinal fluid (CSF) and brain
 Study the time window of drug/intervention efficacy
 Establish a correlation between the window of op-
portunity in animals versus humans
 Establish dose-response curve
 Obtain as much toxicological data as possible
Focus the trial on the appropriate subgroup of patients
 Target the subpopulation of patients most likely to
benefit from the treatment
 Consider important prognostic variables: severity of
injury, age, sex, hypotension, pupillary reaction, ev-
idence of brain injury on computed tomography
(CT), and traumatic subarachnoid hemorrhage
 Exclude patients who are “too good” or “too bad” to
be helped by the test therapy
Confirm adequate drug delivery to the brain
 Establish the pharmacokinetics of the drug in humans
 Establish CSF penetration
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Clinical management
 Standardize clinical management as carefully as pos-
sible within and across centers
 Conduct frequent independent monitoring of patient
management and data quality
 Reduce the amount of data collection to only what
is relevant
 Use centralized reading of CT scans
 Consider that concurrent medications may have sig-
nificant interactions with the study drug
Choose the right outcome measures
 Consider carefully the point at which to dichotomize
the Glasgow Outcome Score (GOS)
 Ensure that the time frame for outcome is reason-
able; a 6-month time point is recommended for most
trials
 Select outcomes that are measurable, standardized,
and relevant to lifestyle
Surrogate outcome measures
 Do not accept a surrogate for clinical outcome in
phase III TBI trials
 Use surrogate outcomes as supplementary data to
guide future studies
 Consider surrogates as outcomes for phase II trials
Statistical considerations
 Power the study adequately
 Employ alternative designs to standard randomized
clinical trial (RCT) where possible
 Have reasonable expectations for size effects; effect
sizes of 5–7.5% could be valuable
 Consider large, simple trials to detect small treat-
ment effects.
Informed consent
 Make every effort to obtain consent from the fam-
ily whenever feasible
 Prepare an abbreviated consent form for the initial
discussion
 Put into place appropriate mechanisms for waived
consent before starting the trial
 Work closely with Institutional Review Boards
(IRBs) to ensure communication with community
and participants during study
Study management
 Establish stopping rules (safety, futility) in design of
study
 Assure availability of drug/placebo formulations be-
fore entering patients
 Report study results within a year of completion of
last follow-up, even when results are negative
 Establish independent safety monitoring board to
oversee trial
Overview of FDA perspective
 A drug can be targeted either to a very specific sub-
group of patients, or to the larger population—this
is not prescribed by the law
 The Food and Drug Administration (FDA) does not
specify the size of the treatment effect—the investi-
gators have to decide what is clinically a worthwhile
effect
 Placebo controlled trials would be the most appro-
priate for TBI since there is currently no approved
drug
 The FDA ordinarily requires two independent posi-
tive trials for approval
 TBI is an appropriate candidate disease for fast track
approval if a big effect is shown
 An effect on surrogate markers only, will probably
not be acceptable for final drug approval
 Clinical outcome needs to be positively impacted
 International trials may be accepted if they are prop-
erly conducted, the patient populations are similar and
the clinical management of patients is comparable.
LESSONS LEARNED FROM 
PREVIOUS TRIALS
Pharmacological Trials
Selfotel (Ross Bullock, M.D., Ph.D.). Selfotel was
commercially developed by CIBA-GEIGY about 12
years ago, and it was the first glutamate antagonist to go
into phase III trials. The drug went through a very ex-
tensive preclinical evaluation process, the kind of state-
of-the-art drug evaluation process that a large company
can bring to bear on a new compound. An important fac-
tor about this compound is that it is a competitive gluta-
mate antagonist, and it binds to the same receptor site as
glutamate. Most of Selfotel’s early evaluation was done
using preinjury dosing paradigms in animal models.
There were five animal studies related to TBI, which were
well done and some of them are published.
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When phase I volunteer studies were done, it was
found that this compound had psychomimetic/psychoac-
tive behavioral effects. This side effect limited testing of
the compound particularly in alert, awake patients. For
TBI higher doses were used, because the patients were
in coma. The drug went on to later Phase II studies,
through The American Brain Injury Consortium (ABIC).
This was the first trial of Selfotel in the United States.
CIBA was feeling pressure in 1992–93 to get the com-
pound into the marketplace, and consequently full analy-
sis of the data from the phase II study was not completed
before the phase III study began. They launched four,
large, “state-of-the-art” phase III trials, with a tremen-
dous amount of input from experts in academia. They
aimed to enroll about 1,200 patients into each of two
stroke trials and about 860 into two trials of severe TBI.
All four trials were negative.
What did we learn from this experience? Some of the
animal studies had shown spectacular neuroprotection.
There had been a few negative studies in animal models,
but the balance of information strongly favored an effect.
In one phase II study (108 patients) there appeared to be
an intracranial pressure (ICP)–lowering effect, exactly
what you would want to see with this kind of compound.
At the time that the phase III protocol was being designed,
we obtained data on the amount of glutamate in tissue
from microdialysis. Because of the long duration of glu-
tamate exposure in the tissue, at least four days of treat-
ment with the drug was proposed in human TBI.
Four concomitant trials in stroke and TBI were in
progress, and the stroke trials began to show higher mor-
tality rates in the Selfotel-treated group. CIBA closed all
four trials. With further analyses, the excess mortality
rates disappeared in the stroke trials. It is possible that
CIBA shut down the TBI trials on the basis of incom-
plete information. CIBA then did a futility analysis, af-
ter unblinding all of the data, and found no efficacy for
the drug in any of the trauma subgroups. What did emerge
was a lower overall mortality rate for TBI, in a well-mon-
itored trial with good data quality.
What can we say in retrospect about the Selfotel ex-
perience? Adequate brain pharmacokinetics was never
done prior to the large phase III studies, during early clin-
ical work-up, or in the animal studies. Adequate drug
binding to the receptor in the presence of high glutamate
concentrations was never shown, and the drug was not
measured in brain. We know that in stroke and TBI, glu-
tamate is present in very high concentrations. Perhaps the
drug failed to bind the receptor competitively in this en-
vironment. In the future, pharmacokinetics should be
done early and thoroughly; however, it is possible that
this compound could make a difference in TBI or in high-
risk cerebrovascular surgery. It appears a safe and effec-
tive drug, in pretreatment paradigms that had been done
in animal models.
Cerestat (Ross Bullock, M.D.). Cerestat (CNS 1102)
was the leading product of a small biotech company,
Cambridge Neuroscience (CNS). Much of the data re-
garding this TBI trial is still confidential, and has never
been released or published. Cerestat is a noncompetitive
glutamate antagonist. It binds in the channel site of the
glutamate receptor, that is, at the magnesium binding site,
and only binds when the receptor is activated by high
concentrations of glutamate, so-called use-dependency.
Thus, the drug should not bind significantly unless glu-
tamate was increased in the tissue; the more channels that
were open, the more drug would bind, and thus “damp
down the ionic storm.” The small size of the company
and the relative lack of resources that could be put into
development of the compound seemed to limit the
amount of pre-clinical testing that was done.
The phase III protocol was designed with input from
academia, including the European Brain Injury Consor-
tium (EBIC); however, there were some points on which
the sponsor had the last word. A 3-month GOS, which
was at that time a departure from the norm, was the pri-
mary outcome measure. CNS enrolled 70 centers across
Europe and the United States. Looking back at the data,
over half of those centers enrolled fewer than five pa-
tients, a major factor in the outcome of the trial. A
planned interim analysis at about 340 patients showed no
benefit and no harmful effect. At the same time, the
analysis of their stroke studies indicated lack of efficacy.
To my knowledge, the final data analysis has not been
published or presented. What can we learn from this trial?
Large intercenter variability was probably enough to sub-
stantially degrade the quality of data.
CP 101-606 (Ross Bullock, M.D.). The most recently
completed trial with a glutamate antagonist was by Pfizer
with CP 101-606. A lot of information on this compound
is currently under confidentiality, since there is ongoing
data analysis. This compound was synthesized using
techniques of molecular pharmacology and drug design.
Molecular techniques were used to discover and clone re-
ceptors to which the compound could then be targeted.
This is a “second generation” NMDA antagonist, and has
fewer side effects than either Selfotel or Cerestat. Be-
cause the compound targets a specific subtype receptor
(NR2B), it tends to have much cleaner pharmacology.
The compound did not have any of the serotonergic ef-
fects that its predecessor, Eliprodil, had. The most inter-
esting aspect of the compound is that it gets into brain
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tissue with apparently a fourfold higher concentration
than seen in plasma. It achieves therapeutic concentra-
tions quickly, and clears quickly when the infusion stops.
Even at high concentrations, it produced no behavioral
side effects in humans. At MCV, we used the compound
in “open-label” phase II studies, and saw a potential ben-
eficial effect and no bad side effects. The “phase IIb” trial
is now completed, with 400 patients enrolled, and data
analysis has been finished but not released. This seems
to have been the best TBI trial to date in terms of proto-
col design, and development of the compound.
The mechanism of glutamate neurotoxicity is not dis-
puted in neuroscience. These three compounds aimed at
that mechanism have been highly effective in animal
models, but have failed, in two of the three human trials.
This is one of the biggest paradoxes that TBI researchers
face. We must change the perceptions of industry and
academia, if we want to persuade them to stay with this
mechanism. Information from basic science presents
many new fields to explore; however, in apoptosis, for
example, there are no clinical drugs, the mechanisms are
far less certain, and the contribution of apoptosis to TBI
is not known and could be insignificant.
D-CPP-ene (Graham Teasdale, M.D.). The protocol
for the Sandoz-sponsored study of the glutamate antag-
onist D-CPP-ene, is presented on the Lancet website. The
data have been analyzed and reported in meetings. D-
CPP-ene was given twice a day for 5 days, and the re-
cruitment time window was 12 h. The initial recruitment
goal was 800 patients, but on statistical grounds the re-
cruitment target was increased. The trial was completed
when the new target was met, and 920 patients were re-
cruited in less than 2 years in about 51 European centers.
The population was well balanced for early severity and
CT scan categories. The protocol did not allow inclusion
into the study unless there was clear clinical evidence of
brain damage on the CT scan. Only eight patients were
lost to follow-up, four from each study group. Overall,
the patients who received the active drug had a slightly
worse outcome at 6 months than the placebo group. The
difference was not statistically significant. This result,
along with findings in other smaller studies that were not
completed, reduced interest in development of either this
agent, or other glutamate antagonists for treatment of se-
vere head injury.
When a lack of benefit is found, it is necessary to ask
if the dose of drug was appropriate. There was evidence
that subjects received enough drug to affect brain func-
tion. Whether it was enough to affect the damage might
be debated. Early in the study, we became aware that
some patients showed abnormal involuntary movements
of a choreoarthrotoid type, associated with hypertension.
It was very likely that they were drug-related, and to man-
age the events would result in loss of blinding. There was
a protocol change so that sedation and paralysis were con-
tinued for 12 h after the last study dosage. The incidence
of abnormal movements then fell quite considerably.
Drug treated patients took longer to come off the venti-
lator, longer to recover motor responsiveness, and longer
to leave intensive care. Another question is if the timing
of initiation of treatment appropriate? Only 4% in either
placebo or treatment group began treatment within the
first 4 h after injury. For those treated in the first 4 h,
outcome was better in patients who received active drug.
In comparing results across studies, there is a trend over
time for fewer patients to receive treatment in that first
4-h “window.”
Question: You said there were well-done animal studies
that had never been published. Why aren’t they in the
public domain? Why will investigators sign on to do
such studies when they will not be published?
Answer: The majority are negative studies, and it is dif-
ficult to have a negative study published. Most such
studies are contractual and reimbursed by the compa-
nies.
Question: Why do you make so much of the fact that
Cerestat is a noncompetitive antagonist?
Answer: It is a critical issue pharmacologically. This
characteristic confers important benefit to the com-
pound for use in TBI, where glutamate is markedly el-
evated. We did not have enough information from
pharmacologists in the beginning with Selfotel; for
Cerestat, we did.
Question: Do you think there was any possibility of de-
tecting a treatment effect in the Selfotel trial based on
how the trial was done?
Answer: In animal studies, with pretreatment, Selfotel
worked extremely well. But, human TBI trials are not
a pretreatment paradigm. We rationalized the design
on the basis that “40% of TBI patients deteriorate later,
so we will focus on those people.” However, we did
not see evidence of subgroup efficacy in those patients.
Comment: Graham, I would like to congratulate you on
what I think is a good use of subgroup analysis. It is
certainly legitimate to take a subgroup analyses and
generate from that a hypothesis that goes into another
trial; indeed, it would be a mistake for the trialists not
to do that analysis.
Answer: The issue of starting treatment soon after injury
was touched on earlier. This may be possible with an
agent that either has been in widespread use, or there
is clear evidence of its safety. Treatment could be
started without prospective consent, with administra-
tion less than 4 h from injury. I do not think that we
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can expect to start treatment so quickly unless we are
using waived consent.
Question: You provided some plasma levels for D-CPP-
ene and said that you were convinced that this was an
active brain plasma level. How do you know in a dis-
ease as complex as an injury what a sufficient plasma
level is?
Comment: The plasma levels achieved in patients were
comparable to the plasma levels achieved in animal
models where efficacy was shown; also, abnormal
movements were seen in patients, and a higher dose
would have been inadvisable.
Question: Over the course of a trial, how does an inves-
tigator ensure that the centers adhere to the protocol?
How do we make the variability of management as
small as possible, so that it is not a major confound-
ing factor for outcome?
Answer: The high protocol compliance in the EBIC study
of D-CPP-ene was illustrated in the very small num-
ber of protocol violations that led to exclusion of a pa-
tient’s data. Of 900 patients, only five cases were pro-
tocol violations, there was 99% follow-up. I think that
there is an “overconcern” about variations in manage-
ment and how this might influence the results of a trial.
Randomization within each center is a simple way to
minimize the issue. Moreover, variations in manage-
ment could be an advantage in enhancing the validity
of the result. At an early stage, looking for proof of
concept, it may be helpful to have a very uniform pop-
ulation, treated in “high-compliance centers.” In con-
trast, in the definitive study aimed to determine the
merit of a treatment for general use, management vari-
ations must be accepted.
Steroids (Raj Narayan, M.D.). Steroids have been in
common use in neurosurgery since the 1960s and were
initially used to treat brain edema associated with brain
tumors. The effect was usually dramatic, and there was
no doubt that glucocorticoids had an important role in the
management of these patients. Laboratory studies showed
that steroids reduced free radical production and had a
protective effect on the brain. Consequently, steroids be-
came commonly used in the management of a variety of
neurological conditions, including head injury. In 1976,
Gobiet compared low-dose and high-dose dexametha-
sone in 93 severe head injury patients to a previous con-
trol group and reported a benefit in the high-dose group.
In the same year, Faupel reported a favorable response
on mortality using steroids in a prospective, double-blind
trial of 95 patients; however, there was a significant in-
crease in the number of vegetative survivors and no im-
provement in favorable outcome.
There were subsequently at least six studies of steroids
in TBI that showed no clear beneficial effect on outcome
or ICP. Gaab reported no significant improvement in a
prospective, randomized, controlled trial of ultra high
dose dexamethasone starting within 3 h of injury. Grumme
reported a prospective, controlled, randomized, multicen-
ter trial of 396 patients with the steroid triamcinalone.
There was a trend towards better outcomes in steroid-
treated patients, especially if they had a GCS of ,8 and
had a focal lesion on CT scan. This combination was seen
in 93 patients; however, there was no statistically signif-
icant difference between the treatment and the placebo
groups at discharge or at 1 year. The authors concluded
that treatment with steroids was potentially helpful in a
subgroup of patients with TBI.
Two additional studies related to steroids are presented
in more detail later. Marshall reported on the results of a
large trial of tirilazad mesylate in TBI. This drug was be-
lieved to be more potent than traditional steroid formu-
lations, without the glucocorticoid side effects. No over-
all benefit on outcome was detected. In a meta-analysis
of randomized controlled trials in acute TBI, Anderson
reported no clear benefit, but stated that there was a pos-
sibility of a small effect. As a result, the group recom-
mended that a larger trial of over 20,000 patients be con-
ducted in order detect this effect.
In summary, the data available to date does not demon-
strate a clear beneficial effect of steroids in severe acute
TBI. It has been speculated that certain subgroups may
benefit; however, this is not proven. The evidence-based
Guidelines for the Management of Severe Traumatic
Brain Injury state, “The use of steroids is not recom-
mended for improving outcome or reducing ICP in pa-
tients with severe head injury.”
Tirilazad (Lawrence Marshall, M.D.). The Tirilazad
database represents approximately 1,700 severe head in-
juries, internationally and from the United States. I am go-
ing to make a few comments about those studies: what
was right and what was wrong. I am not going to com-
ment on the pharmacology, because there are complex is-
sues in the science of free radical scavenging that would
require much more time. Country-specific differences, or
differences in care, are a significant issue: the difference
in mortality for contusions was dramatic between coun-
tries, and in the United States between centers. Intercenter
variation, not explicable by GCS or CT scan, was re-
sponsible for 40% of the variation in the Tirilazad trial.
Some differences could be explained by overhydration ini-
tially. Patients appeared “overresuscitated”—blood pres-
sures were elevated, as were ICPs and treatment intensity
levels (TILs). In patients with intracerebral hemorrhages,
the ones who came in with lower GCS scores, higher le-
sion volumes, and were operated on early had better out-
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come than those patients who had smaller lesions initially,
a higher GCS, but who then deteriorated. The mortality
was half for the patients who were operated on early. Such
regional differences in care are important when looking at
results overall, and serve to emphasize the need to have a
high level of protocol adherence. There is another lesson
here. We need to think through what the target should be
in our clinical trials. Results from the Tirilazad trial indi-
cate that high ICP—whatever the cause of the elevation—
needs to be a primary target.
An additional finding from the Tirilazad trial con-
cerned the wide variety of patients included, and the ne-
cessity to assure that the treatment groups were well bal-
anced. We had real imbalances in both the Selfotel and
Tirilazad trials concerning frequencies of CT scans and
the variety of different CT diagnoses that were made. We
know that these areas are associated with different pat-
terns of outcome. For example, the presence of traumatic
SAH skews outcome. In the Tirilazad trial and in the Self-
otel trial, we found that patients who had minimal in-
tracranial pathology had an extremely low mortality
(,5%), and almost 80% had a favorable outcome. The
inclusion of many such patients is likely to “front-load”
a trial, and make it more difficult to find efficacy of a
treatment. In contrast, patients who have one lesion
greater than 5 cc have less favorable outcome, with a
mortality rate more than three times that of the patients
with minimal pathology. How do we classify the patients?
For the most part, we have used stratification of the GCS,
but the CT scan correlates better with outcome, except at
the very bottom of the scale. If we do use CT scans, then
there has to be a centralized reader. In our experience in
the United States, almost a third of the scans had been
misinterpreted or miscoded using the Traumatic Coma
Data Bank classification.
One positive, but still troubling, observation from the
Selfotel trial was the extraordinary performance of pa-
tients in the placebo group on the GOS. Clinical care has
improved dramatically over the last two decades. Are we
fighting ourselves by sticking to a certain assessment of
outcome? It is going to be difficult to do better than a
mortality of 7% in patients with epidural hematomas, as
occurred in the Selfotel trial. Patients in the placebo group
are doing very well with diagnoses of subdural hematoma.
A few years ago, we would have expected that they would
do poorly and a new treatment would have room to move
people up into better outcome categories. We need to
measure outcome better than we presently do.
Another variable that needs further discussion is trau-
matic subarachnoid hemorrhage (SAH). Using the grad-
ing system developed by Gabrielle Morris for SAH, we
have seen that mortality varies from 13% to 44% among
patients. Recording subarachnoid hemorrhage as “absent
or present” is inadequate, and we more need data to help
us develop a better classification of traumatic SAH.
To highlight the importance of balance within a trial,
we need look no further than the experience with female
patients in the Tirilazad trial. There was such a marked
imbalance in the frequency of shock (4:1 for the Tiri-
lazad group) that it masked our ability to analyze the data.
Thus, given the relatively small number of women in the
trial (incidence of severe TBI is lower in women than
men), the data are meaningless. An additional observa-
tion from the Tirilazad trial, which also appears to be true
in the Selfotel trial, is that the mortality rate for women
is higher; but, in women who survive, cognitive outcome
is better. We need to pay more attention to differences
between men and women when we look at outcomes.
In our analysis of the Selfotel trial, we noted that the
initial value of the ICP is a much more important pre-
dictor of outcome than cerebral perfusion pressure (CPP),
as long as the CPP is at least 60 mm Hg. Neurological
deterioration, which occurred in approximately 30% of
patients, was usually associated with asymmetry of the
pupils and increased the likelihood of death almost six-
fold. These patients would likely benefit from a new treat-
ment, and we should begin to concentrate our efforts in
that select population. But, we must identify the patients
early in the course of the injury. These results also sug-
gest that treatments aimed at improving intracranial hy-
pertension would be appropriate.
In summary, based on our previous experience with
two large international trials and one large U.S. trial, we
would recommend that one should exclude patients in the
diffuse II category with lesions that are less than 5 cc in
size. This criterion would lead somewhat surprisingly to
a more equal distribution of patients with shock among
treatment groups. Trial design should also take into ac-
count targeting elevated ICP: it kills 75% of the patients
who die in the first week and contributes to many later
deaths.
Question: When you say that we should make ICP the
target, do you mean that it should be the primary out-
come in clinical trials, or we should look into devel-
oping trials to treat intracranial pressure?
Answer: We suggested in the paper on the results of neu-
rological worsening that it could certainly be a surro-
gate endpoint. It needs to be validated against a harder
endpoint. I would say that if you do not see a change
in ICP within a trial, you are not going to be able to
show efficacy. These are the patients who ultimately
go on to either have a poor outcome or die.
Comment: Another message from your study would be
that one needs to see that the treatment lowers the ini-
tial ICP and the occurrence of worsening is lower in
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the treatment group; not that the treatment group does
better for a given ICP. You can have a drug in which
the treatment group had a lower ICP, but no better out-
come, as was found in the phase II Selfotel studies.
How soon was ICP measured in your study?
Answer: In the European Tirilazad trial, ICP was mea-
sured when the monitor was first put in, an average of
5.1 h from the time of injury. In fact, 70% of patients
had it within 3.5 h. There is a trend in patients with-
out surgical lesions that early aggressive attempts to
reduce ICP favorably influences outcome. When pa-
tients went to the operating room earlier, the 6-month
outcome in patients with intracerebral hemorrhage was
dramatically better than in patients with delayed evac-
uation of hematomas—even though those patients
were initially better clinically. To me, that is a hint that
the ICP is critical, particularly in patients with an ex-
traaxial lesion, but also in those with diffuse brain
swelling. If one could treat high ICP earlier and more
effectively, it should pay off both in terms of neuro-
logical deterioration, and with 6-month outcome.
Question: Your point is well taken that the assessment
of the patient CT scans should be centralized; how-
ever, trials are getting larger and larger. Should they
require central control and assessment of CT scans for
the Corticosteroids Randomized After Significant
Head Injury (CRASH) study with 20,000 patients?
Also, you suggested several times that subarachnoid
hemorrhage should be quantified. How can that be
done in a huge trial?
Answer: Remember that CRASH focuses primarily on
minor TBI, and only to some extent includes moder-
ate and severe injuries. I think that for milder injuries,
CT abnormalities may not need to play a role in the
study. In severe injury, you can have variations in mor-
tality rates of 6–10%, based on the CT diagnosis, if
you have a large number of patients in the DI I or DI
II categories. Either we limit a study to a targeted group
of TBI patients, (remembering that the scan results
change in 30% of the patients), or we include the en-
tire spectrum. If we include all ranges of TBI, we need
to make certain the treatment and control groups
match.
PEG-SOD (Byron Young, M.D.). I am going to dis-
cuss the results of the PEG-Orgatine (PEG-SOD; super-
oxide dismutase) study. As you know, free radicals con-
tribute to the generation of secondary injury. Before this
study, there were a number of experimental models and
clinical trials suggesting that free radical scavengers
would improve the outcome from severe head injury.
Probably Kontos and colleagues did the most important
animal work in the early 1980s, and later Paul Muizelaar
reported results of a phase II trial that suggested a bene-
fit in head injury patients. Based on these and other stud-
ies a randomized, parallel, placebo-controlled, blinded,
multicenter trial was done. The hypothesis was that PEG-
Orgatine, which was a free radical scavenger, would pre-
vent secondary injury and, therefore, improve the out-
come from severe head injury. The trial was done in 29
centers in the United States, and there were 463 severely
head-injured patients in the study. The patients received
an intravenous dose of either placebo, 10,000 units, or
20,000 units of PEG-Orgatine within 8 h of injury. The
primary endpoint was GOS at 3 months. Patients with
GCS 3 were included in the trial, although some sec-
ondary analyses that eliminated results from these pa-
tients were done later. The planned secondary endpoints
were mortality and the Disability Rating Scale (DRS).
The distribution of patients receiving drug and placebo
was as it should be. The bottom line of this trial was that
there was no significant difference in neurological out-
come (GOS, DRS) or mortality between the patients
treated with PEG-Orgatine and those receiving placebo.
There were, however, better but not statistically sig-
nificant outcomes in the patients who received 10,000
units/kg PEG-Orgatine compared to those who received
the placebo or the 20,000 units/kg dose. At 3 months,
there was an absolute difference of 7.9% improvement,
and at 6 months, a 6% improvement using the di-
chotomized GOS (good recovery or moderately disabled
vs. severely disabled, vegetative or dead).
What questions were raised by this study, and what
have we learned? Why weren’t the statistics significant
even though there was a measurable difference? Was
there is a type 2 error? The study was designed to detect
a difference of 14% with a 90% power. Was that ade-
quate? The trial size and the treatment differences sought
were based on a phase II trial. Did we miss a clinically
significant difference between two arms of treatment? We
would a new trial to detect a smaller, although important,
treatment effect. What about standard care? There was
good adherence to the protocol, but at the time we were
not focused on the intercenter variations in routine treat-
ment of TBI. That may be very important. The only sta-
tistically significant difference in this trial was that the
patients treated with 10,000 units of PEG-Orgatine had
a decreased incidence of acute respiratory distress syn-
drome (ARDS), but that did not seem to make a differ-
ence in mortality.
IGF-1/growth hormone (Byron Young, M.D.). We
have just completed a single-institution, controlled trial
in which we studied whether or not the administration of
insulin-like growth factor (IGF)–1 and growth hormone
and would improve neurological outcome and alter meta-
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bolic sequelae after severe head injury. IGF-1, which is
produced in the liver, mediates the effects of growth hor-
mone, and is important for organ growth. It stimulates
glucose uptake, glycogen synthesis, net protein synthe-
sis, amino acid transport, and DNA synthesis; and, it
causes cellular proliferation both systemically and within
the central nervous system. Patients who have a severe
head injury are hypermetabolic. Their actual metabolic
rate is about 40% more than their calculated metabolic
rate, and they are in negative nitrogen balance. You can
provide enough nutrition to give them a caloric positive
balance, but nitrogen repletion alone will not result in
positive nitrogen balance. By administering growth hor-
mone (GH) and IGF-1 we wanted to push these patients
to a positive nitrogen balance. We thought this might im-
prove clinical outcome by reducing or preventing an-
abolism, and reducing infection, preventing secondary in-
jury, and helping the reorganization of the central nervous
system.
The particulars of the study were as follows. The pri-
mary endpoint was improvement in nitrogen retention.
We also wanted to determine whether this could be done
safely: in the literature there are reports of adverse ef-
fects, primarily from lowering glucose. The patients in
the study had GCS scores 4–10. We started the IGF-1/GH
within 72 h of injury, and we used traditional recom-
mendations for nutritional support. There was no differ-
ence in the demographics between the control and
IGF/GH groups.
We were able to demonstrate that we could achieve
sustained positive nitrogen balance in patients with se-
vere head injury; however, this made no difference in the
outcomes measured. There is no difference in the DRS.
We also did quite a battery of neuropsychological tests,
and there were no significant difference between groups
at any time throughout the trial. We followed these pa-
tients for 24 months. There were more infections in the
patients who were treated than in the control group (not
significant). The conclusion of this study is that IGF-
1/GH blunts the metabolic sequelae of TBI, but does not
improve the neurological outcome, and may increase the
risk of infection. After we finished the study, we com-
pared the pulmonary complications in our patients with
the ABIC database and it appeared that the patients that
received IGF-1 and GH showed a reduction in the inci-
dence of ARDS.
At the start of the trial Genentech provided the IGF-1.
In the middle of the trial there was a corporate restruc-
turing, and they decided to no longer supply the IGF-1.
After about 6 months of conversation with our university
lawyers, Genentech reconsidered. About 6 months after
that, the European trials with GH and IGF-1 were stopped
for safety reasons. Even though we saw no safety prob-
lems, our study was also stopped. Did the early end of
the trial affect its outcome?
Comment: We have a huge discrepancy among TBI tri-
als. On one hand is the small PEG-SOD study show-
ing a 60% better outcome at 6 months, possibly an 80%
better outcome at an earlier time point, for a drug that
is given in one dose and is completely safe. On the
other hand, sits the CRASH trial, designed to include
10,000 patients treated with high-dose steroids, for
which no efficacy has been shown before and where
there are well-known side effects. Surely PEG-SOD is
the better drug for a mega-trial. Focus such a trial on
the emergency room with a single dose given as early
as possible, when free radicals are known to be active.
Comment: There has been expectation that one study will
answer everything—a so-called mega-study. Isn’t this
a bit of an illusion? There is a strong desire to exam-
ine a trial that is negative on its primary, protocol-
specified outcome measure, in order to find a positive
“subgroup.” People are looking at subgroups retro-
spectively and saying, “Well, here is where the action
is. Let’s do a large trial looking at this.” It is treach-
erous to do that.
Nimodipine (Graham Teasdale, M.D.). Studies of Ni-
modipine in head injury began in 1987. At that time, there
was a low level of interest in pharmacological treatment
of TBI, apart from trials of steroids with varying doses
in smallish numbers of patients. There was clear evidence
that Nimodipine was beneficial in spontaneous sub-
arachnoid hemorrhage, reducing the incidence of infarc-
tion and ischemia and improving outcome.
Two studies were done in relatively unselected head
injury populations: HIT-1, involving five British centers
and Helsinki, and then HIT-2, with about 12 centers in
different parts of Europe. These studies showed a 4%
absolute improvement and 8% relative improvement for
favorable outcome, which was not significant. Both of
these involved a 7-day treatment with Nimodipine. In
HIT-1, 20% of patients were recruited and treatment
started within 4 h of injury. HIT-2 was started while
HIT-1 was still going on; however, in this second trial,
the proportion of subjects entered in less than 4 h fell to
10% of those recruited, and the relative difference for
favorable outcome dropped to 2%. Although these re-
sults were disappointing, the recognition of the drug’s
effect in spontaneous subarachnoid hemorrhage, along
with evidence from the Traumatic Coma Databank on
the importance of SAH in head injury, prompted exam-
ination of the HIT-2 data to see what was going on. This
analysis showed overall greater mortality in patients
graded as having traumatic SAH on the CT scan, but
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outcome was better (8% improvement) in patients treated
with Nimodipine.
This finding stimulated two activities: a further retro-
spective analysis of the HIT-1 database and a new
prospective study. The study of the HIT-1 database indi-
cated that traumatic SAH patients did slightly worse with
Nimodipine than placebo. In contrast, a clinical study
(HIT-3) involving 123 patients with CT scan evidence of
SAH, admitted to 12 centers in Germany, showed a dif-
ference in the rate of favorable outcome for Nimodipine-
treated patients. In a meta-analysis of these studies, there
was a “just-significant” improvement in mortality and dis-
ability in Nimodipine treated-patients. HIT-3 had some
limitations. For example, on review of the 123 patients
admitted, 20% were found not to have subarachnoid he-
morrhage. Although the overview resulted in Nimodipine
being registered for the treatment of traumatic SAH in
some countries, it has not been widely accepted as a stan-
dard treatment. A dialogue between clinicians and Bayer
prompted the company to do a further prospective study,
HIT-4. Results are not available at the time of this report.
This sequence of studies illustrate how an interesting
subgroup can emerge from trials, and be evaluated ret-
rospectively and prospectively. In the end, through Bayer
sticking with the area for 12–13 years, a definitive an-
swer will be obtained.
Question: It is my understanding that before the Ni-
modipine trials, there was not a single published pre-
clinical study in any animal model of head injury. I
was wondering how the company could possibly have
convinced themselves to launch a large-scale clinical
trial with no preclinical data available?
Answer: It was firmly established in the 1970s that is-
chemia is a major component of brain damage after
head injury. Demonstration that Nimodipine had a
good effect in models of ischemia seemed to be suffi-
cient to move to patient studies. At that stage showing
a good effect in a model of ischemia seemed to be suf-
ficient to jump to patients with either spontaneous SAH
or head injury. It was not just the company that was
convinced, but the investigators as well. We were cor-
rect for spontaneous bleeding; the position in head in-
jury remains to be defined.
Bradycor (Anthony Marmarou, Ph.D.). There had been
a number of animal studies using bradykinin antagonists
that dealt predominantly with brain swelling. It was on
the basis of these preclinical studies that SmithKline
Beecham elected to use intracranial pressure as the pri-
mary endpoint in the Bradycor trial. A prospective, ran-
domized trial was designed, and began in 39 centers in
the United States with coordination by the American
Brain Injury Consortium (ABIC). After 139 patients were
accrued, the company placed the trial on clinical hold.
The hold was based on new animal work using a second
batch of the drug conducted during the course of the trial.
The first batch of the drug was made in the United States,
and this was the one that we were using in the trial. The
second batch was formulated in Europe, and samples
from this batch were tested in rats by a contract labora-
tory. In a study with 12 animals, all of the rats died. This
event was startling to us because we had observed no
safety concerns with our patients in the trial, and our pre-
clinical data had been clean. We (ABIC and the clinical
centers) continued to hold, but presumed that this issue
would be resolved by additional studies; however, the
trial was stopped and the blinded randomization was bro-
ken. Therefore, I can only report the data that we had
available at that time; the numbers will be small in the
various groups.
There were no significant differences between control
and treatment groups in any of the adverse event cate-
gories. The study groups were balanced with regard to
the intracranial hypertension, cerebral hemorrhage, and
in all other factors.. With regard to the primary endpoint
(the percent time ICP . 20 mm Hg), there was a trend
for reduction of ICP with Bradycor, although not signif-
icant. Looking at the entire intent-to-treat population,
there was certainly variability in ICP, but a trend toward
better control with treatment. With regard to outcome,
we saw a reduction in mortality in the drug group. Ana-
lyzing the dichotomized GOS at 3 months, we saw close
to a 10% improvement. This trend was seen at 6 months
with a difference in favorable outcome between placebo
and drug, but again not significant considering the small
number of patients. Interestingly, we observed an im-
provement (not significant) in neuropsychological in-
dices in the drug-treated group at 3 and 6 months. It is
important to note the cooperation by SmithKline
Beecham in assisting us in proceeding toward publica-
tion of a so-called negative trial.
What have we learned? Firstly, considering the favor-
able effect upon GOS, it is possible to include patients
with GCS 3 and one reactive pupil. This trial shows that,
even though there is devastating injury as evidenced by
the low GCS group with one reactive pupil, some pa-
tients do show measurable improvement. With regard to
interim analysis, we believe that guidelines for breaking
the blind should be firmly established. In this case, the
100% rodent mortality using the second batch of drug
could not be reproduced. This was confirmed by a sec-
ond contract laboratory. It was thought that the rats were
hyperthermic as a result of a heating lamp used during
the testing, but no further work was done to assess the
true safety of the second batch of drug. The investigators
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involved in this trial had no voice in the decision to break
the blind and stop the trial. We believe that we owe it to
our patients, to complete a trial whenever possible, and
to reach a scientific conclusion.
One lesson is to do as much as possible before the trial
starts. Stopping rules (safety, futility) should be stated
clearly and agreed to at the outset. The manufacturing
process and drug supply should be in place prior to en-
tering patients.
Dexanabinol (Nachshon Knoller, M.D., and Anat
Biegon, Ph.D.). Dexanabinol is a novel synthetic chem-
ical analog of the active component of marijuana. It was
designed as a mirror image of the naturally occurring
compound, so it is not recognized by the cannabinoid re-
ceptors in the brain that mediate the intoxicating effect
of marijuana. Preclinical studies demonstrated that Dex-
anabinol is a noncompetitive inhibitor of the NMDA re-
ceptor, a free radical scavenger and antioxidant, and an
inhibitor of the pro-inflammatory cytokine TNF alpha.
Dexanabinol inhibits breakdown of the blood–brain bar-
rier, edema formation, and neurological deficit in a closed
head injury in rats with a therapeutic window of 6 h. It
has also been shown to be efficacious in models of ax-
onal crush injury to optic nerve, and in focal and global
ischemia. Following completion of a phase I safety eval-
uation in healthy volunteers, work started on the design
of the study protocol in severe head trauma. Several phase
II and phase III trials of neuroprotective agents have been
already completed or ongoing (PEG-SOD, hypothermia,
Tirilazad) or were on hold (Selfotel) at that point in time,
such that lessons learned from these trials could be in-
corporated into the design of the Dexanabinol protocol.
Two major design principles were implemented based on
the analysis of pre-clinical data and data from previous
trials so as to increase the likelihood of detecting a drug
effect: (1) tighten inclusion/exclusion criteria and (2) fol-
low the lead from preclinical studies.
Criteria were chosen to exclude patients with a high
likelihood of extreme outcome (death or good recovery)
regardless of treatment. To achieve this end, patients with
enrollment GCS 4–8 were included unless both pupils
were fully dilated and fixed. The latter subgroup was ex-
cluded due to extremely poor prognosis. Evidence of in-
tracranial pathology was required (CT category 2 or
above) but patients with pure epidural hematomas were
excluded since this subgroup has an extremely good post-
surgical prognosis. Finally, due to the potent antiedema
effect of the drug in animal models, there was a strong
emphasis on monitoring ICP (a measure of the brain
edema) in this study such that only patients requiring ICP
monitoring were enrolled.
Treatment parameters (time to treatment, dose, and du-
ration) were kept as close as possible to those established
as safe and efficacious in relevant preclinical models.
Thus, Dexanabinol was delivered within 6 h of injury
(window of efficacy established in closed head injury and
axonal crush models). The doses were derived from com-
parative pharmacokinetics in animal studies where ef-
fective doses in rats (2–5 mg/kg) produced peak plasma
levels of ,2–5 mg/mL, and in the phase I trial. Plasma
levels in this range were obtained in volunteers and pa-
tients at doses of 48–200 mg/subject, so this was the dose
range chosen for the patient study. The drug was admin-
istered only once, since repeated administration in the an-
imal models did not appear to provide additional bene-
fits. In fact, the best treatment paradigm in rats consisted
of one injection within an hour of injury and a second in-
jection after 6 h (additional treatments at 12 and 24 h,
and 3, 7, or 10 days showed no further benefit). Since an
hour after injury was not considered a realistic treatment
time to expect within the framework of a clinical trial, a
single injection within 6 h was chosen.
The study was not powered for efficacy; rather the ex-
pectation was to derive safety data and some indicators
for efficacy through influence on surrogate markers such
as ICP and early recovery. The phase II trial of Dexan-
abinol in severe head trauma took place in all six neuro-
surgical units in Israel between 1996 and 1999. The study
was a multi-center, randomized, double-masked phase II b
trial of a single dose of Dexanabinol intravenous solu-
tion with a placebo control. A total of 101 patients were
randomized to receive a 48-, 150-, or 200-mg dose of
Dexanabinol, or an appropriate volume of vehicle. The
primary outcome (safety) measures were ICP, cardio-
vascular function, and clinical outcome/adverse events.
Secondary outcome (safety) measures were dichotomized
GOS, GOAT, and DRS.
The study patients had the demographic profile expected
for TBI: mostly young (mean age, 30 years), mostly males
(80%), victims of motor vehicle accidents (70%). There
were no statistically significant differences in important
risk factors (GCS, CT, age) between the drug and placebo
groups. Dexanabinol was shown to be safe and well tol-
erated in the dose range tested, as expected from the pre-
clinical and phase I data. The drug did not change the ad-
verse event profile, such that the observed adverse events
and their relative frequency were those characteristic of
the severe TBI population. There were decreases in the in-
cidence of fever, hypotension and mortality, although the
differences did not reach statistical significance. Signifi-
cant effects of the drug were seen on ICP. The drug ap-
peared to prevent the increase of ICP over the first 2–3
days postinjury, such that mean ICP values (which were
initially similar in the drug and placebo groups) rose above
15 mm Hg in the placebo group and remained consistently
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below 15 mm Hg in the Dexanabinol group. The percent-
age of time ICP was above 25 mm Hg was decreased in
the Dexanabinol treated groups at all doses, and the effect
was statistically significant from the second day. This sta-
bilizing effect of Dexanabinol on ICP was achieved with-
out lowering systolic blood pressure; conversely, the per-
centage of time systolic blood pressure fell below 90 mm
Hg was reduced in the Dexanabinol-treated patients.
Examination of the distribution of patients among the
various GOS categories over time results in several ex-
pected and some unexpected observations. The trend to-
wards lower mortality and higher percentage of patients
in the “favorable” outcome categories, observed in recent
clinical trials, continues in this study, such that mortality
is below 20% and a more than 65% of patients achieve
favorable outcome without treatment. Thus, dichotomized
GOS used in the traditional way produces a ceiling ef-
fect, which makes it hard to show a drug effect. Although,
as expected, there were no significant effects of treatment
on 6-month GOS; trends towards better outcome in the
Dexanabinol-treated patients were stronger in the more
severely injured subgroups (GCS 4–6, CT . 2) and at
the earlier time points (1 and 3 months). In fact, the per-
centage of patients achieving good recovery after 1 month
was significantly increased in the Dexanabinol-treated
group. Statistically significant differences in favor of the
drug were found on the GOAT. GOAT scores were per-
sistently better in the Dexanabinol-treated patients
throughout the follow-up period.
These lessons should promote discussion of the design
of future phase III studies in relation to patient selection
as well as outcome measures. Excluding patients without
CT evidence of severe parenchymal damage, or those
above GCS 8 might increase the likelihood of a signifi-
cant effect of treatment. Alternatively, one may consider
the inclusion of patients with GCS 3 and one fixed di-
lated pupil. In terms of outcome criteria, it appears that
a 10% difference in favorable outcome on the di-
chotomized GOS should be replaced by another, more
innovative statistical analysis, which better, reflects the
reality of current outcome distribution in severe TBI. We
should also consider other endpoints with clinical im-
portance, such as ICP/CPP management, evolution in CT
pathology, shorter hospitalization, shorter ICU stay, and
early recovery. From the clinical perspective as well as
in terms of cost effectiveness and reduction of suffering
for patients and families, a drug that facilitates ICP man-
agement, shortens ICU and hospital stays, and promotes
achievement of the good recovery category after 1 month
instead of 6 months, is a very good drug indeed.
SNX-111 (J. Paul Muizelaar, M.D.). Good preclinical
studies are essential for a good clinical trial. We need to
understand the mechanism of action of the drug. There
should be improved outcome in experimental animals.
For most of the trials that were designed before the trial
of Dexanabinol or SNX111, that was really not the case.
What preclinical data existed about SNX111? An im-
portant finding in studies of stroke mechanisms was that
this drug was effective if given 24 h after transient fore-
brain ischemia. This long “window of opportunity” was
one of the attractive features of the drug. In addition the
effect appeared long lasting, and was still present on day
28 after injury. So, before the TBI trial was started, we
determined what the time window for the drug was. In
preclinical work, we chose a dose of 4 mg/kg and gave
that to animals 15 min before the injury, and 15 min, or
1 h, 2 h, 4 h, 6 h, or 10 h after injury. We looked, not at
outcome, but at a very specific measure of metabolic (mi-
tochondrial) function in the brain. We found that this drug
works very well if given 2–4 h after the injury. Then we
looked at mitochondrial function, efficiency and found
again that the drug given later was actually more effec-
tive than when given right after the injury. Next, we
looked at different doses, and these doses were then al-
ways given 4 h after injury. In addition to 4 mg/kg, we
also looked at 0.5 mg/kg and 1.0 mg/kg; 1.0 mg/kg was
still fairly effective, but 0.5 mg/kg was not. So on the ba-
sis of these data, and after testing pharmacokinetics in
animals and in human volunteers, a dose was chosen for
this particular drug. We also felt that this drug in this
dose could be successful in TBI because the time win-
dow allows a later administration. One important finding
from our preliminary experiments was that by targeting
mitochondrial function, we were able to get a dose and
time window using only 39 animals. For behavioral out-
comes, we would have needed 114 experiments.
The trial was designed in 1995 with standard inclusion
criteria for severe closed head injury. The only thing I
feel we did a little bit differently was to use a decision
tree published by Choi. The decision analysis combined
parameters for patient outcome. We used this particular
decision tree to derive strata in the trial for predicting
those patients likely to have a good outcome. We pre-
dicted good progress in patients with bilateral pupillary
responses, under 40 years old (y/o), and GCS . 4; or a
unilateral pupillary response and ,30 y/o; or a motor
score of 5 and ,25 y/o. Other patients were considered
in a poor prognostic stratum.
What have we learned from this trial? The trial was
suspended when it was found that mortality in the pa-
tients receiving the drug was higher than in the patients
who were receiving placebo, and the company has not
yet released the full data. A summary of what we know
follows. We entered 160 patients before the trial ended.
The strata for expected good outcome and expected bad
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outcome were approximately equal in the treatment
groups. There were 40 patients treated with placebo who
were expected to have a poor outcome, and 40 treated
with drug who were expected to have a poor outcome;
the same figures for patients with an expected favorable
outcome. The mortality for the SNX arm was almost
25%, while for the placebo arm it was 15%. It was very
disappointing, because we thought that we finally had a
drug that could be given a long time after the initial in-
jury. At the start, we knew that the drug caused hy-
potension; so, the design stated that treatment was never
given if patients did not have a normal CVP, and if
dopamine and/or phenyl-epinephrine were not already
hanging as an infusion.
From this trial, we can see what very aggressive fluid
management will do. I think I never saw better preclini-
cal data with any drug; but the animals were not as se-
verely injured as many of our patients. Perhaps that con-
tributed to the disappointing outcome.
Anticonvulsants (Nancy Temkin, Ph.D.). The Univer-
sity of Washington has conducted three acute trials 
in epilepsy after traumatic brain injury: Dilantin, 1983–
1989, Valproate 1990–1997, and, currently, magnesium
sulfate. Briefly, the Dilantin study was a randomized, dou-
ble-blind, parallel group study; 404 patients were entered,
treatment was initiated within 24 h, and 24% of the sub-
jects were lost during the 2-year follow-up. The primary
goal of the study was to see if Dilantin prevented epilep-
togenesis. We found that the drug prevented seizures in
the first week after head trauma, but, even though treat-
ment continued for 1 year, there was no effect on late
seizures either during the treatment period or after treat-
ment was stopped. We found that phenytoin had substan-
tial medical and neurobehavioral side effects, especially
early on, in the more severely injured cases. The second
study used a similar design to see if Valproate had an
antiepileptogenic effect. We examined two durations of
Valproate therapy, 1 month and 6 months, with follow-up
continued to 2 years. Of 400 patients entered, about 15%
were lost to follow-up. Conclusions were that Valproate
showed no benefit over phenytoin for early seizures, and
neither drug prevented late seizures. There were essentially
no adverse neuropsychological effects in the Valproate
groups; however, there was a trend towards higher mor-
tality, the cause of which we were never able to determine.
Our current study examines magnesium sulfate: random-
ized, double-blind, parallel group, placebo-controlled,
about 400 patients. The treatment is initiated within 8 h,
and the duration of treatment is 5 days. We are looking at
6-month follow-up rather than 2 years, using a composite
endpoint. In addition to antiepileptogenesis, the study will
evaluate survival and, primarily, neurobehavioral outcome.
If you have two studies, one with 100 patients targeted
to the mechanism of a drug, and another study with 200
patients, but in 100 patients the drug is not appropriate
and has no effect, then you will have the same power for
both of these studies. If more than half the patients who
are unaffected, the effect on the power will be more ex-
treme. As much as possible, you want to know what a
drug is supposed to do, and how to identify patients for
whom that drug might be useful. In our Dilantin and Val-
proate studies, we were looking at effect on seizures, so
we used patients who were at high risk for developing
seizures. In the magnesium sulfate study, the drug effect
is likely very broad, so the inclusion criteria are much
less stringent than in the two seizure studies.
Comment: There are a couple of issues surrounding use
of anticonvulsants to keep in mind. The first is a phar-
macokinetics issue. Those of us who were involved in
the Tirilazad trials learned a very difficult lesson, and
that is that drugs like phenytoin, and even phenobar-
bital, stimulate liver enzymes and enhance the metab-
olism of drugs like Tirilazad. The second issue has to
do with the potential impact of depressant-type agents.
Anticonvulsants are depressant agents and may affect
brain plasticity and recovery after trauma. Animal
work has shown that administration of stimulants dur-
ing a critical phase after injury facilitates behavioral
recovery, and administration of depressants blunts that
recovery. Wholesale, continuous use of anticonvul-
sants in “neurocritical” patients, has to be looked at
very carefully. These trials are very important.
Comment: One has to ask if a particular outcome is an
appropriate measure of the function that you would
like to improve. What is the clinical utility of a par-
ticular outcome? Another issue concerns use of com-
posite scores. While they may be appropriate, one has
to ask, “What is the clinical interpretation of compos-
ites? What does such outcome mean?”
Physiological Trials
Cerebral perfusion pressure (Claudia Robertson,
M.D.). The purpose of this study was to determine if a
management protocol could be developed to reduce the in-
cidence of the most common causes of secondary insults,
particularly hypotension and hypocapnia, after severe TBI.
The first hypothesis was that the treatment protocol, coined
the “CBF-targeted” protocol, would reduce the incidence
of secondary ischemic insults. The second hypothesis was
that if the CBF-targeted protocol successfully reduced is-
chemic insults, the incidence of refractory intracranial hy-
pertension would be reduced, and the third hypothesis was
that neurological outcome would be improved.
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Two management protocols were compared in a
prospective, randomized, single-institution clinical trial.
This information is summarized in Table 1. The control
protocol was called the “ICP-targeted protocol.” This
control protocol consisted of a traditional TBI manage-
ment strategy, where the primary goal of the treatment
was to reduce ICP. The treatment or CBF-targeted pro-
tocol was designed to improve cerebral perfusion and pre-
vent secondary ischemic insults. There were four major
differences in the two treatment protocols. The first dif-
ference was in the end-points for fluid administration. In
the ICP-targeted group, maintenance fluids were given.
In the CBF-targeted group, fluids were given to maintain
a normal central venous pressure or pulmonary wedge
pressure. The second difference was the goal for mean
blood pressure, at least 70 mm Hg in the ICP-targeted
group and at least 90 mm Hg in the CBF-targeted group.
The third difference was the goal for cerebral perfusion
pressure, at least 50 mm Hg in the ICP-targeted group
and at least 70 mm Hg in the CBF-targeted group. The
final difference was in the use of hyperventilation. Al-
though hyperventilation was not used in any patient as a
routine, the ICP-targeted protocol allowed use of hyper-
ventilation as a treatment of intracranial hypertension.
The CBF-targeted protocol did not use hyperventilation,
because, although it lowers ICP, it does so at the expense
of reducing cerebral perfusion.
The inclusion criteria were adults ($15 years), who
were admitted within 12 h of a severe TBI and who had
a motor component of the GCS of 5 or less on admis-
sion. Exclusion criteria included only brain death, con-
traindication to placement of a jugular bulb catheter, or
severe associated systemic injuries.
The primary outcome measure for the trial was the in-
cidence of secondary insults, indicated by the occurrence
of jugular venous desaturation. The secondary outcome
measures were the incidence of refractory intracranial hy-
pertension, and neurological outcome measured by the 6-
month GOS and the DRS. The sample size of 182 was
chosen to give an adequate power to detect a 50% re-
duction in the incidence of jugular venous desaturation.
This sample size would also detect a reduction in the in-
cidence of intracranial hypertension from 27% to 12%,
and an increase in the number of favorable outcomes
(good recovery/moderate disability) from 35% to 54%.
It was recognized that this number of patients would only
detect a very large effect on neurological outcome; how-
ever, this is the improvement in outcome that has been
observed in clinical series with this type of management
protocol.
The patients were randomly assigned to treatment by
time blocks. Each 4-month rotation of neurosurgeons
through the ICU was divided into 2-month treatment
blocks. The treatment protocol was randomly assigned
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TABLE 1. COMPARISON OF THE MAJOR DIFFERENCES IN THE ICP-TARGETED (CONTROL) 
AND CBF-TARGETED (EXPERIMENTAL) PROTOCOLS
ICP-targeted protocol CBF-targeted protocol
General measures for all patients
Sedation Morphine 5–10 mg q1h prn Morphine 5–10 mg q1h prn
Controlled ventilation paO2 . 100, paCO2 35–40 paO2 . 100, paCO2 35–40
Normothermia Antipyretics Antipyretics
Fluids Maintenance fluids Maintain normal CVP (5–8 mm Hg) and
normal PWP (8–12 mm Hg)




Management of intracranial hypertension
CSF drainage 10–20 drops prn 10–20 drops prn
Paralysis Vecuronium, 10 mg q1h Vecuronium, 10 mg q1h
Mannitol 25 g q2–6h prn 25 g q2–6h prn
Hyperventilation paCO2 25–30 None, paCO2 35–40
Management of systemic hyper-/hypotension
Hypertension For SBP . 160: labetalol None
Hypotension For MAP , 70: volume, dopamine, For MAP , 90: volume, dopamine
phenylephrine phenylephrine
ICP, intracranial pressure; CBF, cerebral blood flow; MAP, mean arterial pressure; CPP, cerebral perfusion pressure; SBP, sys-
tolic blood pressure; CSF, cerebrospinal fluid; CVP, central venous pressure; PWP, pulmonary wedge pressure.
for each of the 2-month treatment blocks, and all patients
admitted to the hospital were treated by the assigned pro-
tocol for that 2-month block. In this manner, each physi-
cian group had experience with both treatment regimens,
but the order of this experience was random.
The study required eight 4-month blocks of time to en-
roll the required number of patients. A total of 89 pa-
tients were enrolled in the ICP-targeted treatment months,
and 100 patients were enrolled in the CBF-targeted
months. Because this randomization scheme does not
completely protect against bias, the patients who were
admitted but not enrolled in the study during the time pe-
riod of the study were compared to the study group. The
only differences were those that would be expected be-
cause of the exclusion criteria for the study. The excluded
patients had a lower initial GCS, a higher frequency of
abnormal pupils, a higher frequency of gunshot wounds
as the cause of the injury, and a higher frequency of pre-
hospital hypoxia and hypotension. The characteristics of
the patients enrolled in the two treatment groups were
also compared. There were no significant differences in
any measure of demographic characteristics or initial in-
jury severity.
The CBF-targeted protocol, was very successful in
preventing secondary ischemic insults. The number of
patients who had one or more episodes of jugular ve-
nous desaturation was reduced from 51% to 30%, and
the length of time that jugular venous saturation was de-
creased was significantly reduced. This improvement oc-
curred primarily in secondary ischemic insults caused by
hypotension and hypocapnia, which were the two aspects
of treatment emphasized by the CBF-targeted protocol.
The reduction in ischemic insults occurred with the CBF-
targeted protocol throughout the entire study, that is, it
was not physician-dependent and it did not depend on
which protocol was assigned first to each physician
group. In addition, the treatment protocol remained a sig-
nificant predictor of the occurrence of secondary is-
chemic insults, even when logistic regression analysis
was used to adjust for injury severity. In the final best-
fit logistic model, the ICP-targeted protocol was associ-
ated with a 2.4-fold increased risk of an ischemic insult.
The CBF-targeted protocol, however, did not reduce
the incidence of intracranial hypertension. The mean
ICP, the duration of time that the ICP was elevated, the
percent of patients with refractory intracranial hyper-
tension, and the number of patients who died of in-
tracranial hypertension were similar in the two treatment
groups. The CBF-targeted protocol, did not significantly
improve neurological outcome either. It must be re-
membered that the study was not powered to detect any-
thing but a very large improvement in outcome. How-
ever, the trend was for a higher morality rate, and a lower
percentage of patients with a favorable outcome in the
CBF-targeted protocol. Because of this apparent para-
dox, where a marked reduction in secondary ischemic
insults did not result in an improvement in neurological
outcome, potential complications of the CBF-targeted
protocol, which might have confounded the ultimate out-
come, were examined.
Three complications were possible from the treatment
required to maintain an elevated CPP. A higher blood
pressure could cause delayed or recurrent intracranial
hematomas. Higher fluid intake and prolonged use of
pressor agents could result in pulmonary edema, and high
doses of pressors could be associated with renal failure.
Any one of these complications could have offset any
beneficial effect of reducing secondary insults. Two com-
plications were easy to eliminate: there was only one case
of acute renal failure, and there was no difference in the
incidence of either recurrent or delayed intracranial
hematoma between the two protocols. The incidence of
ARDS, however, was five times higher in the CBF-tar-
geted protocol group than in the ICP-targeted group (15%
vs. 3%, respectively). The aspects of treatment that were
related to the development of ARDS included the fol-
lowing: a greater intake of fluid, a more positive fluid
balance, a higher central venous pressure and pulmonary
wedge pressure, and more prolonged use of pressors (both
dopamine and epinephrine). Finally, the outcome in the
patients who developed ARDS was significantly worse.
Seventy-one percent of the patients who developed
ARDS remained vegetative or died of their injury by 6
months postinjury.
To summarize, the CBF-targeted treatment signifi-
cantly reduced the incidence of secondary ischemic in-
sults, from 51% to 30%, but this reduction in ischemia
did not improve neurological outcome. There may be sev-
eral explanations for these findings. First the sample size
was not large enough to detect a realistic difference in
outcome. Second, because jugular venous desaturation
was treated in both groups when it did occur, this mini-
mized any adverse effect on outcome. Finally, the bene-
ficial effects of reducing secondary ischemic insults may
have been offset by systemic complications, especially
ARDS.
The lessons that can be learned from the experiences
of this study include the following: (1) Management tri-
als can be done in TBI patients. There are many man-
agement issues that exist in neurocritical care, and it is
only through systematic controlled studies that issues
such as this can be sorted out. (2) The current recom-
mendation of keeping all TBI patients at a CPP of at least
70 mm Hg needs to be reconsidered in light of the sig-
nificant complications that were observed in this study
and the lack of benefit on overall outcome.
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Question: Given your findings, how would you change
your management?
Answer: This study suggests that we need to individual-
ize treatment. It does not make sense to maintain all
patients at an elevated CPP, when perhaps only a few
patients really need that level. In doing so, all patients
are put at risk of the complications, while only a few
receive benefits. As a routine now, we maintain pa-
tients with a CPP of at least 60 mm Hg, which is ad-
equate for most patients. However, if some measures,
such regional CBF or SjvO2 or brain tissue pO2, sug-
gest that perfusion is inadequate with a CPP of 60 mm
Hg, then we try to raise CPP. This puts only patients
with potential to benefit at risk of complications.
Comment: I think that CPP is a red herring, and we are
trying to increase a “parameter” that does not really
exist. We need to consider that pulmonary failure po-
tentially exacerbates the brain swelling, and we need
to rethink the whole notion of the CPP calculation. We
need to protect the brain against ischemia, which you
have argued very well. An alternative explanation for
your data is that we need to direct therapy more
quickly, vigorously, and intelligently against ICP.
What we are really looking at early on is cytotoxic
edema and not diffuse intravascular swelling. How
would you go after that?
Answer: Your points are well taken, and I would add
some strength to what you have said. We did not
change the incidence of ischemia associated with in-
tracranial hypertension. We did not design our treat-
ment of ICP-related events any differently in the two
treatment protocols. And the results could suggest that
ICP-related ischemic events are much more important
than those associated with hypotension or hypocapnia.
How to treat is a much more difficult question. I pre-
sume that this type of edema is from the primary in-
jury, which will require a different treatment strategy.
Comment: One point stares me in the face from your data:
You have effectively treated secondary insults, which
we have all been targeting for so many years, but the
primary insult overshadows that treatment. How do we
define the mechanisms for the primary insult?
Question: Some of us have advocated utilizing two dif-
ferent compounds in treating acute head injury. From
your management standpoint has anybody ever thought
about the possibility of combining a particular com-
pound or therapeutic agent with a management style
that could dictate what sort of patient should be a can-
didate for a particular treatment?
Answer: I think that the individualization of treatment for
a particular patient’s injury is a way to approach the
problems that we are seeing. We used a very specific
definition of ischemia; that is, a global ischemic insult
sufficient to reduce the SjvO2 below 50%. I think that
is good evidence that the brain is being hypoperfused.
Whether it is actually ischemic or not is another ques-
tion.
Question: Your previous studies have shown that patients
who have few desaturations do much better. Have you
not shown here that you can potentially improve neu-
rological outcome, but overall outcome depends on the
systemic complications? Therefore, should you try to
find a way to eliminate the systemic complications,
rather than concluding that improving the perfusion did
not improve neurological outcome?
Answer: We would agree that reducing secondary ischemic
insults is a good thing to do. However, trying to main-
tain all patients at an artificially elevated CPP may not
be the best way to approach this because of systemic
complications associated with this preventative treat-
ment. One alternative that can be applied right now is
to only elevate CPP in those patients who really need a
higher CPP to adequately perfuse their brain.
National acute brain injury study: hypothermia (Guy
L. Clifton, M.D.). For the recent hypothermia trial, our
primary question was: Does early induction of hypother-
mia to 33°C for 48 h improve outcome with low toxic-
ity? It did not.
The trial was set to detect a 10% shift in dichotomized
GOS. That is Good Recovery/Moderate Disability ver-
sus Severe Disability/Vegetative/Dead. The inclusion/
exclusion criteria were as usual for most trials in TBI: no
gunshot wounds, randomization within 6 h of injury, ex-
clusion of major multiple trauma. There were 11 U.S.
centers in the trial at different times. Four centers ran-
domized a total of 33 patients before they were dropped
from the trial for various reasons, and two other centers
came into the study rather late; therefore, five centers ran-
domized 88% of the patients. From the very start of the
trial, we paid serious attention to early cooling and com-
plication rates. Our goal was to reach a core body tem-
perature of 33°C by 8 h after injury. Temperature and hy-
pothermia-related complications were reported to the
Performance/Safety Monitoring Board on a regular ba-
sis. We saw no significant demographic differences be-
tween the two treatment groups (hypothermia vs. nor-
mothermia), so our randomization was effective. Within
the hypothermia group, eight patients did not reach tar-
get temperature. In the normothermia group, the mean
temperature in the first 96 h was 37°C. The hypothermia
patients were cooled to reach 33°C by 8.4 6 3h after in-
jury. Randomization was at 4.3 h after injury. Patients
remained hypothermic for 48 h and were re-warmed very
slowly over 18–24 h. From pilot work we knew that this
slow rewarming was very important.
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Overall, there were differences in management of the
two study groups for only two areas. One difference was
that hypothermia patients received more fluids, with a
mean fluid balance of 3 L positive over 96 h. Normoth-
ermia patients were about 1.6 L positive. That difference
was significant. Hypothermia patients also received va-
sopressors for about 80% of their total hours in the first
96 h, and normothermia patients 69% of those first hours.
There was a concern expressed during peer review of
the grant application that this was an unblinded trial, and
everybody wanted it to work; the personnel who most
wanted it to work would manage the hypothermia pa-
tients differently in some way. So we evaluated treatment
intensity using a standard scoring system to quantify the
number and intensity of interventions. It was the same in
the hypothermia and normothermia groups. Despite the
use of hypothermia, there was no evidence that one group
was managed more vigorously. We targeted a CPP of
.70 mm Hg based on the best information available be-
fore the trial. In the first 96 h in ICU, 97% of the patients
had a CPP under 70 mm Hg at some point, so virtually
everybody experienced an episode for some period.
About 40% of the patients had a CPP under 50 mm Hg
at some point. The “percent hours under 50 mm Hg” was
small (about 2% of hours); the “percent hours under 70
mm Hg” were about 10% of the hours monitored. So,
while patients did drop under 50 mm Hg, they did not
stay there long.
Our data show that there are critical management
thresholds which adversely affect outcome if they occur
at all: CPP , 60 mm Hg, ICP . 25 mm Hg, and MAP ,
70 mm Hg. The incidences of these critical thresholds
were the same in both treatment groups.
We saw a difference between the incidence (time) of
ICP . 30 for the hypothermia and normothermia groups,
and it was a big difference, about 25%. We found a de-
crease in the numbers of patients with ICP . 30 mm Hg
and .40 mm Hg in the hypothermia group. It seems that
hypothermia reduced the incidence of high ICP.
The mean arterial pressures (MAPs) were not differ-
ent between the groups; but, considering the occurrence
of MAP , 70 mm Hg, there were more of these patients
in the hypothermia group. The MAP reduction was off-
set by the significant ICP reduction, so that if you look
at the hourly occurrences of CPP , 50 mm Hg, you do
not see a difference between the groups. Overall, there
was a slight but statistically significant increase in com-
plications in the hypothermia group. There was no treat-
ment effect in terms of the primary hypothesis: 56.9% of
patients had poor outcomes in the hypothermia group,
56% in the normothermia group. The mortality rate was
28% with hypothermia and 27% with normothermia.
We looked at the effect of hypothermia on GCS sub-
groups, age subgroups, presence of operative hematomas,
subarachnoid hemorrhage, time to target temperature, and
admission temperature. An effect of hypothermia was
seen in older patients and in patients who were hy-
pothermic on admission. We found that in the patients
over 45 years old, there was an 89% poor outcome in the
hypothermia group, and a 69% poor outcome in the nor-
mothermia group. This difference was highly significant.
The cause of this outcome was an increase in medical
complications; there were statistically significant in-
creases in bleeding, sepsis, and pneumonia in the hy-
pothermia group over 45 years of age.
Over 20% of patients were hypothermic (#35°C) on
admission, and the mean temperature over the first 8 h
for this group was about 33.7°C. The mean admission
temperature for the rest of the patients was about 36.2°C.
The patients who came in hypothermic and who were
randomized to normothermia warmed very slowly over
16–18 h after admission. Patients hypothermic on ad-
mission who were randomized to hypothermia had 61%
poor outcome; “hypothermia-on-admission” patients ran-
domized to normothermia had about a 78% poor out-
come. This difference is significant.
The overall treatment effects for the five largest cen-
ters are summarized: Houston had a 5% positive (15%)
effect for hypothermia; Sacramento, 24%; Pittsburgh,
114%; St. Louis, 214%; and Indianapolis, 220%. There
were significant differences in CPP management among
centers; however, we cannot detect a correlation with
treatment effect. It appears that differences in baseline
variables among centers in numbers of older patients
and/or patients who were hypothermic on admission
caused this effect. My conclusion is that patients over 45
years old should not be cooled. In addition, I think we
missed the treatment window.
Question: If you sort out the subset that was GCS 5-8,
comparable to the phase II Pittsburgh study by Mar-
ion, did that stand up with a significant effect?
Answer: No. We found a 7% treatment effect in the GCS
5–8 patients; Marion reported a 38% treatment effect.
In his study, he actively rewarmed patients who were
hypothermic on admission over a period of approxi-
mately 6 h. In the laboratory, rapid re-warming wors-
ens outcome. In our phase III study, we allowed pa-
tients to rewarm spontaneously. In Marion’s phase II
normothermia treatment group, there was a 66% poor
outcome for the GCS 5–8 patients. Our phase III trial
showed a 52% poor outcome for this group. There had
been an unexpectedly bad result in normothermia pa-
tients the earlier Pittsburgh study. Dr. Marion and I
think that the discrepancy may relate to active re-
warming of the patients. In addition, I think the effect
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seen at Pittsburgh in our phase III trial may have been
due to an increased number (36%)of patients who were
hypothermic on admission.
Comment: In stroke patients who were rewarmed over 
24 h the fatality rate was directly related to increased
ICP. If patients are rewarmed over 48 h, there is none
of the elevated ICP. Frankly, I think that a problem in
your phase III trial was that the treatment groups were
not well matched.
Answer: Fewer older patients in the hypothermia group
in combination with admission hypothermia would
maximize the probability of a treatment effect in any
center.
Comment: Perhaps hypothermia should be viewed as a
potential measure to buy time for the introduction of
other therapies (e.g., drugs), rather than as a primary
treatment.
SCIENTIFIC ISSUES
Developing New Pharmaceutical Agents
(Edward Hall, Ph.D.)
How do we maximize our chances for success in de-
veloping effective drugs for head injury? First, there must
be a target mechanism. We need to demonstrate the time
course of that mechanism in relevant animal models. For
any potential therapy, we must perform rigorous dose-re-
sponse studies to see the effect of the drug (or treatment)
on the target mechanism and any associated pathophys-
iology. For studies advocating neuroprotection, we actu-
ally need to demonstrate histological preservation. 
Ideally, we should show some behavioral benefit of treat-
ment before going forward clinically. The neuroprotec-
tive action should correlate with plasma and brain phar-
macokinetics. We have not done a very good job of this
for many drugs considered in phase III trials.
We need to come up with relevant, easily available
biomarkers. For instance, lipid peroxidation products
have been shown to increase in the plasma in ischemic
brain injury and in subarachnoid hemorrhage patients.
We could use such biomarkers to correlate plasma and
brain pharmacokinetics with modification of the marker
in plasma and brain. This relationship would show that
the drug could actually affect the selected target mecha-
nism.
We need to compare single versus multiple dose reg-
imens. Much of the preclinical evaluation of neurophar-
macological agents involves administration of a single
dose at some time point. Regimens studied have been to-
tally empirical in the majority of preclinical and clinical
trials. There are very few examples of systematic evalu-
ations of the efficacy of a single dose versus sustained
dosing; and, looking at sustained dosing, the duration of
the treatment. An example is found in the National Acute
Spinal Cord Injury Study (NASCIS) II and III studies,
and the story of methylprednisolone in spinal cord injury.
Based on careful preclinical studies, it was apparent that
bolus administration plus an infusion for some period of
time made the most sense. I think that for many kinds of
agents that we have considered for trauma, this type of
regime would make sense. We simply have not done ad-
equate therapeutic window studies in our animal models
in most cases. Furthermore, when we do have such data,
we tend to ignore it when we go to the clinic. Our ex-
cuse has been that the therapeutic window in a rat is prob-
ably not relevant to humans; however, we do not really
know that.
I will quickly summarize how we evaluated methyl-
prednisolone in acute spinal cord injury models, and how
that preclinical work successfully translated into clinical
efficacy. The mechanism that we targeted was lipid per-
oxidation. We had shown that lipid peroxidation in the
injured cat spinal cord is a rapidly evolving process that
begins within the first minutes after injury. We also
showed that you could look at lipid peroxidation in terms
of depletion of antioxidant levels, specifically vitamin E
levels within the injured cord. Vitamin E is consumed as
it quenches lipid peroxidation reactions, and by 4 h
postinjury there is an 80% decrease in vitamin E in the
injured cord, consistent with fulminant lipid peroxidation.
We hypothesized that a steroid drug like methylpred-
nisolone might be useful for inhibiting posttraumatic lipid
peroxidation. In addition, we demonstrated that very high
doses of methylprednisolone were needed, and that there
was a peculiar U-shaped dose response curve. A lot of
steroid was good, but a lot more was not better. We also
picked a physiological parameter, posttraumatic decline
in blood flow within the injured white matter of the cord,
and we showed that the dose-response for the efficacy of
methylprednisolone to reduce decline in the blood flow
was the same dose-response curve that we had seen in
inhibition of lipid peroxidation. We went on to show that
blood flow decline was related to lipid peroxidation.
When we pretreated animals with large oral doses of vi-
tamin E, the expected decline in white matter blood flow
was completely attenuated. We also looked at a marker
of energy metabolism, tissue lactate, which is increased
dramatically at 1 h postinjury. We showed that methyl-
prednisolone could affect that increase, but a 30 mg/kg
dose was required. Again, there was a peculiar U-shaped
dose response curve. We showed that you could corre-
late tissue lactate levels in the injured cord with the lev-
els of methylprednisolone within the injured cord. At the
peak of methylprednisolone concentration after an i.v.
bolus, there was a suppression of posttraumatic lactate
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accumulation. As methylprednisolone levels decreased,
lactate rose. This result implied that a single dose was
not adequate to take care of the pathophysiology, and that
multiple doses needed to be given. We went on to show
that indeed multiple dosing maintained the beneficial
metabolic effect. We also showed this dose regime had
a beneficial effect on neurofilament concentration. By 
4 h postinjury, calpain-mediated degradation results in
tremendous loss of neurofilaments. A single early dose
of methylprednisolone had a small effect, but multiple
doses that maintained the drug levels at an adequate con-
centration had an even better effect.
We went on from there to design a 48-h dosing regi-
men in collaboration with Doug Anderson and Gene
Means, then at the University of Cincinnati. We showed
that an antioxidant dosing regimen of methylpred-
nisolone, facilitated neurological recovery in a cat model
of spinal cord injury. Bracken et al. translated all this pre-
clinical information into success in NASCIS II. The trial
used high “antioxidant” dose levels of methylpred-
nisolone for a 24-h period, and showed that, if treatment
began within 8 h of injury, there was a beneficial effect.
We went on to develop Tirilazad, which is a nonglu-
cocorticoid steroid inhibitor of lipid peroxidation. We did
extensive dose-response studies in spinal cord injury
models, and showed a benefit over a broad dose range.
We showed that there was a 4–8 h therapeutic window,
very reminiscent of the clinical trials with methylpred-
nisolone. Subsequently, the NASCIS III trial looked at
24-h and 48-h treatment with methylprednisolone, as well
as 48-h treatment with Tirilazad. The trial showed that
all of these treatments had some effect and that 48 h of
methylprednisolone was better than the 24-h regimen.
For TBI, we need to compare efficacy in multiple mod-
els, looking at both diffuse and focal injury, subarach-
noid hemorrhage, and ischemia. The most thorough eval-
uation of a single agent for the treatment of head injury
very likely needs to take place in all of these types of
models. Another issue that needs consideration relates to
possible differences in response for male and female an-
imals. We have looked at this issue using the impact ac-
celeration model of closed TBI. We find that during the
first hour after injury (1.5-M weight drop, 500 g) there
is about 25% mortality in males. There is no mortality in
weight-matched females subjected to the same injury par-
adigm; however, there is a “male-like” acute mortality in
ovariectomized females. We also examined blood flow
in the injured cortex (laser Doppler flowmetry), and saw
in males a massive, early drop in flow that was main-
tained over 90 min. Females showed a greater mainte-
nance of blood flow in the cortex after injury, whereas
ovariectomized female rats responded like males. Estro-
gen, the putative source of the post-traumatic difference,
is a very complicated story; however, gender difference
is one of the confounding factors that we need to take
into consideration in future clinical trials.
I support the idea of trying to take the NASCIS II dos-
ing regimen into human TBI. I still continue to believe
that the antioxidants have great therapeutic potential. I
also want to emphasize that we need to think about other
approaches to the treatment of traumatic brain injury. Our
focus has been on neuroprotection, but also we need to
think about neurorestorative approaches. There are a
number of potential strategies that we might use to try to
induce structural plasticity within the injured brain. For
instance, the compound OP1, which is a bone mor-
phogenic protein, has been shown to facilitate recovery
in stroke models with delayed administration until 24 h
postinjury. Aiming at neural cell adhesion molecule
(NCAM) antagonists or antagonists of the myelin-derived
Nogo (ligand recognized by the myelin antibody, IN-1)
protein are other approaches that I think need to be con-
sidered. Neurorestorative strategies might get us around
some of the therapeutic window issues that have plagued
acute neuroprotective strategies.
Question: Was the time window for methylprednisolone
established in animal models of injury?
Answer: No. That was one thing that we did not do ad-
equately. We did not do very complete therapeutic win-
dow studies with methylprednisolone in the cat model.
We did have some data on delayed administration of
methylprednisolone showing less of an effect after 2
h, but we did not look at it systematically.
Question: Do you think that the animal models represent
the clinical situation?
Answer: Yes. I have long wanted to believe, as many of
my colleagues here want to believe, that a 2-h thera-
peutic window in a rat perhaps translates to 8 h in the
human. We do not know that. I think we have to take
the animal therapeutic window seriously as we plan
clinical trials, because we do not really know that they
are different.
Preclinical Testing of Drugs (Tracy McIntosh,
Ph.D.)
The speakers this morning did not blame our current
disappointment with clinical trials on a lack of fidelity of
the animal models to clinical TBI. Head injury is diffi-
cult to model because of its heterogeneity. It is admit-
tedly very challenging to develop a rodent model, or other
animal model, that possesses all of the features of human
injury. Experimentalists acknowledge and respect the dif-
ficulties regarding clinical trials: the heterogeneity of pa-
tients, and the challenge of demonstrating efficacy with
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a single compound, using a single dose. We face many
of the same problems in the laboratory. What then should
be considered when modeling TBI? One issue has been
the relative lack of funding for vigorous preclinical tri-
als. Many sponsors are reluctant to support preclinical
trials that address the relevant mechanisms, such blood
flow, metabolism, and receptor changes. The emphasis
has focused solely on efficacy with one dosing regimen,
one drug, and one outcome measure. This narrow ap-
proach can be frustrating for investigators who have spent
years documenting the pathobiology and clinical rele-
vance of these injury models. We need to recognize that
there are several reasonably good preclinical models of
TBI; then, we need to agree on which ones to use, use
them collectively, and share data.
Most laboratories are all working with models that in-
clude both focal and diffuse injury. However, we know
that the pathobiology of a focal injury is different from
that of a diffuse injury. There is no model of inertial in-
jury (inducing diffuse axonal injury without focal contu-
sions) that is available to all laboratories; but there are
excellent, relevant models of mixed diffuse and focal in-
jury. A number of these models can be used successfully
to mimic those mixed injuries that one sees clinically.
Decades ago the existing experimental TBI models were
not clinically relevant, so people relied on preclinical data
from other diseases. But now several of the models have
been characterized and are believed to accurately mimic
the heterogeneity of human TBI. It would be wonderful
if we could all agree to use these pre-clinical head injury
models as the basis of our clinical trials.
What preclinical criteria should be standard or accepted
before we move on to clinical trials? Clinical trials have
at times gone forward based on results from one labora-
tory, or without any preclinical data from a relevant TBI
model. We must use multiple models (focal, diffuse,
mixed) to evaluate these compounds before they go into
patients. Moreover, in the laboratory we most often use
models of moderate, or mild/moderate head injury. Even
if clinical trials are selecting drugs that we have tested
preclinically, but go forward to test them in severely head
injured patients, are we making a mistake? Should we
widen the scope of trials and test the preclinically effec-
tive drugs in mild/moderately head-injured patients?
Another topic that Ed Hall emphasized is that of
“polypharmacy.” Currently, there are few studies per-
formed in TBI laboratories that combinations of drugs.
It is very difficult to test the interactions of multiple drugs
in the laboratory, but we must recognize that we have
seen the list of pathogenic factors that are active in TBI
increase over the past decade, and continue to get longer.
One treatment is not likely to inhibit or attenuate all the
many pathological mechanisms. Dose-response and ther-
apeutic critical window studies must be performed. I sug-
gest that clinical trials not begin unless the compound or
proposed treatment has been tested in one or more valid
preclinical models of head injury, by several reputable
laboratories looking these issues.
Question: There are many studies that showed protection
utilizing so-called valid preclinical models that have
not translated to the human setting. How can we re-
spond to that?
Answer: Two possible reasons are the differences be-
tween severities of injury and the means of outcome
assessment. Many preclinical studies that have been
used as the basis for clinical trials have not used be-
havioral endpoints as their outcome measures. As we
know, clinical trial endpoints are predominantly behav-
ioral. There needs to be more consistency between the
pre-clinical findings and the clinical studies. If you want
to study the effect of a compound on ICP/edema in head
injury patients, then positive ICP/edema data should be
generated first in some relevant preclinical model. If you
want to assess a GOS at 1 year, it would be inadvisable
to take a drug to trial that has only been shown to re-
duce acute edema. Long-term neurobehavioral end-
points are extremely important in the preclinical data.
Question: What is the best animal model?
Answer: The lateral fluid percussion model in the rat has
been the most successful and widely used preclinical
model to study acute pharmacological intervention.
The pig brain is more gyrencephalic and similar to hu-
mans, but no one has developed suitable behavior tests
for functional evaluation in this species. We are cur-
rently limited to the rodent models with respect to be-
havioral endpoints.
Outcome Measures (Graham M. Teasdale, M.D.)
There is not a gold standard, numerical outcome mea-
sure for “behavioral outcome.” It is always necessary to
compare against something, and different perspectives
can account for the different outcomes that people want.
Perhaps we want to compare people with their healthy
selves: are patients back to what they were before injury?
That is difficult to assess in an individual. We tend to
compare against population norms, but head injuries are
not a random samples of the population. Those who treat
these patients know how bad they were in the early stage,
so that patient survival is a kind of triumph. Yet that
clearly is not sufficient. What is the natural history of
TBI: are the patients getting better faster than without
treatment?
For any particular clinical question, the outcome mea-
sure must be relevant to the question, must be robust
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enough to be used widely, and must influence people to
decide that your findings are valid. The GOS is still the
most widely used index, more than 25 years after Jennett
and Bond described it. It has withstood the test of time
because it has many useful attributes. One of the things
that have happened over the years is that people have
tended to misuse it, and think of it as a scale for physi-
cal outcome. It is not. The authors emphasized social as-
pects of outcome. Really, it is more of a handicap scale
than a disability scale, determining a person’s indepen-
dence in society and return to previous lifestyle.
Many years ago, the categories of survival that makeup
the GOS were subdivided into upper and lower degrees
of severe and moderate disability and good recovery, but
the approach did not really catch on. Consequently, the
five-category scale is the most widely used outcome
scale, and has been for two decades. Whatever we do we
must keep the GOS in the picture, or we cannot compare
what we do in the future against history.
To some extent, the attributes of this scale can be dis-
advantages. It is so easy to use that it can be misused,
and it can be done so quickly that it can be done super-
ficially. It is open to varying interpretations; and doctors
tend to underestimate disability, compared to what a rig-
orous discussion with the patient or caregiver by a psy-
chologist gives. Professor Lindsay Wilson and I have de-
scribed a structured interview for allocating people to the
different GOS levels, getting away from the subjective
approach that had been misused over the years. The ap-
proach sets out the questions that should be asked, and
the answers provide a guide to the allocation of subjects
on the original five-point scale or on the extended eight-
point scale of the GOS. The structured approach dra-
matically increases interobserver reliability. Both origi-
nal and extended scales show very strong correlations
with a host of neuropsychological measures. More re-
cently, we have developed a postal version of the ques-
tionnaire that shows very good correlation with a face-
to-face interview.
Another issue concerning outcome is how outcomes
distribute in real life. Is the “U-shaped” distribution real
in a series of head injury patients? A large proportion die
and, of those who are alive at 6 months, most have made
a good recovery. With the customary approach to di-
chotomization (D/V/SD vs. MD/G recovery), the divi-
sion is at a point where there are very few patients. It is
most difficult to show a treatment effect.
Maas provides an excellent paper that discusses the use
of GOS in TBI trials. Various suggestions are made on
dichotomization of the scale, statistics, and patient se-
lection. Narrowing selection to exclude the most severe
as well as the mildest injuries has the advantage of ob-
taining the same power from a reduced number of re-
cruited patients. This is statistically more efficient and
may also be biologically more efficient.
Nevertheless, I wonder about the message that the ben-
efit of a new treatment is that it increases the number of
people with moderate disability. That kind of result is rel-
evant, but how influential and how generalizable will it be?
The approach to dichotomization needs to be examined,
and the dichotomization point set differently for different
severities of initial injury. Splitting severe versus moderate
and better, the classical unfavorable versus favorable di-
chotomy is probably relevant to severe head injury, as we
have always defined it. In the milder head injuries, a bet-
ter discrimination may be moderate disability versus good
recovery at 1 year. In an unselected series of mild injuries
in Glasgow, we found that at 1 year only 50% of subjects
make a good recovery. By shifting the dichotomization
point from severe/moderate to moderate/good, a valuable
effect in mild injury can be shown with the GOS.
To test this approach, Murray took into account age,
coma score, pupils and CT scan findings to produce four
broad “prognostic bands.” The approach was applied to
the patient population in the EBIC core databank. This
produces a clear relationship between the outcome dis-
tribution and the early prognostic band. Then, in each
band, the population was dichotomized into approxi-
mately equal halves. In the poorest prognosis band, the
relevant dichotomization is between upper and lower se-
vere grades on extended GOS (GOSE). For those with not
quite as bad a prognosis, the dichotomization for outcome
might be drawn between upper and lower moderate dis-
ability; for those with better prognosis, dichotomization
falls between moderate disability and good recovery. With
a population at entry of mostly mild TBI patients, di-
chotomization could move to between upper and lower
good recovery. This may be a way of using the data to
maximum effect, building in early prognosis, and relat-
ing that to the expected effect of treatment. This “roving
dichotomy” gets away from the traditional split in a way
that clinicians will find intelligible and relevant.
Early indices of effect (so-called surrogate outcomes)
may be very interesting biologically, may be very sensi-
tive, but may not predict the eventual clinical benefits.
For dose-ranging or proof-of-concept studies, surrogate
indicators might be useful. If the interest is general clin-
ical adoption, there must be some index of outcome re-
lated to quality of life and function. It would be no 
surprise that I am skeptical about the value of ICP mea-
surements as a surrogate indicator. There are now stud-
ies that show discrepancies between effects on ICP in the
early stage, and ultimate patient outcome. In a classic
study on hyperventilation, high ICP was more common
in the control group, but outcome was actually better.
Two similar examples have been presented at this meet-
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ing. In Robertson’s study, the ICP profiles were better in
the group with worse outcome. In Clifton’s trial, there
was a 20% reduction in ICP . 30 mm Hg in the hy-
pothermia group, but no difference in outcome. As a sur-
rogate index of outcome, ICP clearly has flaws.
Question: Could you address the role of imaging in as-
sessing outcome?
Answer: If the question concerns the degree of swelling,
then magnetic resonance (MR) or CT would be fine. If
your question relates to overall functional outcome there
are problems. In head trauma there is no visible MR in-
dex that correlates with the degree of axonal injury. If
you are going to use MR to look for changes, I think
you must use magnetization transfer or another sort of
numerical index. You need a measure of white matter
injury that will respond to an intervention and that any
change will correlate with later outcome. I think people
have misused the term, “surrogate outcome measures”;
they want to use it as the sole indicator of whether treat-
ment is good or not. I think it is better used as a way to
determine if a treatment is effectively targeted.
Question: I am troubled by the experience in AIDS re-
search, where it took 10–12 years of unfocused work,
lacking progress toward treatment, until researchers
managed to crack the issue of finding the best surro-
gate indicators of their disease, the CD4 counts of vi-
ral load. They had a number of false leads before they
could define a measure of whether a therapy is going
to make a difference. We have to keep looking for that
particular surrogate indicator for TBI.
Answer: In fact, I think that there are many early mark-
ers that correlate with outcome, but we have to go be-
yond that conceptually. The desired early marker must
correlate with the effect of treatment on outcome. Such
a correlation remains to be demonstrated.
Selecting Outcome Measures (Nancy Temkin,
Ph.D.)
In order to have a successful trial, patients need to have
room to improve. Many studies target severe injury based
purely on GCS and select a primary outcome of good re-
covery/ moderate disability on the dichotomized GOS.
For severe TBI, about 64% of patients in our studies do
well at a year, versus close to 100% in trauma (not ner-
vous system) controls; that leaves only 36% of patients
who could improve. If you include moderate injuries
(GCS 9–12) there is only about 13% room to improve on
a dichotomized GOS as the primary endpoint. If you use
other endpoints (for example, performance IQ or return
to work) you can use less severe cases, and still have
plenty of room for these people to show improvement.
What sorts of outcome measures are appropriate? Us-
ing a simulation for the population of the magnesium sul-
fate study, we plan for 400 cases; both moderate and se-
vere head injuries. Inclusion is not limited to GCS 8 or
less, but goes up to GCS 12 or less and anyone who has
an emergency craniotomy. For our simulation, the dif-
ference to be detected is 10% more subjects in the “good”
range on a dichotomized GOS. For the severe cases, there
is 36% room to improve on that outcome; 13% room to
improve for patients with moderate injury. For the di-
chotomized GOS in this trial, there is one chance in four
of having a successful trial to show the difference. If you
use the full GOS, all five categories, power increases to
about 50%, one chance in two of having your trial have
a significant result. If you choose performance IQ, power
goes to a 66% chance of seeing a difference; for selec-
tive reminding recall (a test of verbal memory), the power
is 99%. Based on these calculations, our primary end-
point is a composite measure of survival, seizures, func-
tional status measures, and neuropsychological measures.
We have chosen a different approach to some of the same
problems brought up by others by targeting a broad pop-
ulation with a more sensitive outcome.
Question: What are priorities for research? How much
need is there for identifying good measures of patient
assessment verses the need for better therapeutic agents?
Answer: There is a need for both. There are two aspects
to any assessment question. There is assessment of
severity and type of injury in order to target the popu-
lation and to make sure your treatment groups are bal-
anced, either by design or by modeling in the analysis.
There is also the need to assess outcome, and I think
that the measures exist. We have a lot of data on as-
sessment tools that have not been used in clinical trials.
I think there are unfortunate perceptions, many un-
founded: that the FDA will not accept them, that they
are too difficult, that you cannot train people to give
them, patients cannot take them. Absolutely, it does take
significant oversight to obtain good neuropsychological
data. You cannot provide a one-page instruction sheet.
Examiners must learn the measures, and know them
well; that is a problem if you have two or three patients
per year at a site. But, if you can do trials where you
have even a moderate number of patients at a site, you
can use much more sophisticated outcomes than the di-
chotomized GOS. Neuropsychological testing seems to
be the most powerful but there is also the GOSE, which
has recently been published. We have just submitted a
paper on functional status examination. The note of cau-
tion for any outcome is that you must take into account
in the power calculation that you will not have 100%
follow-up even under ideal circumstances.
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Question: I found your comments regarding the “neu-
ropsych” measure very interesting. How do you assess
patients who are severely injured, with a much less fa-
vorable outcome, where you cannot test?
Answer: For patients who die, we assign the worse possi-
ble score. Some patients, badly impaired or vegetative,
cannot do the tests. We assign them one better than the
least score, but worse than anything that can actually be
assessed. You must specify all these things in the pro-
tocol, but it is not an insurmountable problem.
Question: I think the return to work measure is very im-
portant. Many TBI survivors are more incapacitated by
their behavioral difficulties than by their cognitive dif-
ficulties. Are you looking also at sustained work, that
is, staying at work more than 180 days? What do you
do about the substantial portion of patients who are not
gainfully employed at the time of their injury?
Answer: We did not look at retention, just whether pa-
tients were working or not at the time of their 1-year
assessment. We collect information on the date that
they went back to work and their entire work history
until the end of assessment, 2 years for most patients
in our trials. In our experience, about 20% of the con-
trol and treatment cases were not working.
Choice of Primary Endpoints (Sung C. Choi,
Ph.D.)
A biostatistician’s view of appropriate primary end-
points might be different from a neurosurgeon’s. Prereq-
uisites for an ideal primary outcome measure include the
following:
1. The measure should be ordinal. “Ordinal” means that
the measure must have inherent rank order in its scale.
2. The measure should be able to be interpreted in the
magnitude of a potential treatment effect.
3. The misclassification rate should be minimal.
The most widely used outcome measure in clinical tri-
als of severe head injury is the GOS. The scale consists
of five categories: good recovery (GR), moderate dis-
ability (MD), severe disability (SD), vegetative (V), and
death (D). The GOS is ordinal. In most trials, the GOS
is dichotomized to favorable (good) outcome by com-
bining GR and MD, and combining the other three cate-
gories as unfavorable (poor) outcome. Making SD as a
separate third category could trichotomize the GOS. The
GOS also could be used as a four-category outcome mea-
sure by combining only V and D.
Another outcome measure, advocated by some investi-
gators is the DRS. The DRS ranges from zero to 30, where
zero is the best score and 30 is death. The measure is the
sum of eight individual items. Clearly, each individual item
is ordinal but the DRS would be no longer strictly ordinal.
For example, a patient could have a better DRS than the
second patient simply because he/she has much better
score in communication while the second has a better score
in feeding. Even so, the DRS is approximately ordinal (i.e.,
stochastically ordinal) in the sense that if one patient has
a better score than a second patient, the overall outcome
of the first patient is likely to be better.
The Functional Independence Measure (FIM) is an-
other well-known, potential outcome measure. This mea-
sure might be considered an extension of the DRS. The
FIM is a sum of 18 items, with each item scored from 0
to 8. Like the DRS, the FIM is not strictly ordinal. A
measure such as the DRS and the FIM, which is made
up many items, can be called a composite measure. In
general, composite measures can be only approximately
ordinal, and therefore, the measures do not possess the
property of a desirable measure.
The primary advantage of the GOS is that it is both
easy to interpret and can quantify the potential efficacy
of a treatment. The interpretation can be difficult with the
DRS or the FIM. Suppose that the treatment group has a
better average score than the control group by seven
points, in the mean or median of the DRS. The seven
points could indicate various degrees of difference in out-
come. For example, the seven points could be the dif-
ference between two vegetative states or that between no
disability and a moderately severe disability.
Next, we must consider the effect of misclassification.
The following is an example of hypothetical outcomes of
800 patients (Table 2).
Suppose every patient has a 10% chance of being ran-
domly misclassified to adjacent categories. Among 240
patients in the treatment group with good outcome, 24
would be misclassified to poor outcome, while 16 with
the poor outcome would be misclassified as good out-
come. Thus, the observed number of favorable outcome
would be 232 instead of 240. Similarly, the observed
number of good outcome in the control would be 208,
down from 210. As shown in Table 2, the difference in
outcome between the two groups decreases and the power
is reduced. The power decreases as the misclassification
rate increases. It has been theoretically shown that the
loss of the power due to misclassification can be sub-
stantial.
Clearly, the misclassification rate of an outcome mea-
sure with a large number of categories is likely to be
higher than in a measure with a smaller number of cate-
gories. For example, it is likely that misclassification us-
ing the three category GOS would be higher than in the
dichotomous GOS. Moreover, the misclassification rate
of the DRS or the FIM is expected to be higher than in
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the GOS. It should be noted that a part of the problem
with the DRS and the FIM is that each one of the many
component items can be misclassified, and that could
have cumulative effect on misclassification.
Finally, we consider the results of analysis of a sub-
group of patients from the recently conducted hypother-
mia trial. Briefly, 392 patients aged 16 to 65 with severe
closed head injury were randomized to hypothermia
(33°C for 48 h) or normothermia. The subgroup consisted
of 81 patients with age #45 years and the admission tem-
perature of #35°C. The significant probabilities (p val-
ues) based on the Wilcoxan rank-sum test using four dif-
ferent outcome measures are presented in Table 3.
We expected that the DRS would yield the most power,
and the dichotomous GOS would be the least powerful.
The results are completely the opposite. For this partic-
ular subgroup, the dichotomous GOS is the most sensi-
tive outcome measure. The reason for the seemingly
anomalous results becomes clear if the distribution of the
outcomes is examined (Fig. 1).
Note that the effect of hypothermia is mainly confined
to MD and SD, while the three other categories (i.e., GR,
V, and D) are not significantly affected by the treatment.
In the subgroup, the power decreased because all other
categories became the noise in the analysis. What this ex-
ample shows is that the power does not necessarily in-
crease as the number of categories is increased. Another
partial cause of the decreased power with more categories
in this example may be the increasing rate of misclassi-
fication, and in addition, nonordinality in case of the
DRS.
In conclusion, well-known composite measures such
as the DRS and FIM may be not ideal as the primary out-
come measure for clinical trials of severe head injury.
Such measures are often used as the secondary outcome
measures. These measures were shown to be effective in
monitoring the same group of patients over time. The
measures may also be appropriate in trials of moderately
injured patients in whom the GOS is simply not sensi-
tive enough. It is important to recognize that a larger num-
ber of categories do not always yield greater power. The
ideal number of categories is likely to depend on the ef-
fect of treatment, the misclassification rate and the shape
of outcome distribution. If the outcome distribution is
“U” shaped, as in the case of severe head injury, a smaller
number of categories might be better than a large num-
ber especially when the misclassification is taken into ac-
count.
Question: Scales like the DRS and FIM have not been
designed to create multi-dimensions. But the scales
supposedly have an ordinal and even an integral struc-
ture.
Answer: Some investigators think the DRS and FIM are
ordinal because there is a numerical order in the mea-
sure. Numerical order alone does not make a scale or-
dinal. As stated, the DRS and FIM are approximately
ordinal.
Question: Some of the available clinical data would show
patterns of effects; however, the dichotomous GOS
would not show any difference.
Answer: If all categories of the GOS are affected by the
treatment, then the test based on the dichotomous GOS
would be less powerful than using four or five cate-
gories. The dichotomous GOS would yield more power
when the primary effect of treatment is more or less
localized to two categories, as in the example of the
subgroup in the hypothermia trial.
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TABLE 3. EFFECT OF HYPOTHERMIA IN SUBGROUP (AGE #
45 YEARS AND ADMISSION TEMPERATURE # 35°C), n 5 81
Outcome measures p value
Dichotomous GOS (Favorable, Unfavorable)a 0.031
Trichotomous (GR and MD), SD, (V and D) 0.103
Five categories 0.176
DRS 0.196
aPercentage favorable outcomes were hypothermia 52.0%
and normothermia 75.8%.
GR (Good recovery), MD (Moderate disability), S (Severe
disability), V (Vegetative), and D (Dead).
TABLE 2. EFFECT OF MISCLASSIFICATIONS IN DICHOTOMOUS OUTCOMES: AN EXAMPLE
Without misclassifications With 10% misclassifications
Group Good Poor N Good Poor N
Treatment 240 160 400 232 168 400
Control 210 190 400 208 192 400
Difference (%) 60.0 52.5 7.5a 58.0 52.0 6.0b
ap 5 0.033.
bp 5 0.088.
Question: I think your point about misclassification is ex-
actly right. Misclassification is always a problem, and
if it is random it will reduce the power of the study. I
am a little concerned at your assertion that DRS and
FIM are not ordinal. I think that if that criterion were
applied, the IQ would not be ordinal. The predicted
value from a logistic regression with more than one
variable would not be ordinal, because it is made up
of a combination of parameters.
Answer: Some composite scores may be more ordinal
than others. I believe the DRS is less ordinal than 
the IQ because IQ is composed of fewer items than the
DRS. Similarly, the FIM is likely to be less ordinal
than the DRS. The predicted probability from a logis-
tic regression is most likely ordinal because the re-
gression coefficients and the prediction are mathemat-
ically determined from the data, such that the predicted
values based on the regression are order preserving.
The other point with the composite score is that it is
not clear how different items are weighted by giving
different range. The weight assigned to each item
seems subjective.
Question: You indicated that the number of misclassifi-
cations is linearly proportional to the number of cate-
gories. What is the evidence for that?
Answer: Clearly, if we create more categories by divid-
ing some or all of the categories, misclassifications will
tend to increase. In the GOS, for example, if we sim-
ply dichotomize, we would not have misclassifications
between good recovery and moderate disability.
Realistic Expectations from a Traumatic Brain
Injury Drug (Anat Biegon, Ph.D.)
Neuroprotective agents or therapies are defined by
their ability to prevent neuronal death in groups of neu-
rons damaged distally at the time of the original insult.
This is achieved through inhibition of physiological
processes (e.g., excitatory neurotransmission, cytokine
release, free radical formation, and temperature regula-
tion) that are acutely overstimulated following brain in-
jury. Thus, a neuroprotective agent is expected to im-
prove outcome by preventing the propagation of injury
to remote brain regions, in contradistinction to neu-
rorestorative interventions, such as growth factors and
transplants, which are expected to improve outcome by
replacing dead neurons. Based on this theoretical frame-
work and on what was considered to be relevant and en-
couraging pre-clinical evidence from animal models, 
several neuroprotective agents and procedures (e.g., Tir-
ilazad, Selfotel, Cerestat, hypothermia, D-CPP-ene) were
tested in phase III clinical trials in TBI and stroke. All
of the above trials failed to show efficacy of the test drugs
or procedures, and in some cases the outcome of the
treated group was actually worse than the outcome in the
control group (e.g., hypothermia in TBI, Selfotel in
stroke). The following detailed examination of the gap
between the expectations from neuroprotection based on
animal models and the results in human clinical trials may
contribute to our understanding of the failures in the
clinic, a well as to the design of more appropriate pre-
clinical testing and better clinical trials in the future.
Table 4 summarizes the features of the latest neuropro-
tection trials and the preclinical data used at the time to
support their testing in humans.
It is easy to see that the clinical trials and animal stud-
ies differed significantly in design and execution. In gen-
eral, the conditions under which the agents were tested in
humans have never been validated in animal models. Min-
imizing the gap using the strategies outlined below may in-
crease the likelihood of positive clinical trials in the future.
The lack of efficacy in humans can be largely attrib-
uted to the unrealistic therapeutic window (time between
injury and effective initiation of treatment). Animal mod-
els invariably show that glutamate antagonists, antioxi-
dants, and hypothermia are most efficacious when ad-
ministered before or during the insult. The efficacy of
these interventions drops precipitously with time, with no
effect seen for treatment delayed by more than 1–2 h. To
illustrate, Cerestat was never tested later than 15 min post
insult in a TBI model, and the hypothermia literature in
animal models showed conclusively that delayed appli-
cation of hypothermia is not neuroprotective. While it is
theoretically possible that the treatment window in hu-
mans might be somewhat longer than in animals, there
is no data currently available to support this notion or to
otherwise define the relevant treatment window in hu-
mans. The clinical experience with tPA, demonstrating
the drug is not efficacious in human stroke when given
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FIG. 1. Glasgow Outcome Scale scores at 6 months postin-
jury in patients ,46 years of age and admission temperature
%35°C.
more than three hours after onset, actually suggests that
the treatment windows for thrombolysis in animal and
human stroke are quite close. An optimistic expectation
that the time windows in human TBI will be consider-
ably longer was not supported by the results.
While late intervention can explain lack of efficacy, it
cannot explain unexpected toxicity. The detrimental out-
come of neuroprotective treatment observed in some of
the clinical trials (Selfotel/stroke, Cerestat/stroke; hy-
pothermia/TBI) is possibly attributable to the difference
in treatment duration. Blockade of NMDA receptors, cy-
tokine release, or core temperature regulation beyond the
therapeutic window appears to be useless and can be risky
since it might interfere with recovery. A growing body
of literature suggests that normal levels of NMDA re-
ceptor stimulation and TNF-alpha production are essen-
tial for neurodevelopment, CNS tissue remodeling and
plasticity. These processes are the basis of spontaneous
recovery of function.
In support of this explanation, in a recent experiment we
have shown that repeated (6 days) administration of the po-
tent NMDA antagonist MK801 in animals with middle
cerebral artery occlusion resulted in a significant increase
in the number of deaths over a 60-day follow-up period,
when compared to a single administration. Mortality rate
was 23% in vehicle-treated animals, 0% in the single treat-
ment group, and 38% in the repeated treatment group.
Similarly, Work from the McIntosh laboratory has
demonstrated that TNF-alpha knockouts have better short
term outcome (48 h), but worse long-term outcome in a
brain injury model compared to wild-type animals. TNF-
alpha knockouts actually simulate a chronic blockade of
the cytokine; and provide another example for the risk
involved in long-term blockade of processes that are only
activated acutely following brain injury. It is important
to note that the hazards of overlong treatment with neu-
roprotective agents cannot be predicted from repeated ad-
ministration paradigms in toxicological studies per-
formed on healthy animals or volunteers, since the risk
may very well derive from interfering with recovery
processes that only occur in the injured brain.
A common outcome measure in animal models of brain
injury is infarct size at 1–3 days postinsult. Recent hu-
man and animal data suggest this is not a valid or pre-
dictive endpoint. Results from the RANTTAS (Random-
ized Trial of Tirilazad in Acute Stroke Patients) stroke
trial show a poor, nonsignificant correlation between in-
farct size on CT in the early days after stroke and clini-
cal outcome after three months. Short- and long-term out-
come studies in animal stroke or TBI models are rare,
but data from spinal cord injury models in animals had
shown instances of dissociation between short-term re-
ductions in infarct size and long-term functional outcome.
These observations underscore the need to include func-
tional (“clinical”) endpoints in future pre-clinical studies
of neuroprotective agents.
The clinical outcome measures commonly used in clin-
ical trials in TBI are not problem-free either. The primary
outcome measure for the majority of recent clinical tri-
als in TBI required a 10% shift towards favorable out-
come on the dichotomized GOS. When this requirement
was formulated, severe head trauma (described in the
seminal paper from the traumatic coma data bank) en-
tailed a mortality of more than 40% while good neuro-
logical recovery was relatively rare. Over the last couple
of decades, a decrease in mortality and shift towards good
outcome has been observed in all recent clinical trials,
such that a 10% difference in favorable outcome is math-
ematically impossible to achieve. Thus, once the mortal-
ity rate drops below 20% in placebo treated patients (e.g.,
the Selfotel trial), a 10% shift in favorable outcome can
only be achieved if the drug reduces mortality by more
than 50%. This problem can be overcome if the patient
population is heavily weighted towards poorer outcome
by imposing inclusion criteria such as GCS , 7, CT .
2, or presence of SAH, but this may slow enrollment con-
siderably. On the other hand, detection of a 10% or more
improvement in good recovery is quite possible in the
broader severe head trauma population (GCS 4–8, CT
2–6, with or without SAH) as well as in the subgroup of
the less severe patients (GCS 7–8, CT 2).
Finally, assessment of clinical improvement by global
CLINICAL TRIALS IN HEAD INJURY
529
TABLE 4. FROM BENCH TO CLINIC: WHERE IS THE GAP?
Animal models Clinical trials
Parameter Stroke/TBI Stroke TBI
1. Treatment window Mostly ,1 h 3–8 h 4–8 h
2. Treatment duration Single treatment Several days Several days
3. Outcome measures Infarct size Clinical (e.g., GOS) Clinical (e.g., GOS)
4. Follow-up Mostly 1–3 days 3 months 6–12 months
5. “Adjunct” therapy None Multiple Multiple
6. Study population a. Young males Elderly men and women Mostly young men
b. Pure strains Genetic variability Genetic variability
scales such as GOS assigns unequal weight to rescuing
neuronal populations of equal size, thus contributing to
the extreme variability in outcome. Thus, damage to the
optic nerve will result in blindness (bad outcome on
GOS). Severing of the entire corpus callosum, a much
bigger axon bundle, will not be detected on GOS at all.
To decrease outcome variability, a scale based on re-
gional/functional systems (similar to EDSS [Expanded
Disability Status Scale]) is more likely to reflect the ex-
pected effect of a neuroprotective agent, that is, rescue
of neuronal populations at risk anywhere in the brain.
Data gathered from a variety of animal models of TBI
and stroke demonstrate that neuroprotective agents ad-
ministered within their therapeutic window have a reli-
able and highly reproducible effect on early outcome
measures such as infarct size or neurological function at
24–72 h postinjury. These results cannot be taken to im-
ply persistent long-term (3–6 months) benefit in animals
or humans. The only way to predict the long-term effect
of neuroprotective agents is to increase the length of fol-
low-up in the animal studies such that it is comparable
to the intended follow-up period in clinical trials. Inter-
estingly, in the very few studies evaluating the effects of
neuroprotective agents on functional, long-term outcome
available to date, it appears that the duration of the ben-
efit depends on the severity of the initial insult. Thus, in
moderate or mild insults, the early treatment benefit di-
minishes and disappears as control animals recover spon-
taneously over time. A stable, long-term benefit of treat-
ment is only observed in more severe injury models, such
that full recovery is not feasible with time alone.
Taken together, these observations suggest that neuro-
protective agents can be relied on to accelerate recovery
in all patients, but improve final outcome only in those
least likely to achieve good recovery without additional
intervention beyond standard care, rehabilitation, physi-
cal therapy etc. Thus one could expect neuroprotective
agents given to humans to reduce neuronal cell death and
improve neurological function at early time points, such
that treated patients will regain consciousness, leave the
ICU, leave the hospital and reach their final level of im-
provement faster than untreated patients. In terms of hu-
man suffering and medical costs, acceleration of recov-
ery might be almost as important as a difference in
long-term outcome. Therefore, it may be beneficial to add
early outcome measures to future clinical studies.
Obviously, patients within clinical trials should not be
denied any supportive or concomitant treatment that is
part of the standard of care in TBI. For a preclinical study
to be predictive of efficacy in the clinic, the drug/inter-
vention need to show efficacy in animal models in con-
junction with essentially similar supportive treatment,
such as maintenance of blood pressure, resuscitation etc.
Preclinical studies need to include both sexes and
young as well as old animals to be predictive of outcome
in the broad patient population.
A critical review of the available pre-clinical and clin-
ical data recently obtained with neuroprotective agents
leads to the following conclusions and recommendations:
 Neuroprotective agents should be tested within the
therapeutic window associated with their mechanism
of action in animals or, if the data are available, in
humans.
 Treatment duration in clinical trials should not ex-
ceed that which was found to be effective and safe
in animal models of TBI or stroke (not healthy ani-
mals or volunteers).
 Preclinical studies should include long-term func-
tional outcome measures and encompass more ge-
netic variability, both sexes and a variety of age
groups.
 Clinical trials of neuroprotective agents should em-
phasize speed of recovery by including appropriate
measures of this parameter as primary outcome cri-
teria.
 Dichotomization of GOS between “good recovery”
and “not good” (MD, SD, V, D) better reflects re-
cent trends in outcome and has the potential to pro-
duce larger group differences and smaller sample
sizes.
 A new scale for measuring brain system improve-
ment, constructed from EDSS with the addition of
items for cortical and subcortical regions gleaned
from recent functional imaging studies, employed re-
peatedly over time, might offer an advantage for as-
sessing the efficacy of neuroprotective agents.
Alternative Trial Designs (Charles Contant,
Ph.D.)
We are generally familiar with the nomenclature of
clinical trials as phase I, II, III, and perhaps IV. Pianta-
dosi has proposed an alternative naming system that I feel
is somewhat more descriptive. We seem to have the per-
ception that, in our field, we start with six mice and then
do a trial in 600 people. While this is hyperbole, I would
like to discuss the types of studies that occur between six
and 600. These are the phase II trials, or the safety and
efficacy studies discussed by Piantadosi. Phase II stud-
ies are performed to determine if evidence exists to con-
tinue the development of the treatment. These trials may
be performed to determine the safety profile of the treat-
ment, to determine the safest and most effective dose
(dose finding or dose ranging), and to evaluate whether
the treatment is efficacious enough to warrant further
study. These types of studies should be performed and
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evaluated before the commitment of resources to a large
randomized clinical trial. I do not believe that patients
should be exposed to a treatment unless there is evidence
that the treatment works in humans at the dose selected
without causing harmful side effects.
There are a large number of perfectly acceptable phase
II designs. I am often asked if a recipe exists for phase
II trials. Unfortunately, no template is available; most
phase II designs are crafted to answer the question being
asked. There are broad classes of designs. One important
caveat for the designs that follow is that most require that
the trial response variable can be quickly determined.
Few of the designs are appropriate for the 6-month out-
come assessment time used in most phase III TBI trials.
Therefore, one is usually assessing a surrogate indicator
of the 6-month outcome of interest. Such surrogates re-
quire much further investigation. One might argue, how-
ever, that if the treatment does not have an effect on a
pathophysiology induced by the injury, it has little like-
lihood of affecting the long-term outcome.
Fixed sample size trial. These studies are performed
to estimate a property of the treatment to a certain pre-
cision, or to determine if the treatment is better, in some
sense, than a “historical” control. In the first case, an ex-
ample would be to estimate the rate of a serious adverse
event so that the 95% confidence limit around the rate
was only 10% (65%). The actual rate is of less concern
than the precision with which it is estimated. The second
circumstance might occur as follows. Assume that the
current consensus is that a treatment works in approxi-
mately 40% of the patients, and that the new treatment
would be useful if it works in 60% of the patients. Un-
der these conditions, only 38 patients are needed to de-
termine if the rate is about 40% at the alpha level of 0.05.
This evidence is not sufficient to conclude that the drug
is actually better than the historical record, but only that
the drug is probably worth further development. The
fixed sample size designs can be appropriately used for
long-term outcomes.
Staged designs. The most versatile type of phase II trial
is the staged design. In this type of trial, one or more de-
cision point is designed into the study at which the study
can be continued or terminated. For example, the trial
may be conducted until a certain number of patients have
received the new treatment. At that time, the outcomes
are evaluated. If the treatment has performed up to a pre-
specified design criterion, the study continues in a sec-
ond group of patients until the final sample size is
reached. If the treatment does not reach the design crite-
rion, the study is terminated and the new treatment is re-
jected as not worth further consideration. The most well
known staged phase II design is that by Simon (Simon,
1989). This two-stage design is based on a binary re-
sponse (e.g., success/failure). The historical and new
treatment response rates are prespecified. Assume that
these rates are 0.40 and 0.60 as above. Unlike the fixed
sample size example, these rates define three regions. If
the treatment success rate is 40% or lower, the drug is
not worth further development. If the rate is 60% or
higher, continued development is assured. Between 40%
and 60% is the “indifference zone.” Should the treatment
success rate fall in this zone, factors other than treatment
efficacy will be used to determine further development.
Staged designs require fairly rapid assessment of out-
come.
For a Simon two-stage trial comparing 0.40 to 0.60,
the study proceeds as follows. Initially, 16 patients are
enrolled and evaluated. If seven or fewer patients have
successful outcomes, the trial is stopped and the treat-
ment rejected. If eight or more respond positively, a sec-
ond group of 30 patients are enrolled and evaluated. From
the final total of 46 patients, if 23 or fewer have suc-
cessful outcomes, the drug is rejected. Otherwise, the
drug is accepted for further study. Under this type of de-
sign, the sample size is either 16 or 46, with the average
being just 25.6.
Staged trials can also be designed for evaluating com-
plications, for selecting among doses, or selecting among
treatments. A staged-hybrid of the phase II and III trial
exists where the information from the phase II design is
used to determine the sample size of the phase III trial,
and all the patients are included in the final analyses.
There is clearly a wealth of possible staged designs,
which I believe should be used in the treatment devel-
opment process.
Selection trials. Selection designs are for a very fo-
cused group of phase II trials that are designed to select
a group of the best “treatments” from a larger group of
possible treatments. The best known of this type of de-
sign is the “dose-finding” study, in which the “treatment”
is the dose of the drug to be delivered. One potentially
useful definition of “treatment” is clinically distinguish-
able subgroups of the population. As we have head in
earlier talks, focusing a phase III trial on those patients
who have the greatest likelihood of responding to the
treatment is one way of improving the efficiency of a
trial. Designing a study to select these groups from the
larger population may be worth considering. For exam-
ple, a trial to select the best subgroup from a group of
four subgroups so that there is a 95% chance the actual
best subgroup was selected and that the response rate in
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this group is above 20% requires 53 patients per group.
While this seems like a large trial (212 total), if the gain
in power in the final trial is large, the total sample size
for the two studies may actually be lower than if the se-
lection had not been performed. Selection trials can be
used with long-term outcomes.
Sequential clinical trials. Sequential clinical trials fall
into two distinct groups: grouped sequential and fully se-
quential. Grouped sequential trials examine the data at
fixed proportions of the total accrual, or at fixed times.
Interim analyses are examples of grouped sequential 
designs. Whitehead has described the fully sequential de-
signs extensively. Technically these designs are not phase
II designs, as they require a randomized control group.
They also require an outcome that is rapidly available,
and are therefore only suited to the “surrogates” of the
long-term outcome. I am presenting them here because
they can be conducted fairly quickly and with potentially
much smaller sample sizes than a full-scale phase III trial
of long-term outcome.
Whitehead also proposed triangular designs. These de-
signs are based on selection of a region on a graph where
the null hypothesis is rejected, one where it is highly
likely that the null hypothesis will not be rejected, and a
region where the current information is not sufficient to
decide. Consider a study that has as its outcome a sim-
ple binary assessment of whether the patient experienced
transtentorial herniation during the first week following
severe brain injury. The horizontal axis is proportional to
the amount of information accrued, and expressed as the
total sample size. The vertical axis is the difference be-
tween the two groups. The area within the triangle de-
fines the region where there is not enough information to
make a decision. The rest of the graph defines areas where
a decision has been reached. The procedure is to graph
the statistic defining the current difference between the
two groups against the current information, or sample
size. Initially, the trial is in the “undecided” area. As the
trial progresses, the graph is updated with the new in-
formation. If a new point lands outside the “undecided”
region, a decision point has been reached. This is called
crossing the boundary. If the boundary is crossed between
points A and B, the decision is reached that treatment is
better than the comparison. If the boundary is crossed be-
tween points C and D, the decision is reached that the
comparison group is superior to the treatment group.
The sample size required for the herniation study, us-
ing a classical fixed sample size phase III design, is 194.
The sample size of the triangular design is actually a ran-
dom variable. The average sample size is 100 at the null
hypothesis, and 128 at the alternate. Fifty percent of the
trials run using this design will require 92 or fewer pa-
tients if the null hypothesis is true, and 123 if the alter-
native is true. At the null hypothesis, 90% of the trials
will terminate with 160 patients; at the alternate hypoth-
esis, 90% of trials will terminate with 199 patients.
Clearly, the sequential design has a high likelihood of
terminating sooner than the fixed sample size trial. The
worst case (rare, but possible) is that this design might
actually require far more patients, up to 296.
Sequential designs best illustrate why the outcome
should, preferably, be rapidly available. At any point in
time, there are patients who have been randomized but
have not reached the end of the assessment period. If two
patients are randomized a week, a 1-week outcome as-
sessment period leaves only two patients in “limbo.” If
the assessment period is 6 months, this number increases
to 48 patients. This large number would have a large like-
lihood of crossing back into the undecided region at some
point in the six months after stopping the trial. While it
is possible to include this scenario in the original design
of the trial, it results in a greatly inflated sample size re-
quirement.
Summary. I would argue that we ought to be doing
more phase II studies in the development of treatments
for TBI. Before proceeding to a phase III trial requiring
800 patients, we perhaps should have better evidence that
the treatment shows some evidence of efficacy. A phase
II design can be performed with relatively few patients,
and might help avoid the need for large, and expensive,
phase III studies using treatments that do not work. While
the designs can be complex, collaboration between clin-
icians, clinical trial specialists, and biostatisticians can
produce efficient and practical designs. I would argue that
more of this collaboration is needed.
Question: Given the problem of heterogeneity in TBI,
there might be patient characteristics that are not in-
dependent events.
Answer: If you mix a population of people in whom the
drug will work with a population where it will not, you
need a much larger sample size to see the effect. A se-
lection trial may be a way to focus on the group that
is most likely to benefit from the treatment.
A Call for Larger, Simpler Trials (Michael
Bracken, Ph.D.)
Over 200 randomized trials of therapies for TBI are in
the literature but no therapy has been shown to be effec-
tive. The Cochrane Library (1999, issue 4) includes six
systematic reviews of some of this body of evidence—
for barbiturates (five trials), calcium channel blockers
(four trials), corticosteroids (19 trials), hyperventilation
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(one trial), mannitol (three trials), and therapeutic hy-
pothermia (eight trials). All conclude that the therapies
studied were either ineffective or that evidence of effi-
cacy remains inconclusive. This presentation focuses on
methodological issues in phase III trials of pharmaco-
logical agents since these have been most commonly con-
ducted.
It is generally agreed that there is unlikely to be a “sil-
ver bullet” for head injury, that is, a therapy that influ-
ences a broad range of head injury to a large degree. Trau-
matic brain injury trials have been typically designed to
detect effect sizes of 15–30 percentage point absolute re-
ductions in mortality; for example, if mortality in patients
not treated with the new therapy is 50%, can it be re-
duced to 35% or even 20%. But how realistic is this type
of effect size?
It is unlikely that any pharmacological regimen will
lead to complete recovery from TBI, particularly injuries
classified as moderate to severe, which are those most
frequently studied in trials. If we postulate that half of all
mortality from TBI would be amenable to protection from
any neuroprotective agent, then effect sizes of 20% are
attempting to identify 40% of the total pharmacological
effect in a single therapy. Many might consider this
equivalent to testing a “silver bullet-sized” effect.
Designing trials to detect smaller effect sizes, say in
the 5%–10% range for mortality reduction, is likely to be
more realistic. Dickinson et al. have shown that only eight
of the 203 extant TBI trials could detect 10% or lower
reductions in mortality, and none could detect reductions
of 6% or lower. It is interesting to note a Cochrane re-
view of six trials of immediate hypothermia, for exam-
ple, shows a reduction in mortality of 8.1 percentage
points based on 230 randomized patients. A total of only
1,040 patients would need to be randomized in a trial to
confirm this important degree of benefit from this ther-
apy.
Many TBI trials fail to offer a satisfactory rationale for
their chosen effect size. Some appear to be based on ex-
trapolations from animal data, or on availability of pa-
tients to a hospital or trial network, and few use data from
phase I or II trials or from other related phase III trials.
Only one ongoing trial of corticosteroids for TBI in Eu-
rope (the CRASH trial) based its effect size on the re-
sults of a meta-analysis of earlier related trials.
Detecting small effects requires trials with more sub-
jects. If it is realistic to expect modest or even small ef-
fects, trials should be designed which are large enough
to detect them by excluding moderate bias and random
error. Small trials have a high probability of type 2 er-
ror, which effectively stops research on promising com-
pounds. Based on prior corticosteroid trials, CRASH is
designed to detect a 2% reduction in mortality (from 17%
to 15%) and may require 10,000 patients per treatment
group. It has been suggested that a 2% reduction in mor-
tality offers very little benefit; but, if we consider that
over the next decade there will be approximately 5 mil-
lion head injuries in the United States and 30 million
worldwide, a case fatality reduction of 2% would over a
decade save 100,000 and 600,000 lives, respectively. The
respective lives saved with a 5% reduction in mortality
are 0.25 and 1.5 million. Considering lives saved over a
decade is justified if this represents the time frame be-
tween major therapeutic advances.
How feasible is it to conduct trials of 20,000 subjects?
Three trials, of stroke and myocardial infarction, provide
sound evidence of feasibility. The Chinese Acute Stroke
Trial (CAST) randomized 21,106 patients with suspected
ischemic stroke in 413 hospitals to either aspirin or
placebo. Absolute 4-week mortality was reduced by 0.6
percentage points (from 3.9% to 3.3%) in the aspirin
group, an effect that could prevent 90,000 stroke deaths
in China over the next decade. The International Stroke
Trial (IST) randomized 19,435 patients after stroke on-
set in 467 hospitals in 36 countries to a factorial design
for heparin, aspirin, both or neither. Absolute mortality
was reduced by 0.4 percentage points (from 9.4% to
9.0%) in the aspirin group. This small effect could save
400 lives per 100,000 cases. The Second International
Study of Infarct Survival (ISIS 2) randomized 17,187 pa-
tients with suspected myocardial infarction in 417 hos-
pitals in 16 countries to a factorial design for streptoki-
nase, aspirin, both or placebo. Absolute 5-week mortality
was reduced by 4.0 percentage points with streptokinase,
3.8 with aspirin, and 5.2 with both. Considering the high
frequency of myocardial events in the population, ISIS 2
also showed substantial clinical benefit.
It has been argued that a large trial of corticosteroids
would divert resources and patients away from other tri-
als. Of half a million patients who sustain head injuries
in the United States this year, very few (and sometimes
none) are in trials at any one time. Twenty thousand pa-
tients in 1 year would represent only 4.0% of available
patients. There would appear to be plenty of opportunity
for randomizing many more patients to trials than cur-
rently occurs.
Large trials require major clinical endpoints, such as
survival or major changes in morbidity. One of the most
commonly used outcomes from traumatic brain injury is
the GOS and, more recently, the extended scale, GOSE.
There is substantial evidence that these scales are valid
and reliable and their use in large trials is justified. The
degree of improvement in GOSE that a trial is designed
to detect should be clinically significant and indisputable.
There is no value in conducting large trials of debatable
clinical importance. The same rationale argues against
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designing large trials with surrogate clinical endpoints
such as disease precursors or physiological and molecu-
lar endpoints. Documentation of improvement in any-
thing other than major clinical endpoints is unlikely to
influence clinical practice.
Attempts to collect physiological endpoints, or data
which may explain mechanisms, is likely to encumber a
trial to such a degree that testing the primary clinical hy-
pothesis may be jeopardized. Trials that collect substan-
tial amounts of physiologic data are overly expensive,
have lower protocol compliance, take longer to complete
and experience decreased accrual, all of which reduce the
chance of answering the primary clinical question.
Research into therapeutic mechanisms should be done
before a phase III trial or in small random subsets of the
larger trial but should not be allowed to jeopardize crit-
ically needed phase III investigations. Post trial research
may be required to refine knowledge of clinical effects
observed in a phase III trial. Few reports of phase III TB1
trials reference phase I or II clinical work, which is where
one might expect mechanistic studies to be reported. A
rush to phase III trials in the face of quite limited, or even
no phase I or II trial data, may explain some of the fail-
ure of phase III TBI trials. Another unsatisfactory char-
acteristic of some phase III TBI trials has been basing
their rationales on evidence from trials of related condi-
tions, such as stroke, as a substitute for phase II trials.
It may be naive to expect that the dose regimen stud-
ied in the first clinical trial of any drug is likely the cor-
rect dose. First trials are likely to underdose with respect
to efficacy because of concerns about safety with higher
doses. With documented safety, dose escalation becomes
possible. It is dispiriting to contemplate therapies that
may have been abandoned because of lack of efficacy in
their first trial, despite good evidence from animal and
in-vitro studies of possible therapeutic benefit, which
supported further phase III work. Before a phase III trial,
drug escalation studies can help determine what a safe
and therapeutic dose is likely to be. Reports on phase III
TBI trials often do not reference such studies, suggest-
ing they were not done and increasing the risk of phase
III failure.
TBI trials have used a broad range of therapeutic win-
dows. Sometimes these windows are long and include pa-
tients initiating treatment several days after injury. To
preserve homogeneity, it is important in small trials to
have narrow windows and these will vary by drug, drug
dose, and type of injury. However, very large trials may
establish broader windows that can be stratified in analy-
sis to identify particular therapeutic effects. This is an
important aspect of the large trials because the opportu-
nity to identify beneficial therapies for some patients may
be missed if too narrow a window is prematurely defined.
The majority of TBI trials are limited to severe or mod-
erate injuries. One might argue that these are patients
most in need of a successful therapy but this focus may
reduce the likelihood of identifying effective therapies.
The more severe the injury, the more likely the underly-
ing physiologic response to injury is complex and less
amenable to a single therapy. Documentation of benefit
in mild injuries may be easier to achieve and may pro-
vide clues for treating more severe cases. Trials of mildly
injured patients pose some practical problems (they may
be more difficult to follow-up), but this hardly seems rea-
son not to study them. Moreover, a majority of TBIs are
mild injuries. Thus, while the individual burden is less,
the public health burden may be greater. This is particu-
larly so in light of increasing evidence that mild injuries
carry more significant and longer lasting disability than
heretofore appreciated. Further, it is important to enroll
as broad a diagnostic classification of patients in phase
III trials as are likely to be treated with the therapy should
it prove efficacious. Very large trials can include the en-
tire range of TBI and there are substantial methodologi-
cal reasons for doing so.
If a therapy leads to an overall shift in improvement
across a range of severities, examination of only part of
the disease spectrum may be misleading. This bias has
been called stage migration or the “Will Rogers Phe-
nomenon.” Paradoxically, if a therapy is effective in in-
dividual severe TBI patients, it may erroneously appear
to make the group of severe TBI worse. This is because
with therapy, some of the most severe group survive
rather than die and they “migrate” to the severe group,
thereby worsening average neurological recovery in the
surviving severe group. A therapy can reduce mortality
and increase the number of patients achieving recovery
while appearing to worsen the average neurological
scores in survivors. Studying a broad spectrum of injury
severity reduces the likelihood of this bias being missed.
In the last 20 years, both public and private organiza-
tions have established exclusive networks of trial inves-
tigators. The rationale is that only specialized centers
have the expertise to conduct trials. This idea may have
validity for phase I and II trials, where more detailed in-
vestigation is often required, but it has been a flawed con-
cept for the conduct of large phase III trials. The concept
errs because it assumes the need to collect large amounts
of complex data in phase III trials when this is not the
case. Even large networks are too small for trials requir-
ing several hundred centers, and generalizability from ex-
clusive networks may be difficult because they are not
representative of hospitals where the majority of patients
are cared for. Difficulties surrounding protocol adminis-
tration and compliance may be underestimated in special
networks. The importance of bringing expertise and ex-
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perience of RCT methodology to many more hospitals
than a select few cannot be overemphasized for increas-
ing the infrastructure necessary to conduct large scale tri-
als and, importantly, decreasing the time for newly iden-
tified therapies to become more widely adopted.
More successful models establish scientifically credi-
ble coordinating centers that can recruit several hundred
participating centers using minimal rather than maximal
criteria. The CAST (Chinese Acute Stroke Trial), IST
(International Stroke Trial), ISIS (International Study of
Infarct Survival) and CRASH trials are all examples of
this approach. Other examples are the Oxford-Vermont
Trials Network with 360 participating newborn intensive
care units and the Toronto Maternal, Infant and Repro-
ductive Health Research Unit with over 100 trial centers
in 25 countries.
Trials with many thousands of patients cannot afford,
and do not need, to collect large amounts of data per pa-
tient. Traditional trials typically collect tens of thousands
of data points on each patient, although only a fraction
of them are likely to be analyzed and contribute to the
study’s primary clinical conclusion. Collecting these data
comes at a high cost. The threats to recruitment, reten-
tion and protocol compliance, and sometimes to the in-
tegrity of the trial itself, were discussed earlier. The eco-
nomic cost is also high. A typical NIH-funded trial may
cost $10,000 per randomized patient, and some pharma-
ceutical company trials may cost much more. At these
rates a trial of 20,000 subjects would cost $200 million
per trial, well beyond the capacity of funding agencies.
It is imperative that very large U.S. trials be designed
which cost no more than $500–1,000 per patient, or
$10–20 million per trial. Widespread adoption of recent
proposals to pay research subjects substantial sums based
on wage-payment models are of concern and would have
a chilling effect on our ability to conduct very large 
trials.
A reduction in the cost of trials cannot be accomplished
without considering more donations of physician and
nursing time and the absorption of many trial expenses
into patient-care cost. In the context of the present U.S.
health care system, this may be an exercise in wishful
thinking, and very large trials may continue to be con-
ducted, to a large degree, outside of the United States.
Greatly reducing the data demands of a trial should help
alleviate some concerns. Unfortunately, large pharma-
ceutical companies, because of their willingness and abil-
ity to pay very high per patient costs in trials, have had
a negative influence on some hospitals’ agreement to par-
ticipate in low-cost trials when that opportunity is pre-
sented to them.
A further continuing problem in paying for trials in the
United States is the unwillingness of health insurers and
other third-party payers to reimburse the cost of thera-
pies administered to patients in trials that seek to obtain
valid evidence of efficacy and safety. This stands in stark
contrast to their payment for many therapies, outside of
trials, for which evidence of benefit is either weak or
nonexistent. The strategies proposed here for improving
the design of phase III trials of TBI suggest that trials
should be simpler and much larger. The adoption of very
large trials will provide the power and precision to de-
tect small but important improvements in critical clinical
endpoints, identification of therapeutic windows and pa-
tient subsets where therapy may be especially beneficial,
and the inclusion of more hospitals in important clinical
research.
Question: In the CRASH study, the estimate of efficacy
is 2%. Was that based on studies of severe and se-
vere/moderate patients? Do you include severe, mod-
erate, and mild injury?
Answer: It is a very conservative estimate. I think there
are now 17 steroid trials in the literature that include
mostly severe patients (some moderate), and many dif-
ferent steroids (some given two weeks after injury and
some given at very low doses). I think the CRASH
trial investigators have quite properly estimated the to-
tality of evidence from these trials, found a hypothe-
sis, and will test that hypothesis. The eligibility crite-
ria include up to GCS 15.
Comment: The mortality rate you quoted of 35% applies
only to severe head injury, which is only 10% of the
total spectrum of injuries. The estimates of lives saved
are therefore grossly overestimated.
Comment: That kind of grouping does influence the num-
ber of patients. A large number of head injuries in the
US are mild. I am not saying that the large trial on all
severities could not be done, just that we need to be
cautious.
Comment: This is precisely the point. The strategy is to
go in, in advance, and look at all of these patients. We
(CRASH investigators) planned in advance to stratify
on severity, which gives you the option of stopping the
trial early in certain groups, if not in all groups. This
is a different strategy than limiting this trial to severe
head injury patients. If we got an effect in severe we
would need another trial for the moderate patients, and
years from now, another trial in minor head injury.
Comment: Right now most trials fall between the two ex-
tremes. They are not big enough to detect plausible ef-
fects, nor are they focused enough to show the treat-
ment effects that Robertson described earlier. If a drug
is going to be useful, it has got to do more than work
in a few centers where everything is tightly controlled.
It has got to work in a large number of centers, so that
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you will see the same effects when the drug is in com-
mon practice that you are seeing in the trial.
Question: Is there any limit on the amount of informa-
tion that you should collect about patients if you are
doing large trials?
Answer: Yes. You cannot conduct these trials and collect
the same amount of data that we collect in the usual
NIH-sponsored trial. In those cases there are more vari-
ables on one patient than there are patients in the trial.
Unfortunately, much of this data are never analyzed. I
have run trials like that, so I am talking about myself
as much as anybody. For a large trial, you will collect
limited, but absolutely critical pieces of data. That data
have got to be collected on a large number of the pa-
tients, and measures have got to be valid. You do not
want to collect data relating to mechanisms. Data
dredging can absolutely kill these trials; you never get
around to answering the main question.
Comment: Some data collection is FDA-mandated. Some
companies want CT data, and evidence of no harm af-
ter drug.
Comment: There are discussions ongoing now in the FDA
about what sorts of data requirements there ought to
be for various indications. It is not necessary to col-
lect all the information that you think—or a drug com-
pany thinks—you need. Certainly, there are discus-
sions that companies can have with the FDA about
what is to be collected. When you are talking about
things like mechanistic data and imaging studies, there
would be no requirement beyond what good clinical
practice involves. When you are talking about labora-
tory screens for safety, you would not have to get labs
on 10,000 patients every 3 weeks. The FDA would re-
quire some safety data on every patient that is enrolled
in a trial, but perhaps fewer data than you think.
The Long-Term Perspective (John Whyte, M.D.,
Ph.D.)
I am a rehabilitation researcher, and most of my work
concerns subjects who are the failures of neuroprotective
research. It has been intriguing for me to see how many
of the problems in acute trials are also found in rehabil-
itation, though sometimes in somewhat different terms or
viewpoints. How do the outcomes that result from clini-
cal trials, or from the natural course of events, play out
over time, and what implications do they have for re-
search design?
The hierarchy of outcome concepts, described by the
World Health Organization’s ICIDH (International Clas-
sification of Impairment, Disability and Handicap)–2 or
recently published by the Institute of Medicine, is criti-
cal to an understanding of clinical trials in brain injury
and to selecting the appropriate outcome measures for
such trials. In this lexicon, pathology refers to lesion vol-
umes, degree of diffuse axonal injury, ICP and so on—
that is, damage at a cellular and tissue level. Impairment
refers to the dysfunction of organ systems that might be
manifested by such things as reduction in level of con-
sciousness, paralysis, or memory deficits. Disability (or
activity, depending on the system of nomenclature) re-
sides in a person rather than an organ system, and in-
cludes functional abilities, self-care or mobility, and so
on, that is, the ability to perform the normal tasks of daily
life. Handicap (or participation) exists at the interface be-
tween a person and an environment or society and re-
flects an individual’s ability to assume expected social
roles. So, a person’s ability to be employed is a product
of their own skills and abilities in interaction with fac-
tors such as the types of jobs that are needed in the com-
munity and the accessibility of transportation.
Quality of life represents a global assessment of an ag-
gregate of many features taken together. In theory, one
could measure the outcomes of clinical trials at any of
these levels, but there are clearly tradeoffs in doing so.
The question is then how do you select among those var-
ious outcomes for research purposes? The “microout-
comes,” that is, the ones closest to pathology, show the
greatest sensitivity to biomedical interventions. All of the
treatments and agents that have been discussed at this
workshop are designed to influence most directly tissue
pathology. Thus, the linkage between successful inter-
vention at this level and reduced neuropathology will be
tightest, and dependent measures of neuropathology will
be most sensitive to the effects of such agents. How-
ever, the outcomes that people and society are most in-
terested in are at the other end of the spectrum—the
more “macrooutcomes” of disability/activity and handicap/
participation, which reflect the ability to return to inde-
pendent living and quality of life. Those “macroout-
comes” are more tenuously related to the early biomed-
ical factors. A person who has a traumatic brain injury
may have other coexisting conditions (e.g., osteoarthri-
tis, diabetic neuropathy) or other concurrent trauma (e.g.,
traumatic limb amputation) that may influence outcome.
These multiple pathologies may collectively lead to a va-
riety of impairments (e.g., paralysis, balance deficits, re-
duced proprioception). Any given neuropathologic lesion
may produce more than one impairment, depending on
its size and location. Thus, there is no simple one-to-one
correspondence between TBI and any particular set of
impairments, though some are certainly more common
than others.
Moreover, several impairments together may impinge
on a functional ability. For example, stair-climbing abil-
ity is related to muscle tone, balance, strength, and pro-
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prioception. If neuroprotective agents in the above ex-
ample reduce paralysis and normalize muscle tone, this
will not erase the effects of diabetic neuropathy and limb
loss on balance and proprioception. Thus, the “success-
fully treated patient” (in the sense of early neurosurgical
intervention) may still show a stair-climbing disability.
Obviously, stair-climbing may be a minor contributor to
return to work (a handicap/participation outcome), but
that depends on whether one is an office worker or a let-
ter carrier.
In summary, while one may successfully reduce neu-
ropathology through acute neuroprotective intervention,
tracing that effect up this conceptual hierarchy to daily
activities and societal participation, over months or years,
inevitably results in the loss of considerable explanatory
power. Even highly successful biological treatments will
account for only some of the variance in these multifac-
torial biopsychosocial outcomes because they affect only
some of their causative mechanisms. At the most sim-
plistic level, if one wishes to perform clinical trials that
involve “macrooutcomes” as the dependent variables
(and the GOS is such a measure), this will always require
a larger sample size to account for the noise produced by
the many coexisting causal factors operating at these
“macro” levels. Another issue to consider is that recov-
ery in traumatic brain injury continues for a prolonged
period of time. We do not really know how long that is,
and the duration depends on how we define recovery. For
example, as long as the person retains some conscious-
ness and is able to learn, at some rate, skill development
and adaptation to disability or environmental challenges
will continue over years, if not indefinitely. Even at a
more biological level, we have a small number of indi-
viduals who have been vegetative or minimally conscious
for 2 years who then have regained consciousness or had
substantial increases in function. When following pa-
tients for prolonged periods, as physiatrists often do, one
does see some ongoing change, though the rate slows
over time.
In clinical trials, one may want to measure the level of
a “final outcome,” but when is an outcome final? At what
point in time should one measure? If one wishes to mea-
sure outcomes relatively early (e.g., 6 months after in-
jury), and chooses something like neuropsychological
performance, there will be whole populations of people
who cannot be validly assessed. The “outcome” becomes
very complicated to analyze. Another approach is to look
at the time until some standard outcome is reached. This
is essentially a “survival analysis” methodology, where
one can ask, “What is the time until consciousness or a
certain neuropsychological profile is obtained?” There
are methods of censoring data for subjects who have not
reached that endpoint by the end of the observation in-
terval. Typically, this design has a lower statistical power
than a fixed point in time for each subject.
In my own research, early biological variables tend to
account for less of the outcome variance over time. For
example, evoked potential testing can predict outcome
when done within the first 2 or 3 days after injury. We
were interested in seeing whether results of somatosen-
sory evoked potentials (SEPs) obtained months postin-
jury, predicted further recovery in a severely injured
group of subjects. While there was a statistically signif-
icant relationship between late and further recovery, be-
havioral measures of function were far more strongly pre-
dictive of further functional change than were SEPs.
Similarly, in our work on predicting and influencing re-
covery of vegetative and minimally conscious patients,
we find that among patients who are still at this level at
least 4 weeks postinjury, early GCS scores and biologi-
cal measures offer little predictive value. Current func-
tional measures and short-term change in those functional
measures are strongly predictive, accounting for about
70% of the variance in subsequent recovery of con-
sciousness. Thus the importance of biological variables
as outcome predictors or stratification tools appears to di-
minish over time.
There is an additional sampling issue that is faced, par-
ticularly in performing interventional research at later
time points. In rehabilitation research, we see that the pa-
tients who are treated in rehabilitation settings are a 
biased sample being neither “too good” nor “too bad.”
Studies that seek to enroll patients at that point in time
or to follow patient outcome are going to seriously mis-
represent the total spectrum of TBI patients.
What can we recommend from some of these per-
spectives? As a physiatrist researcher, I may risk accu-
sations of heresy, but I believe that it is a mistake to use
more “macrooutcome” variables for research on early
stages of neuroprotection after TBI. As mentioned, such
measures will be relatively insensitive to treatment-re-
lated changes taking place at the biological level. A more
reasonable approach is to focus on fairly “microout-
comes,” things close to the pathology level, during the
initial phases of research. The ideal scenario would be,
for example, to study the impact of a neuroprotective
agent on proximate pathologic variables such as reduc-
tion of ICP, improvements in brain metabolism, and time
until consciousness is regained. Very likely, such re-
search would identify subgroups for which the treatment
was highly effective and other subgroups where it was
not, given the heterogeneity of injury mechanisms in TBI.
Surely, it would only make sense to expect improved mo-
bility and self-care in the subgroup that actually had re-
duced neuropathology. Thus, a second wave of research
could focus on the effects of this same neuroprotective
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treatment, but now in a more restricted subject group that
is known to benefit at the level of pathology. This same
logic can be followed up the conceptual hierarchy, rather
than expecting a discernable effect of the neuroprotec-
tive agent on such outcomes as employment in a highly
mixed population. The argument here is rather than do-
ing a huge trial to detect the needle in the haystack, do
earlier phases of research to identify ways to predict the
subgroups whose pathology will be ameliorated. Then
use those as selection approaches for larger studies that
extend findings to ask whether function is improved, and
move forward step by step.
Another thing that is evident from research in our lab-
oratory is the importance of descriptive outcome model-
ing in guiding clinical trials. Today, speakers have ad-
dressed the utility of surrogate markers, but surrogate
markers are useful only if their relationship to the true
outcome of interest is well understood. In our work on
prolonged unconsciousness, we have invested a lot of en-
ergy in identifying the predictors of our outcomes of in-
terest, so that we can then look with greater confidence
at factors that influence those predictors, in the hopes that
they will also influence the outcomes of interest. If there
is little relationship between a particular early factor and
a later outcome, then it does not make sense to study that
early factor.
In summary, clinical trials of neuroprotective agents
need to pay careful attention to the conceptual level of
the dependent measures chosen, and should attempt to
carefully and sequentially trace the impact of treatment
from the level where the treatment acts to the levels of
desired impact. Tracing these effects across levels and
through time is a painstaking process and each step risks
the loss of explanatory power.
Question: I agree with the notion of focusing attention
on early outcome of biomedical interventions, but there
is danger in not looking long-term in those situations.
For example, in coronary artery bypass, if you select
the early outcome of graft patency, you can conclude
that the procedure is efficacious for all subgroups of
patients, whereas if you consider longer-term out-
comes, such as death or disease progression, you find
very different answers.
Answer: That is certainly true, but your question assumes
that any one of these stages works alone, and I am ar-
guing for a programmatic sequence of research. Take
the flip side of your example: in the initial study we
find that coronary artery bypass grafting does not re-
sult in patent vessels for some patient subgroups. Will
we want to go on and study functional outcome in those
groups, when the basic mechanism of treatment has
not been obtained? Suppose we discover that a partic-
ular type of vessel stays patent when grafted, while an-
other type tends to reocclude. We may then want to
design our functional outcome study around the peo-
ple receiving the biologically successful graft. We
might postpone a functionally oriented study on the
other subgroup until we have identified a surgical pro-
cedure that is equally successful in retaining graft pa-
tency.
PRACTICAL ISSUES
Staffing for a Clinical Trial (Nancy Temkin,
Ph.D.)
I shudder to hear about trials where centers are enter-
ing a total of five patients. It is unlikely that such a trial
will have tight quality control and good compliance. For
large trials, even at a single center, if the study person-
nel are not on top of the patient enrollment and follow-
up constantly, the entire trial is lost. Problem areas are
everywhere, from enrolling patients in a timely fashion
through ensuring that patients return for testing. The TBI
population is difficult to work with. Many are “risk-tak-
ing” young men, and coming back for follow-up is not
their highest priority. Adherence to the protocol sched-
ule is difficult, and only gets more difficult over time; a
2-year follow-up can be a daunting task. One of my fa-
vorite stories illustrates the problems study coordinators
face. An individual came back for the 2-year follow-up,
and we asked if he wanted to know what treatment he
was on. He said, “Yes.” We broke the blind and told him
he was on placebo and he said, “and to think my friends
were paying good money for those pills.”
Our Dilantin study was a 1-year treatment, and it was
an interesting job keeping compliance at an acceptable
level. People with severe head injuries often have other
systems injured. Their metabolism changes over time,
and to keep a consistent drug level, we had to keep ma-
nipulating the dosage. It takes a large and really dedi-
cated group to pull off one of these trials; our group has
50 people. The ones who make the trial go are the nurses
and the outcome examiners. They interact closely with
the patients, and must bond with them to get the high fol-
low-up rates. Our study nurse describes herself as a pit
bull with good social skills.
Data Collection in Traumatic Brain Injury
Trials (Lorraine Yurkewicz, Ph.D.)
Due to the medical complexity and severity of acute
TBI, and the inherent difficulty in demonstrating the ef-
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ficacy and safety of new therapies, there is a tendency to
collect as much information as possible in clinical trials.
This additional information has often proven useful ret-
rospectively, in determining some of the contributing fac-
tors (i.e., patient heterogeneity, differences in medical
management) in failed clinical trials. Despite its useful-
ness, the volume of data collected in a TBI clinical trial
can become enormously resource-intensive, both for the
research staff and for the sponsor. It is therefore impor-
tant to determine which data are critical for the assess-
ment of key efficacy and safety parameters for scientific
validity and regulatory approval. The resource burden for
any additional data collected must be carefully weighed
against its potential benefit.
I am currently conducting the Pfizer study in severe
head trauma. I would like to talk about some very prac-
tical issues surrounding data collection that I have been
dealing with for the last two years.
 Patient population. There are complex issues of pa-
tient entry criteria for TBI. It is important to decide
whether or not to include minimum GCS scores of
3 or 4. The baseline criteria between the two treat-
ment groups (drug vs. placebo) need to be balanced,
and there may be ways of stratifying at baseline to
ensure this. Which types of TBI to include, as evi-
denced by CT scan, is controversial; yet it is critical
to determine beforehand what patient population will
be studied. Should gunshot wounds be included?
Open and closed head injuries? The precise patient
population to be included will also depend on the
drug’s mechanism of action.
 A consistent treatment paradigm. One of the biggest
practical obstacles that we must deal with is time
from initial injury to dosing. It is important to ad-
minister the drug as soon after injury as possible, but
we have the practical constraints of obtaining writ-
ten informed consent. There needs to be a balance
between making the window as short as possible for
maximum drug effect, but long enough to obtain
consent and enter patients into the study.
 Optimal drug dosage and duration. Rely upon infor-
mation gained from early phase trials and pre-clini-
cal studies. Be practical with the regimen to reflect
the necessities of treating severely injured patients.
 Endpoints. One must define the primary endpoint in
terms of efficacy. There is some disagreement as to
what is the best primary endpoint. Until now, most
people have used the dichotomized GOS, and I know
Pfizer is using it in our study. According to Dr. Choi,
it seems to be the most sensitive outcome scale in
terms of power, but maybe there are other endpoints
that will prove to be more sensitive and will better
reflect improved cognition. It would be very useful
to find a physiological endpoint that could be used
to show drug efficacy earlier than at 6 months, and
that predicts long-term outcome.
From a sponsor’s point of view, every data point col-
lected involves resources: research and hospital staff, a
study coordinator, a field monitor to come out and ver-
ify every data point against the source documents, a data
manager, a staff for data entry, a statistician, and a pro-
grammer. In our study we have attempted to streamline
our casebook, yet we have about 50 pages and at least
3,000 data points per patient. Someone has calculated that
it costs a company $100 for each data query. For prod-
uct approval there must also be proof of safety, and this
requires reporting all adverse events, whether or not they
are considered to be related to the study drug. These re-
ports are resource-intensive. To understand and interpret
the results and to determine the safety profile of a new
agent, one needs to collect a lot of data regarding a mul-
titude of medical issues for each patient. In severe head
trauma there are many adverse events. Issues regarding
the collection of laboratory data for safety must be de-
cided early on. Does one collect all of the data or only
selected parameters? What types of treatments are in-
volved other than the study drug? Should there be spe-
cial chemistries, EKG profiles, or CT scans collected 
during the study. Will these demands affect patient man-
agement and standardization across centers? In our on-
going study we have spent a great deal of energy on stan-
dardization of patient management. These issues are
critical in terms of outcome.
One may choose to evaluate secondary measures or
exploratory endpoints in a study. For example, collect-
ing data for subpopulation analyses, including baseline
characteristics and patient management, may determine
which parameters are most critical in influencing out-
come. Planning resources for these analyses at the start
of the trial will avoid surprises later and will help in fo-
cusing the efforts of the investigators.
In addition to the primary efficacy endpoint (such as
the GOS), it may be useful to include a cognitive neu-
ropsychological scale. It is important to avoid the danger
of secondary scales being too lengthy. This would rep-
resent a burden, both for the research staff and for the
patient. Complex outcome instruments may make the pa-
tients less willing or able to cooperate. Another parame-
ter to consider including would be a measure of the eco-
nomic risk/benefit ratio for study drug treatment. This
may become more important in the future, and it is a very
difficult measure. One option is to compare treatment
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groups with respect to length of hospital stay or the time
needed in acute care. What may become more important
eventually is to examine the overall cost of illness. This
is quite complicated, because billing practices vary from
one hospital to another.
Additional data that may be useful to collect are found
in the medical history. One thing that is very important
to know is whether or not a patient has had a previous
brain injury; that certainly might affect outcome. It would
also be important to know if a patient had any kind of
cognitive impairment prior to the TBI, because that could
confound the interpretation of results. Two items that are
necessary to collect but that are also very resource-in-
tensive are concomitant medications and concomitant
treatment. Without this information it is difficult to in-
terpret any kind of abnormalities or adverse events.
The kind of information that may be useful to collect in
terms of standardization across sites and patient manage-
ment are pupillary status, GCS, vital signs, and ICP. In the
acute care period, one may be collecting ICP and vital signs
every hour, for several days, resulting in a huge number
of data points. The intensity of treatment intervention re-
quired to reduce ICP may be very important in comparing
treatment groups. In fact, if the research drug is working
and the trauma centers are practicing aggressive patient
management, the only difference between treatment
groups may be the amount or intensity of intervention. One
would expect the placebo group to require more aggres-
sive treatment than the active drug group.
Comment: There are ways in which data collection can
be reduced. In studies where the treatment is very
acute, but outcome is assessed at 6 months, the FDA
would not ordinarily require collection of every data
point throughout the time of the assessment, as they
might in a study where drug is given chronically for
six months. At the FDA, we are toying with the idea
of requiring “labs” be collected only for perhaps five
half-lives of a drug. The reality at FDA is that the spon-
sors (drug companies) come to us and we review their
protocol; if it is reasonable, we say it is possible to be-
gin the trial. Companies rarely ask us if they can do
something different; we would consider other reason-
able safety protocols. It is not necessarily the case that
every single concomitant medication a patient takes
must be recorded and examined. There is some room
for discussion. People seem to love to assess and an-
alyze secondary endpoints. Secondary endpoints can
present problems, and are not usually considered when
the FDA decides whether or not a drug is effective.
When the primary outcome is negative, people in-
vested in the trial may try to resurrect it by saying that
a particular secondary outcome is positive.
Quality Assurance in Intensive Care Unit Data
(Anthony Marmarou, Ph.D.)
We had the unique opportunity to explore variation in
ICU management over the last few years. The advent of
the Guidelines sponsored by the AANS (American Asso-
ciation of Neurological Surgeons) and the Brain Trauma
Foundation gave us a “before and after” from which we
could compare. In March 1996, the Guidelines were sent
to all the surgeons in the AANS registry and were pub-
lished in the Journal of Neurotrauma in November 1996.
We considered that we had two data collection periods:
before Guidelines (1995–96) and after Guidelines
(1997–98), and we assessed the degree to which the rec-
ommended procedures were being followed.
ABIC treatment centers collected CT scans and acute
care parameters of ICP and TIL for 6 days. Copies of the
medical records were faxed to the consortium center
where we read the CT scans and reviewed patient man-
agement. Reports, tables, and graphs were sent back to
the study center to show them problems or deviations
from protocol. Our hope was that center staff would at-
tend to these recommendations and improve their man-
agement.
Our study population was 326 patients from two
prospectively randomizing clinical trials at 104 centers,
which represents a reasonable sample of what was hap-
pening in TBI trials the United States at that time. The
patient ages ranged from 18 to 65 years. The inclusion
criteria for both trials were “one reactive pupil and ab-
normal CT” and the selected populations did not include
the most severe end of the spectrum (GCS-3). The study
investigator received graphed reports that compiled the
first 120 h of the intensive care record: blood pressure,
ICP with threshold for treatment, cerebral perfusion pres-
sure with a threshold (listed as an option by the guide-
lines) to maintain above 70 mm Hg, and TIL. In the re-
ports we can see individual treatment profiles: as a result
of high ICP, there is aggressive therapy and significant
reduction in perfusion pressure. We can also pinpoint
possible protocol deviations or failure to comply with the
Guidelines. In one example, we saw an elevated blood
pressure with the TIL consisting of sedation, frequent
mannitol, and hyperventilation, but no ICP monitoring.
What was guiding this therapy? It looked as if the inten-
sive care staff was using a shotgun approach. This find-
ing called for our contacting the center and discussing
the reasons for the deviation.
If you look at the compliance with Guidelines from
April 1996 to 1998, you see that only 58% of patients
were managed according to suggested practices. If you
look at the reasons for noncompliance, most of them dealt
with sustained hyperventilation (.4 h). In some of the
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cases there was no need for sustained hyperventilation
because there was no ICP problem. The other deviation
was the absence of pressor use with CPP ,70. Surpris-
ingly, in 14% of centers there was no ICP monitoring.
When we looked overall to see deviations from the
Guidelines after publication in 1996, it looked as if there
was a reduction in those deviations that were considered
moderate; however, the number of severe deviations in-
creased! There was marked reduction in instances of 
insufficient CPP, and the ABIC centers were using more
pressors; however, there was a decrease in ICP monitor-
ing, up to 27% of centers. I could not believe this, but
there it is! There did not seem to be an improvement in
treatment after publication of the Guidelines. What are
reasons for this noncompliance 18mos after distribution
of this new information? This result is rather discourag-
ing for those who plan and direct clinical trials. Non-
compliant centers had more difficulty in trying to control
ICP, and the percent time for CPP , 70 mm Hg was very
high in these centers. If you look at the effect of 
compliance on 6 months GOS, 44% of patients from com-
pliant centers had good outcome versus 34% from non-
compliant centers. This was the first evidence that ad-
herence to the Guidelines can have an effect on outcome.
Another important point in running clinical trials is cen-
ter compliance. In our analysis, centers that enrolled
fewer than five patients had a 45% compliance rating,
whereas centers that enrolled more than five patients had
a 65% compliance rating.
We have a significant number of deviations from the
recommended Guidelines among ABIC centers. There
did not seem to be any improvement in the overall fre-
quency of deviations in patient management after Guide-
lines were publicized. The greatest number of deviations
was associated with centers accruing fewer than five pa-
tients, which heightens our concern about center differ-
ences in management of severely head injured patients
for the conduct of trials. Adherence to compliance guide-
lines appeared to have a favorable impact on outcome,
although more data are needed to confirm that this is sig-
nificant. Our recommendation for trials is that an in-depth
clinical review be an essential component of the study.
In a clinical trial designed to detect small effects, sub-
optional management would completely invalidate the
outcome. An educational process on the importance of
following the Guidelines must be ongoing and must ex-
tend to neurosurgeons, intensivists, trauma specialists,
and any staff who are involved in the acute treatment of
severe brain injury.
Question: It is a little bit disturbing to me that your study
and the Guidelines focused on CPP , 70 mm Hg. We
tend to forget that cerebral perfusion pressure is a de-
rived value that depends on several factors.
Answer: We are now looking at the effect of CPP on out-
come, and there is a significant effect, albeit that the
initial ICP is extremely important. I do not believe
these data speak to the “appropriateness” of where to
intervene. The threshold for CPP was set at 70 mm Hg
in the Guidelines. Is 50–60 mm Hg more appropriate?
We are not sure. We do have data on the percent time
spent at these different levels, and that issue should be
sorted out.
Comment: In the phase III hypothermia trial we found
that CPP of 60 mm Hg or less was the critical num-
ber, with really no effect at 70 mm Hg. No one has
found much effect of CPP . 70 mm Hg. If you target
CPP 5 60 mm Hg for the “alarm to sound,” the value
will be less than this for some of the time; it looks to
me that you need to aim for about 5–6 mm Hg over
the critical variable.
Answer: Another piece of important information was that
even a single event of CPP , 40 mm Hg was devas-
tating. So, we are in search of critical thresholds—
whether percent time, or frequency, or level.
Question: You criticized sustained hyperventilation as a
serious violation of the Guidelines. But, the ABIC
Guidelines include hyperventilation as an option; not
perhaps standard treatment, but an option. Were the
participating centers all neurosurgery units or also gen-
eral trauma?
Answer: These were all ABIC neurosurgical centers. The
guideline was not to use prophylactic hyperventilation
in the absence of elevated ICP.
Consent Issues in Acute Care Trials (Charles
Wade, Ph.D.)
Most of our work has been looking at hypotensive pa-
tients, and in that group, traumatic injury to the brain is a
subpopulation. I am going to use some abbreviations: the
IRB and the legally authorized representative (LAR). We
must have informed consent from the subject or the sub-
ject’s LAR in order to carry out experimental studies.
Defining that individual can get very difficult: a wife, a
family member, or parent. The LAR must be defined be-
fore you begin, and it is different in various states. Institu-
tions can impose requirements in addition to the state law.
Another issue that lawyers have a tough time with is, “Can
somebody who has traumatic, physical injuries or their rep-
resentative at that time provide informed consent?” Does
the medical situation that we are working in constitute an
inappropriate place for an individual to give informed con-
sent? Consider the situation for a family member of a pa-
tient who has been in a traffic accident. It is late at night;
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there are helicopters and paramedics, emergency room per-
sonnel, resuscitation, and severe injury. These activites
were designed to save lives and optimize outcome, but can
you expect an LAR give true informed consent in that en-
vironment? There are lawyers who say no.
We face a disease with grave consequences and no
proven pharmacological therapies. Patients with acute
traumatic injuries surrender control over early care deci-
sions—they have entered a system of transport, ER, ICU,
OR. Often they are not aware of or do not understand the
procedures. They are in a mode of passive acceptance
and loss of autonomy. Once in the system, they tend to
roll with it, even after they get out of surgery, or acute
care. This state of mind is referred to as “institutional
transference.” What should investigators do?
1. Try to get informed consent by the patient when fea-
sible. Remember that the patient always has the right
to decline, so you have to give them that option. Even
if you think they are drunk, dizzy, unaware of sur-
roundings. If they decline, they decline.
2. Propose consent by family or the LAR when feasible.
In the TBI trials, you are usually trying to get consent
within the first six hours. I am trying to get consent
in the field, pre-hospital, to administer fluids before
the ER, or immediately upon admission.
3. Have a scripted, abbreviated consent form. I went back
and looked at some work we had done in 1983. The
consent form in that environment was three pages
long, in 14-point type. Our consent form today is 14
pages long, in 12-point type, single-spaced, and there
are descriptions in it where I wondered what was go-
ing on. Consent is supposed to be in layman’s terms.
Sponsors have gone to an abbreviated consent form
for this emergency environment. The patient or LAR
can read one clear page very rapidly, sign it and go
forward. The lengthy document comes later.
4. Independent approval or the use of a consent excep-
tion by a second physician prior to enrollment. Such
an arrangement should be in place prior to the begin-
ning of the trial.
5. Repeat the consent to continue when an exception to
prior consent has been utilized. Throughout our work
we have learned to periodically ask the patient if they
want to stay enrolled in any particular study. This pro-
cedure is useful especially when we are following sub-
jects for a long period of time. We give them an op-
tion throughout the whole study to withdraw if they
wish. That vigilance helps in terms of the ethical is-
sues involved. There are reports on studies done on
patients in the emergency room. In one study (not TBI)
prospective consent was given by 6% of the patients.
Enrollment criteria required a blood pressure ,90 mm
Hg and major traumatic injuries. The questions in us-
ing prospective consent are, “Is the patient with ma-
jor traumatic injury competent? Is the family member
competent?” In this study, independent approval for a
consent exception (waiver of consent) was given in
almost 94% of cases. They used a second physician
to independently evaluate the patient and determine
inability to consent. For research done in the field, i.e.,
emergency or prehospital care, the institution has to
take responsibility for this consent approval process.
Getting an institution to do that can be a problem.
Consent to continue is used in 89% of the patients.
Usually, the investigators ask a family member within 
24 h and then later talk with the patients. The average
time for consent to continue obtained directly from pa-
tients was 13 days later. I want to emphasize that we keep
asking the patient over and over to affirm that they want
to participate. We get the family members and the pa-
tient to play a role in continuing consent and get them to
sign off on it.
Continued IRB review has to be implemented in this
particular environment. It is difficult for many IRBs to
assign someone to oversee emergency research because
it is a major activity. Another requirement for using
waived consent concerns community consultation and
public disclosure. There has been a real issue of inter-
pretation here. What are we to do and how do we know
it is appropriate? I will give you an example. For a study
in an East Coast state on trauma patients in the ER, the
investigators went to church groups, radio talk shows,
and such activities. When the study started, the typical
trauma patients were young males, and this population
did not typically appear in church or listen to talk radio.
Do you earmark this “information” effort towards your
patient population? Or to society as a whole? It was sug-
gested in one case that investigators go to the gangs, and
discuss the proposed research. That is how extreme this
is getting.
Our field needs to discuss the objective in emergency
medicine research. Should it be potential improvement in
survival? We have the possibility of getting a positive re-
sult, and survival is the bottom line. That is what has been
accepted among the trauma community and acute care
community. In most of the studies we are discussing, we
would administer the standard of care and add to it. We
are looking for something that we believe is of benefit in
addition to standard care. In our comparison between hy-
pertonic saline and standard of care, we saw that with the
group of subjects with GCS,8 there was an increase in
survival. The treatment significantly elevates blood pres-
sure by expanding blood volume. That increase persists
into the ER, and we see an increase in survival. There
NARAYAN ET AL.
542
was only one group that showed benefit when we looked
at it in terms of using an AIS (Abbreviated Injury Scale)
of .4. There is a problem: When is that determination
made? It is made a couple of days later, when I have the
CT scan, the autopsy report, and the whole record. Is the
determination of AIS biased? We looked at this when we
did the meta-analysis; we used 1,080 patients, and we
had 224 classified as having head injury with AIS .4.
When we used the GCS ,8, we had 52% of the patients
who actually had head injury.
To convince an IRB to allow very early studies, we
need adequate basic research. In terms of hypertonic
saline/dextran, we had done over 400 animal studies prior
to clinical studies. There must be adequate preclinical re-
search, and it has to have been evaluated. We must take
published data to set a reference point or a standard. A
good IRB will look for that.
Question: It is my understanding that about 4 years ago
the staff at FDA and OPRR determined that “deferred
consent” is an inappropriate term. (The Office for Pro-
tection from Research Risks no longer exists. Recent
reorganization has created the Office of Human Re-
search Protections within the Department of Health
and Human Services.)
Answer: That is correct. The terminology is “waived 
consent.” As I said before, you cannot give up getting
consent. All you can do is waive consent for a period
of time.
Changing Clinical Practice in the Real World
(Jamshid Ghajar, M.D., Ph.D.)
There is a gap between science and clinical practice. I
think we can close the gap, but not by lecturing or going
to conferences. It must be done using databases to track
patient assessment and treatment. I think Dr. Marmarou’s
talk addressed two things. One was compliance with the
guidelines, and the other was the difficulty that ABIC had
in convincing the trauma centers to follow their protocol.
We are all facing the question, “How do you make trauma
centers follow protocol?”
In 1991, the Brain Trauma Foundation (BTF) surveyed
about a quarter of the 1,000 trauma centers in the US.
We found that 26% were not monitoring ICP routinely
yet were using severe hyperventilation and steroids. The
BTF and the AANS developed the Guidelines hoping
that, by bringing together all the scientific knowledge and
distributing it, treatment practice would improve.We re-
peated the survey after publication of the Guidelines. We
had three nurses working full-time who contacted the
American Hospital Association and every single state de-
partment of health, and drew up a list of trauma centers
in the US. We had 90% participation in the survey. For
50% of the trauma centers, the TBI patients came in, and
then were transferred at a later time to another trauma
center. That is an important point, because there are data
to show that transferring patients can increase mortality.
I think we can state that about 500 trauma centers in the
United States are really taking care of all the head injury.
We then sent questionnaires to those centers, with 35
questions relating to how many patients were seen every
month? Who heads the ICU? In preparing the question-
naire we went through the Guidelines: prehospital issues,
trauma systems, indications for ICP monitoring, the
threshold technology, thresholds for CPP, hyperventila-
tion, mannitol, barbiturates—all ICU issues except nu-
trition were addressed. The forms also included case sce-
narios of how the center would manage a head injury
patient.
Our scoring scheme was this. Full compliance: the cen-
ter had ICP monitoring routinely in 75% or more of qual-
ified patients, followed the ICP treatment threshold, the
technology, hyperventilation, mannitol, and steroids. Par-
tial compliance: the center monitored ICP routinely as
above. Minimal compliance: no routine ICP monitoring.
Results indicated that two-thirds of the trauma centers
were out of compliance. Only about 15% were in full
compliance and about 18% in partial compliance.
If you look at each question of the survey and then
look at level I (the highest designation), level II, and level
III you see a significant difference in the level I trauma
centers compared to level II and level III in terms of ICP
monitoring. Level I trauma centers had a much higher in-
cidence of ICP monitoring compared to level II and level
III. Mannitol and barbiturates were used significantly
more in the level I trauma centers. Steroids were used
significantly less in the level I trauma centers. Level I
centers were clearly much more “Guidelines-compliant”
compared to level II and level III. The level I trauma cen-
ters saw much higher volumes of TBI (.15 cases/month)
than the level II or level III. These level I centers saw in
the range of four to 14 patients with severe head injuries
each month. It seems that high volume and being a level
I trauma center led to more compliance with the Guide-
lines, than did a low patient volume or level II or level
III status.
Using just routine ICP monitoring (.75% of qualified
patients) and technology (ventriculostomy) as indicators,
we had 26% compliance in 1991. The Guidelines were
published in 1995, and ICP compliance went up to 33%.
That looks optimistic, and if we wait another 50 years
we might see full compliance. I think what this report
and what ABIC’s data are saying is that we cannot just
publish a book and have things work. How can we reed-
ucate physicians and medical personnel? This is a big
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question for all areas of medicine, and for TBI clinical
trials.
We are trying to develop guidelines, implement them,
and conduct clinical research in order to create a contin-
uous feedback loop of science and practice. The really
tough part of having practice guidelines is implementing
them. The BTF was fortunate through a grant from the
Soros Open Society Institute to develop an educational
program in Eastern Europe. The effort created an Inter-
net database that included the CT scans, so we had cen-
tral CT reading in this project. The interactive Internet
database to assess the efficacy of the Guidelines demon-
strates improvements in patient outcome and allows on-
line education of physicians. The program is now ongo-
ing in seven countries in Eastern Europe: the Baltics,
Czech Republic, Hungary, Slovakia, and Croatia, in the
major trauma centers. In each center there is a neurosur-
geon in charge of the program and data entry.
There are about 1,000 patients in the database, and it
includes everything from prehospital vital signs through
6-month outcome. We combined the databasing effort
with an annual conference for the centers, and many of
the authors of the Guidelines attend and give lectures or
hands-on workshops. CT scans were transmitted back to
use in New York over the Internet, and two neuroradiol-
ogists at Cornell read and graded the scans.
Results from 850 patients include the following: Mo-
tor vehicle accidents were the leading cause of injury.
Age range was 3–60 years. Forty-one percent of the pa-
tients were transferred. GCS was 3–5, noted after resus-
citation in 66% of patients. There was ICP monitoring in
58% patients. In the first three days, there was a very low
mortality when ICP was ,25 mm Hg for the entire time
or was .25 mm Hg for ,40% of the time. There was a
high mortality in the group that was not monitored and
in patients with ICP . 25 mm Hg for .40% of the time.
ICP data are clearly important in predicting outcome.
Our data indicate that CPP levels above 60 are not
strongly prognostic. What is prognostic is mean arterial
blood pressure. We used low MAP as 85 mm Hg, and
we found that for high ICP (.25 mm Hg)/low MAP,
there is 26-fold increase in mortality at 2 weeks. For pa-
tients that show low ICP/low MAP, there is a sevenfold
increase in mortality. This data indicated that we should
not be looking at CPP as much as ICP and MAP indi-
vidually, and really look for an adequate level of MAP.
Was our education effort successful at our 10 centers?
We looked at ICP monitoring as an indicator of follow-
ing the Guidelines, and when we began there was mon-
itoring in fewer than 10% of patients. Just by walking in
and shaking the physicians’ hands, we saw that monitor-
ing went up to 40% of patients. The investigators enter-
ing information on their patients knew that it would be
in a database, and they wanted to do the right thing. But
you can see that over the years ICP monitoring has con-
tinued to climb. I think that “databasing” makes a big dif-
ference in compliance with the Guidelines.
This original database, called TBIS, was very expen-
sive. There now is a new database, TBI-trac, which is
very short and can be done in 30 min on a patient after
2 weeks. New York State is funding this grant, and there
are have five trauma centers participating now. They are
online through the Internet starting June 1, 2000 and they
will enter all the acute data from patients from the mo-
ment of the accident through two weeks. At the end of
each month, centers will get a report about their patients,
showing which patients were “guidelines compliant” and
which not. When they enter a patient’s data the program
will immediately show them online whether the patient
is compliant with the Guidelines or not. We include
whether the particular guidelines compliance is at the op-
tion, a standard, or guideline level.
The New York State project also has an educational
materials website (TBI_trac.edu) that has the Guidelines
on it. This site allows medical personnel to see videos,
and to access every abstract and evidentiary table that
was used in developing the Guidelines. The BTF has also
developed prehospital guidelines for severe head injury
under a grant from the U.S. Department of Transporta-
tion. This education effort is spreading very quickly, be-
cause the 800,000 EMS people are taught by this agency.
There is one office in Washington, D.C. responsible for
education, and once we had their approval, we moved
rapidly. These guidelines are detailed and include a
trainer manual, a student manual, and films. We had pi-
lot sites in Anchorage, Alaska; Navajo Nation, Arizona;
Galveston, Texas; Birmingham, Alabama; and Washing-
ton, D.C. The project is now moving into several other
states.
In summary, for physician reeducation, I think you
have to do databasing and you have to do active educa-
tion.
Comment: You have an opportunity to do some ran-
domization here. Perhaps randomize hospitals to dif-
ferent procedures within the guidelines. If you do tri-
als in that area you would be contributing to some of
the general knowledge on how to implement guide-
lines in any specialty. I believe that neonatologists are
doing this type of thing. I would encourage you to try
and think of an experimental design.
The Perspective from the Food and Drug
Administration (Russell Katz, M.D.)
My division at FDA (Division of Neuropharmacolog-
ical Drug Products) has not interacted regularly with the
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neurosurgical community in general, or the head trauma
experts in particular. I do not know exactly why that is,
but one reason is that meetings like this are not held very
often. I think it is very important that we get a chance to
talk about the FDA standards and what the rules are for
drug approval. I know that your perceptions of them are
largely through your interactions with the pharmaceuti-
cal industry, and it may be useful for you to hear from
us. There might be a number of myths out there, and I
will explode some, confirm some, and perhaps create
some new ones.
There is a statutory standard for determining effec-
tiveness. The Federal Food, Drug and Cosmetic Act says
that in order to approve a drug there must be substantial
evidence that the drug will have the intended effect. What
exactly does “substantial evidence” mean? Everything
with regard to effectiveness is related to the labeling.
What claim is the sponsor proposing, and does the evi-
dence support that claim? It is a vague standard because
claims vary from drug group to drug group, within a drug
group, and even within a particular therapeutic area.
You have identified many questions for the design of
TBI trials: large simple trials or specific trials, the entire
range of head injury patients or specific subjects, Glas-
gow Outcome Scale or neuropsychological testing? The
reality is that any of those options are potentially appro-
priate. There is no specification from the FDA about what
type of trial needs to be conducted. All of those things
are potential areas for negotiation. For example, a drug
could be approved just for severe head injury, or for head
injury in a very global sense, covering a range of sever-
ities. There is no limitation from the point of view of the
statute (the law) as to what can be approved.
Generalizability of findings. Generally speaking, the
FDA is not as concerned about a couple of things that
sponsors and investigators talk a lot about. One is the
generalizability of the treatment to the larger community
of patients. We are looking for trials that show a drug ef-
fect, that is, a difference between the treatment and con-
trol group. The drug does not have to be for everybody
who has that disease; it could be limited to a very re-
stricted subgroup. Remember that the samples of patients
in clinical trials are not random samples of the popula-
tion that has the condition. They are what my predeces-
sor used to call “samples of convenience.” The FDA
wishes to ensure only that the trials are designed in a
manner that the effect we see is a bona fide effect, even
though the patients in a TBI trial do not represent all pa-
tients with TBI.
Size of treatment effect. We also do not care so much
about the size of the treatment effect. We are interested
in trials that can demonstrate a difference between the
drug and the control, a proof of principle. You must show
that the drug has a pharmacological effect on an outcome
that means something clinically, in an appropriate sam-
ple. In the world of epilepsy, we used to look at 50%
seizure response. In other words, a patient was a re-
sponder if there was a .50% decrease in his/her seizures.
But what about a 48% reduction? It is hard to call that
person a failure. We at FDA do not set a standard for the
size of the treatment effect. As long as a bona fide dif-
ference has been demonstrated between the drug and the
control, that is good enough.
“Substantial evidence”. The law also specifies that you
need adequate and well-controlled investigations, in-
cluding clinical investigations that demonstrate that the
drug will have the effect it is represented to have. Again,
consider the proposed labeling. “Clinical” has been de-
termined to mean human, so you have must do studies in
humans. “Investigations” is written in plural, and we have
invariably interpreted that to mean that you need at least
two adequate and well-controlled trials. What is an ade-
quate and well-controlled trial? The regulations written
to interpret this say there are about five different types,
and they can overlap: (1) placebo control, (2) active con-
trol, (3) fixed-dose response, (4) no treatment/concurrent
control, and (5) historical control. These are all appro-
priate in certain settings. Of those types of trials, the one
currently most appropriate for traumatic brain injury
would be the placebo-controlled trial, because there is no
drug approved and recognized to be effective.
The FDA Modernization Act. In 1997 the law was fun-
damentally changed and is now the FDA Modernization
Act (FDAMA). This statute permits many things that the
previous law did not, but it does not obligate the FDA to
utilize any of these new provisions. The new law states
that the Secretary may determine, based on relevant sci-
ence, that data from one adequate and well-controlled in-
vestigation, and confirmatory evidence, are sufficient to
establish effectiveness. The Secretary may consider such
evidence as “substantial evidence.”
However, there are some important issues relating to
the new law that must be pointed out. We have no idea
from the statute, or from the regulatory history, when it
would be acceptable to establish a ruling of “substantial
evidence” of effectiveness on the basis of a single trial.
We do not know what “confirmatory evidence” means.
At least, we do not know what Congress had in mind
when they passed the law. The agency has developed a
document that addresses the circumstances under which
one trial might be sufficient to establish effectiveness. It
would have to be a large trial that establishes an effect
CLINICAL TRIALS IN HEAD INJURY
545
on mortality or very serious morbidity. What would be
the characteristics of such a trial? There would have to
be an internal replication in a single multicenter trial:
many centers showing significance of treatment, perhaps
several of them showing statistical significance on their
own. The trial might show that there were multiple sub-
groups of patients within the study that had a similar re-
sult. There would be very low p values, suggesting that
the trial was not positive by chance. Perhaps there would
be multiple outcomes, all showing statistical significance.
Also, one might have a trial that could not or should not
be repeated on ethical grounds.
Our view is that this provision, while it can be used,
is rightly seen as a deviation from the standard. Only in
those cases where we really cannot repeat a study would
the “one trial” approach be appropriate. We ordinarily re-
quire that there be at least two trials showing an effect
on appropriate outcome measures. This requirement for
replication is to make sure that the drug effect is not due
to chance, bias, or perhaps even fraud, and that the ef-
fect is real.
Crossover indications. A request is sometimes made
to approve a drug for a new indication, based on studies
for a different indication. Generally speaking, we do not
find that terribly compelling; however, there are situa-
tions where we have allowed one trial to suffice for sub-
stantial evidence of effectiveness. It has been done with
anticonvulsants. For instance, if a drug has been shown
in two adequate and well-controlled trials to be effective
as an adjunctive therapy, and the company wants to have
it approved for monotherapy, it is possible that a single
trial on monotherapy would be sufficient. For a certain
seizure type, if there are studies showing an effective
therapy in adults, a single robust trial in children could
be adequate to support that indication. The FDA looks at
the totality of evidence in making a decision on what is
necessary. If you are looking at two entirely different dis-
eases, for example, stroke and head trauma, I think those
disorders would require separate trials. One trial in TBI
and one in stroke would not constitute substantial evi-
dence.
Fast track approval. Another new provision that is ap-
plicable to head trauma is called “fast track”. The phar-
maceutical industry certainly knows about this: since No-
vember 1997 every drug that has come to the FDA has
been proposed for the fast track. FDAMA says that the
Secretary shall facilitate the development and expedite
the review if the drug is intended for the treatment of a
serious or life-threatening condition, and there is the po-
tential to address unmet medical needs. A drug for TBI
is a perfect candidate for being “fast tracked.” It obvi-
ously is intended for the treatment of a serious or life-
threatening illness, and would fulfill an unmet medical
need. While this is a new provision in the law, there have
been regulations concerning these sorts of drugs for a
long time. Some of you might have heard about “subpart
E,” which was an attempt in the regulations to expedite
the development and approval of drugs intended to treat
such illnesses if the drugs had an effect on mortality or
irreversible morbidity. We have routinely classified (at
least provisionally) drugs to treat stroke and head trauma
as subpart E drugs. The value of being a subpart E drug
is to encourage a development program whereby if the
adequate and well-controlled trials were positive, one
would not have to do extensive Phase III safety testing.
If the drug had a beneficial effect on “extreme outcomes,”
that is, irreversible morbidity and mortality, we would not
need to wait for another couple of years to see the com-
plete adverse event profile. We would be willing to ap-
prove something that had a big effect relatively quickly.
It is important to realize that nothing in the fast track
law or regulations should be interpreted to mean that the
usual requirements for substantial evidence are sus-
pended. I bring this up because often sponsors will come
in and say, “Well, we have a fast track drug (or subpart
E drug), so we only need one study.” That is not true. It
may be true under the new provisions of FDAMA—one
study and confirmatory evidence—but the default posi-
tion is two studies, even for a fast track drug or a sub-
part E drug.
A great advantage of being designated fast track is that
the FDA must review the new drug application within
six months of submission, whereas the standard review
time is ten months. That only says we would have to take
an action, it does not mean drug approval. It might be a
provisional, “approve-able” action that would require the
sponsor to do more work.
Surrogate endpoints. The FDAMA also introduced
into law the concept of potential approval for a drug based
on its effect on a surrogate endpoint. The regulations have
talked about surrogate endpoints since about 1992, but
now it is in the law. It says that drug approval can occur
upon a determination that the product has an effect on a
surrogate endpoint that is reasonably likely to predict
clinical benefit. For example, antihypertensives or cho-
lesterol-lowering agents are drugs for which trials have
shown an effect on a surrogate endpoint. The endpoint
in and of itself has no clinical meaning; no one is symp-
tomatic if their blood pressure is slightly up or their cho-
lesterol slightly elevated. The reason that the agency has
approved such drugs is that there has been overwhelm-
ing evidence, based on long-term outcomes, that lower-
ing blood pressure or cholesterol is good.
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But the law says “reasonably likely to predict clinical
benefit,” which is a very different phrase. It says we do
not know if the surrogate is validated, but the Agency
has the authority to approve drugs on the basis of surro-
gate outcomes. At the time this was written, people at the
FDA were very nervous, because they thought this pro-
vision violates the requirement for substantial evidence.
The Agency interpretation is that you still have to have
substantial evidence of efficacy; it just has to be for the
surrogate endpoint. Nevertheless, it still does not permit
the use of surrogates that have not been validated against
long-term outcome.
Why are surrogates useful? If the outcome you really
care about happens well into the future, for example years
from now, you cannot practically do those studies. In such
instances, you try and identify a marker that can be quan-
tified early, and then demonstrate that it predicts the out-
come. The regulation also says that when the clinical ef-
fects are easily measured, nonvalidated surrogates are not
likely to be acceptable. It gives as examples epilepsy, de-
pression, and psychosis. Trials for these indications are
certainly do-able, and we approve drugs on the basis of
their effects on the clinical measures. In traumatic brain
injury the effects on clinical outcomes are also measur-
able fairly quickly. These are not studies that need to be
years long. If you consider outcomes at 3–6 months af-
ter injury, those studies can certainly be done. Hence, sur-
rogate endpoints are harder to sell as the primary out-
come measures in TBI trials.
What are the problems of surrogates and why are they
treacherous? The treatment may have an effect on the
surrogate, but may be dissociated from the disease-caus-
ing mechanisms. If there are many different mechanisms,
as seems to be the case in TBI, the surrogate may be in
one pathway and what you really care about is in a dif-
ferent pathway. Tom Fleming, a statistician at the Uni-
versity of Washington, has written about the problems in
validating surrogates. Recently at a meeting he gave a
rather extreme example to illustrate the point. People who
smoke have discoloration of their fingernails and they die
of lung cancer. If you put gloves on a smoker you will
have an absolute effect in eradicating their fingernail
problem, but you are not going to do anything for the
outcome that matters. The big problem in aiming trials
at surrogates is that the treatment may affect the clinical
outcome in unintended negative ways, but may have an
expected, beneficial effect on the surrogate. An example
of this would be a trial that looked at the effect of a drug
on suppressing arrhythmias, as a surrogate marker of ef-
ficacy in cardiac patients. The drug did in fact suppress
arrhythmias, but there was a higher mortality among
those patients than among the controls. Had we relied on
the effect on the surrogate, we would have been very
wrong in approving the drug. The consideration is whether
or not the effect of the treatment on the surrogate uni-
formly predicts the effect on the outcome. It has to be
much more than a correlation.
Another problem with validating surrogates is more
complex. It might be the case that the drug has the in-
tended effect on the surrogate and for the outcome that
you really care about, but the effect may be drug-specific
or specific to a pharmacological class of drugs. In order
for a surrogate really to be validated there should be a
robust finding across all relevant pharmacological classes
of drugs showing that the surrogate and the outcome of
interest always go in the same direction.
The take-home message is that surrogate outcomes are
very difficult to validate. There are, however, some fac-
tors that might make a surrogate acceptable, and it has to
do with the biological plausibility. In other words, there
is a lot of evidence: animal models robustly show the ef-
fect, there is a well understood disease mechanism, the
mechanism of the drug is well understood, and the sur-
rogate occurs late in the pathway of the pathophysiology.
The agency will also consider the public health when
looking at approval based on surrogates. Such consider-
ations include: the treatment is directed at a serious ill-
ness, there are no treatments available, it is very difficult
to study outcome endpoints, and there is a large safety
database. Those are compelling reasons to rely on the sur-
rogate, and that is, I believe, the situation that we have
for TBI.
International versus U.S. trials. It is perfectly permissi-
ble for the Agency to approve a treatment entirely on the
basis of non-domestic studies, but there are a number of
caveats. The population studied would have to be similar
to that in the U.S. population, and the sponsor would have
to make that case. The standard of care would have to be
very similar to the United States. There may be drugs used
routinely in the foreign studies that are not even available
here. The standards of record keeping would have to meet
U.S. requirements and be available for inspection. It is an
integral part of our review to actually go and look at the
primary records and ensure that things are as the sponsor
says they are. There is a new document out by the Inter-
national Committee on Harmonization, (ICH) which says
that the host country, in this case the United States, can
ask for a trial in its country for no particular reason. We
would certainly ask for a domestic trial if the foreign data
were from a place where we had no experience. In one re-
cent example a country had undergone a revolution dur-
ing the study, and the documents were unavailable. That
struck us as rather problematic. However, we do see many
multinational trials that include US and foreign sites, and
it is usually not a problem.
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Question: You mentioned the concept of not being able
to repeat a trial. Would you say more about that, con-
sidering a situation in which the medical profession is
happy with one trial and considers doing a second
placebo-controlled trial unethical?
Answer: There have been cases where we have not been
happy with trials that the academic community liked,
and that can be a problem. But, generally speaking for
large trials with a robust effect on mortality or another
definitive outcome, I don’t think the agency would try
to enforce a higher standard than the scientific com-
munity accepts. We cannot say that you have to do an-
other trial and look at mortality if no one is willing to
do such a trial. I have just recently come from a meet-
ing with another community of experts, who want ac-
tive-control trials. They have some drugs that are ap-
proved for their indication and they want to show
equivalence of the new and the old. Generally speak-
ing, we think those studies are not interpretable, and
cannot be used to support a labeling claim.
Question: In the happy circumstance that one gets a pos-
itive result in a particular trial, and there are other on-
going trials, what is your philosophy about whether
those ongoing trials would have to change in order to
reflect the newly found knowledge in the area?
Answer: It may become inappropriate to study a new drug
against a placebo control when a drug is approved.
However, the scientific community may believe that
even though the drug has been approved, that its ef-
fect is minimal and they are therefore unwilling to
switch their patients to that drug. It is the case in
Alzheimer’s disease. It has recently been true in MS,
although this may change. When a drug really has only
a symptomatic effect, has no effect on the underlying
disease, or does not prevent any real serious harm, I
think people feel very comfortable in doing placebo
control trials even though some drugs have been ap-
proved. Generally speaking, we would ask the spon-
sors to change the informed consent in other ongoing
trials to tell patients what their other options are.
Question: How do you go about determining that the
community is not willing to run another placebo-con-
trolled trial?
Answer: We might initiate it, if the effect were truly spec-
tacular. Most of the drugs we approve do not have
those huge effects, and it has not really been a prob-
lem. Another way we would know about it is through
meetings like this. Sponsors tell us. Sometimes the
study designs that sponsors propose, because they be-
lieve placebos are unethical, are trial designs that will
give uninterpretable results.
Question: Is there any particular advantage to a disease
having an orphan status?
Answer: Advantages accrue to a sponsor whose drug ap-
plies to an orphan disease, that is, prevalence of less
than 200,000 cases. I believe they get seven years of
exclusivity. They are exempted from the requirement
to do pediatric studies. They are not exempt from the
standards of law for approval, which is substantial ev-
idence of effectiveness. They still have to do the tri-
als. We would certainly negotiate with a company
about how much data they would need, given the ac-
tual prevalence of the disorder.
REPORTS FROM WORKING GROUPS
For the second day of the workshop, the participants
were divided into two large working groups to discuss
and make recommendations on four areas of particular
concern in the conduct of TBI trials. These areas were
selected by the organizers ahead of time and assignment
of membership made at the end of the first day. The cho-
sen topics were preclinical testing, clinical trial design,
outcome measures, and surrogate endpoints. Reports
from the working groups are presented below, as sum-
marized by the discussion leader.
Preclinical Testing (Tracy McIntosh, Ph.D., 
et al.)
This subgroup discussed the best ways to test drugs in
animal models to ensure a thorough evaluation before
recommending them for clinical trial. Our conclusions
are summarized below:
Targeting mechanisms. The group felt that more re-
search is needed to identify pathophysiological mecha-
nisms of TBI and then to generate compounds that are
specifically targeted to these mechanisms. The new fields
of genomics and proteomics are greatly enhancing our
ability to understand these basic mechanisms. We need
to determine whether these mechanisms are common be-
tween animal models, between models of diffuse and fo-
cal injury, in subarachnoid hemorrhage and in contusions.
The group agreed that it would be desirable to target ther-
apies towards these different types of injuries.
Extent of preclinical testing. How extensively should
a drug be tested in preclinical models prior to the initia-
tion of clinical trials in TBI? The group felt that a com-
pound should be evaluated not just in one model, but also
in multiple animal models. It is preferable that two or
more different labs, ideally using different experimental
TBI models, evaluate compounds. At least one of the labs




Animal models. There are excellent clinically relevant
animal models that have been established in rodents, for
example, the lateral fluid percussion model. The group
had long discussions about the utility of moving up to
more gyroencephalic species (larger animals) to test the
compounds that seemed promising. There was a consen-
sus in the group that if something is likely to work clin-
ically, it needs to have a robust effect in several differ-
ent animal models.
It was felt that the pig is a good model to move to af-
ter the rodent, because it reproduces human anatomy
fairly well. However, it was recognized that moving to
higher species might be problematic, especially for in-
vestigators working outside the United States. While rec-
ognizing and acknowledging this problem, it was never-
theless felt that there is a need to develop and characterize
trauma models in these animals (e.g., pigs or primates).
The model needs to imitate the mechanism of injury,
should be reproducible, and include behavioral endpoints.
The development of adequate, appropriate, and validated
behavioral indices in these large animal species will be
a major challenge to the field.
Window of treatment. The third point for discussion was
the concept of a “critical window of opportunity” during
which a drug may be expected to have a positive effect.
There is truly a lack of knowledge of the critical window,
both in humans and in animals. How the critical window
in an animal model correlates with the window in humans
in largely unknown and may well be different for each drug.
Research priorities. Based on discussions between the
basic scientists and clinicians in the group, the following
research priorities were articulated:
1. Model traumatic coma. Most of the currently used
models represent mild to moderate TBI.
2. Establish animal ICUs to be able to study severe TBI
and to look at surrogate markers of outcome.
3. Study pharmacokinetics in multiple animal models in
order to establish how much of the drug needs to be
given, how soon, how often and for how long.
4. Evaluate drug interactions, particularly considering
the variety of treatments given to head injury patients.
5. Evaluate drug cocktails aimed at the different mech-
anism of injury.
6. Study age-related differences, including pediatric and
geriatric TBI.
7. Focus more study on late (chronic) events in animal
models.
8. Model field or ER therapies, targeting clinically rele-
vant secondary insults, such as hypoxia, ischemia, he-
morrhage and hyperventilation.
9. Evaluate female/male differences, not only with re-
spect to drug efficacy, but also in terms of outcome
differences without pharmacological therapy.
Minimum preclinical development. One of the main
charges to the group was to develop a set of criteria that
were the minimum needed before a compound could be
deemed ready for clinical trials. The following criteria
were agreed upon:
1. Establish efficacy in multiple rodent models of TBI.
Although it is desirable a to also show efficacy in
larger animals, the consensus was that this may not
always be practical.
2. Establish the pharmacokinetics of the drug and use
this information in establishing the clinical protocol.
3. Evaluate the long-term effects of the drug both phys-
iologically and behaviorally in the animal models.
4. Establish efficacy in rodent models ranging in sever-
ity from mild to severe.
5. Utilize more sophisticated statistical design and analy-
sis in preclinical trials.
6. Establish greater communication between the basic
scientists, the clinicians, and the pharmaceutical in-
dustry in reaching decisions regarding drug develop-
ment.
Question: Are you suggesting that if you showed a repli-
cated effect in a model of predominantly white matter
injury, but not in a model of gray matter injury, that
you might not go forward with the agent?
Answer: Our group would likely suggest that it might be
more useful to test that compound in patients who show
predominant white matter injury.
Question: The human head is very mobile versus the
trunk, and is very heavy (especially in children). This
is likely a cause for the inertial loading injury, and I
do not see any animal model that is quite appropriate.
I wonder what species comes close enough to look at
this kind of injury?
Answer: There is a need to incorporate bioengineering
into our modeling, and there are bioengineers inter-
ested in this field. We need to cultivate that interest
and bring them in to our laboratories to address such
issues more thoroughly.
Question: What kinds of increased statistical involvement
in design of preclinical trials does your committee have
in mind?
Answer: Many of the preclinical studies to date have been
performed using a simple, one-way analysis variance
model. Many times it is very interesting to look at a
combination of factors (for instance, an experimental
agent tested at two different severities of injury).
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Rather than creating four or five different studies, we
could do a two-way design, which would allow ex-
amination of the interactions.
Question: I am surprised that the optic nerve stretch
model has not had a bigger place, because it produces
axonal injury in a biomechanically defined way. Is it
not a model where much greater progress can be made,
rather than trying to model diffuse axonal injury in the
“whole head” of small animals?
Answer: The optic nerve stretch model is a relatively pure
model of axonal damage, and it is an in vivo model,
so one can evaluate pharmaceutical compounds. How-
ever, our group was focused on recommendations for
the preclinical studies that would provide the most
comprehensive and relevant data with respect to future
clinical studies. For that we need not only mechanis-
tic data, but also behavioral endpoints. The optic nerve
stretch model unfortunately does not provide these.
Question: You mentioned evaluation of concurrent med-
ication to reproduce the clinical setting. What about
initial sedation, anesthesia, or paralysis?
Answer: Most labs do not standardize their anesthesia
paradigms, and different anesthetics and sedatives can
have profound effects on the way animals respond to
the traumatic injury. More attention needs to be paid
to this.
Comment: It would be very interesting and important to
look at previous drugs that failed in clinical trials and
to test them in animals in the way that they were used
in the hospital. There is a big difference between how
compounds are tested in animals and in humans. If we
gave a rat four doses a day of Selfotel for a week, what
would be the results?
Answer: We have recommended the incorporation of sec-
ondary insults such as hypotension and hypoxia into
the models, and looking at drug effects in a more clin-
ically relevant context.
Clinical Trial Design (M. Ross Bullock, M.D.,
Ph.D., et al.)
The ideal design of clinical trials in TBI remains to be
defined. However, much has been learned from the tri-
als conducted to date. After extensive discussions, the
group endorsed these general principles for future clini-
cal trials:
1. Demonstrated mechanism: A mechanism of injury
should be demonstrated in animal models as well as
in human TBI. The test drug should be active against
that mechanism.
2. Brain penetration: The drug should be shown to pen-
etrate the brain in appropriate concentrations.
3. Safety profile: The drug should have been demon-
strated to be safe in human TBI. In addition, the drugs
should be shown safe in combination with other agents
that are currently used clinically, such as anticonvul-
sants.
4. Time window: The drugs should be administered in
the appropriate time window. We have to define that
time-window not only in rodents, but also in the gyren-
cephalic animals and in humans. Treatment windows
are a major issue in the conduct of these trials. Early
treatment seems desirable. We need to move towards
conduct of trials in the prehospital setting, with EMS
or ER personnel giving the trial drugs. As we do that,
we will come up against the issue of consent. Most of
the time, it will not be possible to get full informed
consent in these circumstances. We should revisit the
“waiver of consent” issue. Clearly, the government
agencies are concerned with this area, and we need to
consult with them to define approved ways to use
waiver of consent for head trauma patients. A com-
bined meeting between representatives of the funding
and oversight agencies with ABIC could be valuable.
Other interested groups would include those who
study epilepsy, cardiac arrest and emergency medi-
cine and bioethics. Organizations such as the Brain
Trauma Foundation and the Brain Injury Association
can also play an important role.
5. Alternative trail designs: Alternatives to the con-
ventional prospective, randomized, controlled trial
were considered. Mega-trials are very interesting, but
only need to be considered when looking for small
drug effect. Most of the trials that have been conducted
in TBI have been over-ambitious in setting the ex-
pected treatment effect at 10% improvement. This 
expectation has been based on animal studies, which
have sometimes yielded dramatic separation between
control and drug groups. It has been subsequently as-
sumed that our error was in underpowering the trials
(too few patients to show the desired effect). The ac-
tual error may well have been in expecting an unre-
alistically great effect! A serious issue for mega-trials
is that there are no appropriate assessment tools for
moderate and mild-injury. It is impractical to use com-
plicated neuropsychological testing for 10,000 sub-
jects, and the GOS is probably inappropriate for this
patient group since 95% of subjects will probably be
found to have a “good recovery.” More thought needs
to be directed at outcomes issues in moderate and mild
TBI. We have been saying this for three successive
meetings on outcomes, so we need to do something!
Another alternative to the conventional prospective,
randomized clinical trial (PRCT) is subpopulation-fo-
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cused trials, for example, the Bradycor trial. These trials
have got to be based on adequate and well-analyzed phase
II studies to identify the mechanism of interest. What
would be the optimal trial design for a PRC? No generic
boilerplate design can be proposed, and we should tailor
the protocol specifically to mechanisms that emerge from
animal studies, and are tested in phase II studies. There
are adequate strategies available to make sure that the
treatment groups are equally randomized.
6. Careful monitoring of management: There needs to
be aggressive and proactive feedback to individual
centers on protocol violations, data inadequacies,
management deviations and so forth. That will require
a more dynamic role for the PI and the sponsoring
agency conducting the trials.
7. Stopping rules: The group felt that trials should be
completed if at all possible. The sponsors need to guar-
antee the investigators that they intend to take the tri-
als to completion. Interim analyses are appropriate in
guiding the conduct of the trial and safety of patients.
However, over use of futility analyses may end a trial
prematurely. These issues need to be clearly debated
with sponsors before the trial starts and there must be
predetermined stopping rules. Sponsors should agree
to independent safety monitoring boards, to oversee
the conduct of the trial. This is a necessary for the
safety of the patients and to maintain scientific cred-
ibility.
8. Publication of results: Independent and full analysis
of the data should be the standard. The guidelines for
analysis and publication should be clear, and papers
should be prepared for publication within a year of the
completion of the trial.
Comment: There are outcome measures available for
moderate and mild head injury. It may be possible to
evaluate at 1–3 months, use the GOSE, and not di-
chotomize but use the full range of outcomes. We
(Temkin et al.) have a new measure that will go down
to the lowest level of impairment, and compare pa-
tients to themselves not the general population, in any
of nine areas. We have used this assessment in the val-
proate trial, which was not developed to look for a neu-
roprotective effect. This measure and the GOSE are
being used in our current magnesium sulfate study.
Question: Could you talk for a minute about what the
specific problems will be with the exception from in-
formed consent procedure?
Answer: These patients arrive at the hospital in a highly
emergent situation: There are many things being done
to them simultaneously, and it is often very difficult to
superimpose informed consent upon all this. Moreover,
the severe TBI patient is by definition comatose, and
very often there is no family member immediately avail-
able to give consent. If it is shown that a drug needs to
be given within 2 hrs of the injury, either the emergency
squad has to administer it at the scene, or it has to be
given soon after the patient enters the ER. Most of the
time, there is no family member at the scene of the ac-
cident or waiting in the ER to give consent. Hence, if
research in this field is to move forward, a mechanism
for waived consent needs to be established.
Question: Could you comment on waiver of consent
rules? Are they complicated?
Answer: Since these new regulations have been pub-
lished, two drug trials have been started in which the
pharmaceutical companies chose not to request waiver
of consent. The OPRR (Office of Human Research
Protections, DHHS; this office no longer exists. The
current office most relevant to these issues is the Of-
fice for Human Research Protections, DHHS.) created
such complex hurdles that the companies decided that
this was not a battle they wanted to fight. These reg-
ulations make it so unpalatable that the “waiver op-
tion” just is not being used.
Question: I am interested because we in the FDA never
get to hear about this. What specifically are the major
hurdles? Is it the community consultation or locating
family?
Answer: The interpretation of “community” is the issue!
How do we know that notice been given to the com-
munity? How many talk shows do you have to go on
and how many churches do you need to visit? Is that
really the population you want to reach? All of these
issues remain undefined and could be challenged. If
you have waiver of consent available in a multi-cen-
tered study, and one IRB refuses to accept it, that de-
cision must be promulgated by the pharmaceutical
company to all of the other IRBs concerned. It creates
a level of uncertainty about completion of the trial and
center participation. The justification is unknown for
these regulations.
Comment: Our center (San Diego) entered the third largest
sample of patients in the Tirilazad trial in the United
States, but we are now “out of business” for severe head
injury trials, because of the rules of waiver. We have
not been able to satisfy these regulations in a meaning-
ful way. They are burdensome. They obstruct research.
I chaired the IRB in San Diego for five years and I can
tell you that this is the single biggest impediment to find-
ing new treatments for TBI and other acute conditions.
It is really unethical if you cannot figure out a way
around this to continue to do research in cardiac dis-
eases, for example. Somebody with acute chest pain—
can he/she really give informed consent?
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Answer: Researchers are concerned that these analyses
are more often used to provide support for an economic
argument to stop a trial, and not share the data with
the scientific community. We are not learning anything
from such studies to help us in the future. I agree it is
unethical to put patients at risk for a drug that is harm-
ful. When there is a high probability that you will not
find the difference you were powered for, surely you
should not put them at risk for getting the drug at all?
We are only talking about that point where the null hy-
pothesis is liable not to be rejected.
Comment: I think using a futility analysis in a circum-
stance where there are no treatments for a disease, loses
information. So is the fact that a trial will not show a
10% effect, a reason to stop? If you go to completion
you may see a difference of 5%. That is potentially
important information.
Comment: Futility analyses are tools that should be used
by DSMBs (Data Safety Monitoring Boards) in mak-
ing appropriate decisions about a research risk for the
patient.
Outcome Measures (Claudia Robertson, M.D., 
et al.)
There was a lively discussion with many opinions ex-
pressed, but the group did come to agreement on several
points. The consensus can be summarized as follows:
1. In general, for an intervention or a treatment to be ac-
cepted into general clinical practice, investigators
should show benefit on an index relevant to lifestyle.
2. The size of the benefit and the exact outcome scale
should be related to the population and the treatment
being studied. These scales can vary, and the utility
of the measures in TBI patients requires ongoing in-
vestigation.
3. An evaluation at 6 months after injury probably pro-
vides the best assessment of the ultimate outcome and
is least influenced by the confounding effect of other
associated injuries. There is general enthusiasm for us-
ing the GOSE.
The rationale behind the last recommendation is that
the GOSE provides a better distinction between levels of
disability, particularly with the severe disability group,
while the GOS tends to lump a wide range of disability
into one category.
There was absolutely no enthusiasm for economic as-
sessment (e.g., length of stay or cost of stay) as part of
outcome assessment. We heard earlier that often the acute
cost of hospitalization could be more expensive in some-
one who might ultimately have a better outcome. This is-
sue could be very confusing if added in as an important
outcome measure.
We noted that outcome measures might have to be de-
signed for the specific goals of the patient populations
who will be included in individual trials. Every trial that
we do is a little different, and every patient population is
a little different, depending on the inclusion/exclusion
criteria. We cannot rigidly apply the same outcome mea-
sures for each trial. There may be trial circumstances
where a dichotomized GOS might be best divided be-
tween good recovery and moderate disability, and other
situations where the cut might need to be made between
moderate disability and severe disability.
There is also considerable enthusiasm for the concept
of comparing observed outcome in a trial to outcome pre-
dicted by initial injury severity. Teasdale and Maas de-
scribed this kind of analysis at this meeting, and the group
would like to see it implemented in future trials.
In general, there was agreement that we have been
overly enthusiastic, or overly optimistic, in designing tri-
als to achieve a 10% improvement in the overall outcome.
We should seriously consider using 5–7.5% improvement
for upcoming trials.
Question: On your suggestion for using actual outcomes
versus predicted outcomes, did you all feel that is
something that could be translatable from one center
to the other or would you need to develop a prediction
model based on data derived from individual centers?
Answer: I suspect that each trial would require some kind
of prediction. The inclusion and exclusion criteria
would be different for each trial, and there may be
unique aspects for a particular trial. But I am not sure
that it would have to be specific to each center within
a trial. These are things that will have to be worked
out. In general, this may be the way that trials should
be designed in the future.
Question: Are you saying that predicted outcomes could
be used instead of controls?
Answer: No, absolutely not.
Question: I would like to ask Dr. Katz how the FDA
views that. Consider that we have lowered the hypo-
thetical differences between the treatment/control
groups to 5%, and the study was large enough to show
statistical differences. What is the acceptable differ-
ence between two groups to get a drug approved?
Answer (Dr. Katz): There are no a priori levels. If the
medical community felt that this sort of a difference
was something that mattered clinically, we could be
convinced. Any final decision about approving a drug
will be a risk/benefit comparison. We look at the data
closely to see what the risks and the benefits really are.
Comment: Dr. Katz made an important point: where you
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set the bar is really clinical opinion. I think that the
10% bar was established rather arbitrarily based on
hope. I think that we may be able to achieve a more
targeted outcome with fewer patients—that may sup-
port the 10% difference.
Comment: Whatever is done for the first approved treat-
ment will set a precedent. The result will become a
standard in the field that will be very difficult to
change. I think we need to give considerable thought
to what that standard ought to be. Sometimes, if there
is nothing available, you set the standard relatively
low, just to get something out there. But this approach
perpetuates itself. Several “me-too” drugs come along
using the same standard of marginal efficacy, and the
field becomes full of treatments of marginal signifi-
cance. I would suggest that we want to give some se-
rious thought to whether or not we embark on looking
at smaller effects and whether that is meaningful for
patients.
Surrogate Endpoints (Graham Teasdale, M.D., 
et al.)
The second task of this group was to look at surrogate
endpoints, and our discussion yielded diversity and con-
sensus. It was agreed that outcomes or other surrogate
measures observed in the first two weeks after injury
could not provide a satisfactory index of benefit, and sup-
port the clinical adoption of a treatment. Nevertheless,
early indicators can be of interest in two ways:
First, they may provide confirmation that treatment is
in some way affecting the biology of the injured brain;
this information is useful as a “proof of concept.” Sec-
ond, surrogate measures may be useful in assessing dose-
ranging effects by providing a biological marker that in-
dicates drug activity or adverse effects. For example,
while using a drug that is aimed at reducing the ICP, one
can decide upon the appropriate dose range based on the
effect on ICP and blood pressure.
When using some early information to predict later
benefit it is required that the surrogate predicts the even-
tual outcome, not just that it shows a general relation to
outcome. The other concept that came through was that
any correlation between an early effect and change in
later outcome would need to be revalidated, perhaps us-
ing more than one index, in more than one study. It
would also be essential to repeat this process of valida-
tion before coming to a conclusion about another new
agent. For example, it would not be sensible to trans-
late an early ICP effect from drug X to a similar bene-
fit of drug Y, if X affects cerebral blood volume and Y
affects axonal damage.
One value of an early surrogate outcome could be in
shortening the time to obtain an answer, either in a sin-
gle patient or in a trial. Nevertheless, this reduction in
time frame is probably not so important in head injury.
A shorter time is essential if the eventual answer takes
5–10 years to obtain; for example, survival in cancer or
AIDS. Shortening the observation period in a TBI trial
from 6 months to 1 week may not be a sufficient advan-
tage. A surrogate may also be useful in obtaining an an-
swer in fewer patients if there is truly a large effect. Such
information might be valuable in a sequential trial de-
sign, providing an early index from which to decide
whether to continue the trial, or to change the design.
Will a surrogate index be sufficient in and of itself as
evidence in support of final drug approval? If a surrogate
is to be used, what should its features be? The index
should produce data that are quantifiable in a well-cali-
brated way so that it indicated the severity, extent, and
type of brain damage. Thus, measures that only reflect
secondary effects of brain trauma, such as ICP or CBF,
have their limitations. It was also agreed that the mea-
sure should be dynamic, so that it is possible to observe
changes in the individual patient in response to inter-
vention, preferably in a way that is related to the mech-
anism of the drug.
With further discussions it was recognized that there
are other important technical features of an early index:
how easy it is to measure, its feasibility in severe injuries,
its cost, how frequently it is necessary to make observa-
tions, and the complexity of data analysis (e.g., functional
imaging). Some candidate surrogate markers and their at-
tributes are listed in Table 5.
Intracranial pressure. It is certainly quantifiable and
measurable. It can be summarized in many ways (e.g.,
percent time at different levels; mean value). Unfortu-
nately, it has only an indirect relationship to the severity
of brain damage, and primarily reflects the amount of
brain swelling produced by the trauma. Does it relate to
the severity of axonal injury? Axonal injury may be the
main determinant of the quality of recovery in survivors.
Even though high ICP is a good acute predictor of mor-
tality, it may not be a good predictor of the quality of re-
covery in survivors. ICP is dynamic: one can see changes,
and they depend upon the treatment. In general, if the
drug is targeted to reduce ischemic brain damage with its
consequent swelling, but does not show an ICP effect, it
is unlikely that the drug will work. ICP measurements
certainly have to be considered to be useful, but may not
an entirely reliable index if used as a sole indicator.
Therapy intensity level. We recognized that there is
some interaction between ICP and the type of treatment
a patient receives; they should be looked at together. It
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is possible to rank therapy intensity level (TIL), but that
is not quite the same as quantifying it is a well-calibrated
way. Any relationship of TIL to severity of brain dam-
age is indirect, and it is too “operator-dependent” to pro-
vide consistent information. It is probably necessary to
record TIL to interpret ICP data, but by itself TIL is not
much use as a surrogate.
Jugular venous oxygen saturation. It is possible to
count how often episodes of jugular venous oxygen de-
saturation occur, how long they last, and how severe they
are, so that quantification is achieved. However, it is not
absolutely clear how they relate to the quantum of brain
damage. Do desaturations indicate the threat of worsen-
ing brain damage, or reflect how badly the brain is al-
ready damaged? They are dynamic, but is it possible to
say that they have been prevented in an individual pa-
tient? If the intervention is designed to raise CBF, its ef-
fect should be reflected in “higher” SjvO2, but this will
be the case for an agent working on various cellular
mechanisms.
Structural imaging. It is possible to quantify the num-
ber of contusions, the extent of midline shift, whether or
not the basal systems are compressed, and so on. As a
consequence, this approach can be useful for space-oc-
cupying lesions. In contrast, in even fatal diffuse axonal
injury, imaging can be completely normal. Imaging does
not lend itself to dynamic measurements. Lesions or brain
shifts can get bigger or smaller, but these changes take
place over long periods and may have very little rela-
tionship to the mechanisms of a pharmacological agent.
It is difficult to conduct imaging studies in acute, severe
head injuries. Methods such as SPECT or PET may be
very useful as research tools, but they are not easy to use
in critically ill patients.
Metabolic measurements. There are a lot of data about
metabolic measures, but how these should be interpreted
is less clear. The results may reflect severity of injury in
some brain areas, but any relationship to overall damage
remains to be shown. Measurements can be dynamic, but
they may show irrelevant changes in metabolites or drug
concentrations.
Neurological worsening/neurological improvement.
Worsening either happens or it does not, so it may or may
not be quantifiable. Improvement (time to reach a certain
index or proportion of patients who are at a certain level
at a particular time) might provide graded information.
These events are dynamic, and they are likely to relate to
the amount of brain damage. They will describe how long
the damage lasted or how quickly it resolved, but the mea-
sures are probably not related to a drug mechanism.
Summary. Our group felt that no single “surrogate”
was ideal, and though useful information can be gained,
there is need further development. Neurological worsen-
ing/improvement might be components of a quality as-
surance system for different centers or might be early in-
dicators of improvement and recovery.
Question: Did the group discuss use of these outcomes
in phase II trials? If an effect on a certain parameter is
seen in phase II, should that measurement be a part of
the phase III trial?
Answer: These surrogates by themselves were considered
not to be primary endpoints for phase III. They were
seen as quite valuable for phase II. We did not discuss
whether or not they were necessary and essential in
phase III. Their place in phase III could be in a se-




TABLE 5. SURROGATE MARKERS IN TRAUMATIC BRAIN INJURY
Index of brain
Quant damage Dynamic Mechanism
ICP 111 Indirect Ö Ö /?
TIL 1 Very indirect ? 0/?
SjvO2 11 ? Ö 0/?
Anatomical imaging 11 111/0 0 0
MRS ?/11 ?/11 ? 0
Microdialysis ? ? Ö ?
NW/NI ?/11 Ö Indirect 0
Desirable features: Quant 5 degree quantifiable; index of brain damage; dynamic 5 does the measure change with time or treat-
ment; mechanism 5 relationship to drug mechanism. Clinical measures: ICP 5 intracranial pressure; TIL 5 treatment intensity
level; SjV02 5 jugular venous oxygen saturation; MRS 5 magnetic resonance spectroscopy; NW/NI 5 neural worsening/neural
improvement.
Comment: Imaging is probably not dynamic, but if its use
could shorten the time period of assessment from sev-
eral months to a week, it would be valuable.
Answer: Yes, but you can only image the people who are
still alive.
Comment: I think that you are “downgrading” the dynamic
aspect of imaging because you are only thinking in terms
of acute injury. What about the brain picture at 2 weeks
or 1 month, versus the 6 months necessary for behav-
ioral assessment? Perhaps using spectroscopy or mag-
netic transfer imaging may predict outcome.
Answer: At present, MRI is expensive, cumbersome, and
difficult to perform in TBI patients, even after 1 wk; and
the data are difficult to interpret. We did not think imag-
ing would be crucial in the immediate future. There are
opportunities for further improvements in techniques.
Question: What about MR spectroscopy or PET?
Comment: At the present, I think that your comments on
the difficulties of imaging the head injured patient in the
acute phase are correct; but the results of research are
very promising. On the basis of our (Marmarou) spec-
troscopy work, there is a strong prognostic value for re-
lease of N-acetylaspartate and recovery. In patients who
do not do well, values drop acutely and stay low; in pa-
tients who recover, the values increase. Perhaps such an
index assessed within a 10-day period would give us a
handle on what will occur 6 months later.
Comment: Imaging techniques are fertile areas for re-
search, and could move the field forward through both
basic and clinical studies. Imaging cannot be the pri-
mary endpoint in a Phase III trial, but the techniques
hold promise for elucidating mechanisms that would
be the targets for drug trial design.
Answer: There are a number of biochemical or metabolic
markers that seem to relate quite well to the amount
of damage, but whether those are sufficiently dynamic
is a question. It has been suggested that late rises in S-
100 protein concentrations in the blood might corre-
late with secondary insults.
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